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Abstract 
Motor neurons elongate axons over great distances during development, with some extending 
from the spinal cord to the distal limb, but little is known about extracellular signals that 
control this growth.  The TGF-β superfamily includes two major classes of ligands: Nodal-
like and BMP.  BMP signalling is essential for neuromuscular synaptic growth and plasticity 
in Drosophila; however, a similar role for the pathway in mammalian motor neurons has not 
been described. 
It has previously been shown that the E3-RING ubiquitin ligase Arkadia enhances signalling 
through the Nodal branch of TGF-β signalling.  A second Arkadia locus was previously found 
to contain two isoforms; the C-terminal isoform (Arkadia2C) contains domains critical for 
Arkadia’s activity.  This project addresses the in vivo function of Arkadia2C in mice. 
Arkadia2C was found to be expressed specifically in the nervous system throughout 
embryonic development and adulthood.  In a neuronal context Arkadia2C enhances signalling 
through the Smad1/5/8 branch of the TGF-β pathway in a RING domain-dependent manner.  
Mice null for Arkadia2C display motor neuron disease-like symptoms including weak motor 
control and difficulties breathing and eating, leading to postnatal mortality in the majority of 
mice.  A subset of Arkadia2C null embryonic innervation defects was analysed; the majority 
of the motor axons of the dorsal forelimb fail to form synapses with their target muscles while 
the phrenic nerve exhibits shorter terminal branches.  Postnatally, a failure to maintain 
neuromuscular junctions was observed leading to atrophy of several muscles. 
Active BMP signalling was observed in the neurons that innervate the limb and diaphragm 
and genetic reduction of BMP signalling in asymptomatic Arkadia2C heterozygous mice 
caused the appearance of the same muscle innervation defects observed in the null 
individuals. Together, these findings suggest that Arkadia2C’s enhancement of the BMP 
signalling pathway is critical for the growth and connectivity of certain motor neurons. 
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1 Main Introduction 
 
1.1 Motor neuron connectivity 
The assembly of neural circuits is complex and highly specific; precise polarised connections 
to a target cell are required for normal neuronal function.  Progenitors and early postmitotic 
neurons acquire an intrinsic genetic program that controls circuit assembly steps including 
polarisation of the cell to produce a single axon and a large number of dendrites and the initial 
steps of axonal pathfinding towards a target cell.  Further axon growth, guidance and 
synaptogenesis occur in response to extrinsic signals produced by both the environment 
through which the axon grows and its eventual target (Shirasaki and Pfaff, 2002; 
Hippenmeyer et al., 2004; Salie et al., 2005; Stiess and Bradke, 2010).  Once formed, certain 
synapses are maintained for long periods while others display a high degree of plasticity (Frey 
et al., 2000). 
Many of these aspects of neuronal connectivity have been extensively studied, however axon 
elongation is rarely recognised as a process distinct from axon guidance that requires unique 
environmental signals.  It is therefore unclear whether known mechanisms of local growth 
cone advancement are sufficient to drive axon growth.  This question is of particular 
relevance to cells, such as motor neurons, which extend axons over long distances through 
non-neuronal tissues which themselves express numerous signalling factors.  These 
exceedingly long peripheral axons must be maintained as the animal ages and the factors 
expressed by the surrounding tissue change.  The role of peripherally-expressed factors in 
both the growth and maintenance of motor neuron axons and the identity of such factors have 
not previously been explored. 
1.1.1 Axonal growth and guidance 
Axon growth in response to extrinsic signals is initiated at the highly dynamic growth cone 
found at the axon’s distal tip.  The structure of the growth cone is different to that of the main 
axonal shaft and is critical for its function (Figure 1.1a).  The axon shaft consists of a stable 
cytoskeleton of microtubules along which vesicles and organelles can be transported to the 
distal regions of the axon.  The central (C-) domain of the growth cone contains the plus end 
of these microtubules where polymerisation occurs via the addition of GTP-tubulin dimers.  
Surrounding the C-domain is the transition (T-) zone which contains contractile actomyosin 
structures known as F-actin arcs, which form a hemicircumferential ring around the C-domain 
and regulate the advance of the microtubules.  The outer peripheral (P-) domain consists of 
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dynamic finger like filopodia and a veil of lamellipodia-like structures.  Both are actin-based 
with F-actin bundles perpendicular to the T-zone actin arcs, constituting the filopodia and F-
actin networks producing the lamellipodia.  Pioneer microtubules also grow from the C-
domain into the P-domain, and are usually found close to F-actin bundles (Lowery and Van 
Vactor, 2009; Stiess and Bradke, 2010).  
The cytoskeleton within the growth cone has been observed to continually turn over priming 
the axon for growth (Figure 1.1b).  In filopodia, ATP-actin molecules are added to the plus 
(barbed) ends of F-actin filaments which face the leading edge.  Disassembly of ADP-actin 
occurs at the minus end in the T-zone and the actin is transported towards the leading edge in 
a process known as treadmilling.  This continual growth of the F-actin should cause 
protrusion of the filopodia and growth of the axon, however, growth is balanced by the 
retrograde flow of F-actin.  Contraction of Myosin II in the T-zone causes the proximal end of 
actin bundles to buckle, pulling the leading edge back towards the axon shaft.  Proteins such 
as actin-depolymerising factor (ADF)/Cofilin or myosin II itself have been suggested to sever 
the buckled actin bundles and depolymerise the filaments, allowing monomer recycling.  
Pioneer microtubules present in the filopodia are coupled to the F-actin bundles by putative 
linker proteins and their polymerisation is also balanced by the retrograde flow (Lee and 
Suter, 2008; Lowery and Van Vactor, 2009). 
Three continuous and overlapping steps have been shown to prevent retrograde flow and 
allow axon growth.  Receptors on the growth cone bind to the extracellular adhesive substrate 
and a complex forms between the receptors, which are now stationary in comparison to the 
extracellular environment and F-actin bundles.  While this coupling is weak, the retrograde 
flow of actin is not disrupted.  However, the link between the actin and microtubule breaks 
ending the retrograde flow of the microtubule within this filopodia.  This allows recruitment 
of microtubules to the adhesion site and the transport of signalling molecules which 
strengthen the substrate-growth cone interaction ending the retrograde flow of F-actin (Lee 
and Suter, 2008; Lowery and Van Vactor, 2009).  This filopodial protrusion is followed by 
engorgement during which the F-actin bundles between the adhesion site and the C-domain 
are removed (possibly by severing) and the F-actin arcs reorient.  These events create a 
corridor from the C-domain to the periphery allowing many microtubules to invade the 
adhesion site.  The final step of outgrowth is consolidation whereby the most proximal part of 
the growth cone compacts into a new portion of axonal shaft by F-actin arc mediated 
compression of the microtubules (Lowery and Van Vactor, 2009). 
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Axons require a “pathway” of adhesive molecules to grow along; these can be provided by 
the extracellular matrix (laminin and fibronectin) or can be transmembrane molecules on 
adjacent cells such as cadherins.  Additionally anti-adhesive surface bound molecules exist 
including slits, ephrins and chondroitin sulphate proteoglycans.  The presence of these can 
prevent axons growing into a tissue and map its route along the permissive pathway.  There 
are also diffusible chemotropic cues which can act in both a permissive and restrictive manner 
upon the growth cone.  These include the classic guidance molecules such as netrins and 
semaphorins but also secreted transcription factors, growth factors, neurotransmitters and 
morphogens (Lowery and Van Vactor, 2009). 
Two adjacent axons might respond completely differently to the same set of environment cues 
(Lowery and Van Vactor, 2009); for instance, depending on the neuron type, Wnt molecules 
can act as either attractive or repulsive cues in the spinal cord (Charron and Tessier-Lavigne, 
2005; Schmidt et al., 2009).  Additionally a single cue can have differing effects on the same 
axon dependent upon the context; Shh has been shown to act as an attractant of commissural 
axons before and as a repellent after they cross the midline (Bourikas et al., 2005; Charron 
and Tessier-Lavigne, 2005).  The response of an individual axon to environmental cues has 
been suggested to be in part determined by the complement of receptors expressed in the axon 
and growth cone.  However, the expression patterns of intracellular proteins that control the 
cytoskeleton in response to receptor activation are also thought to play a key role (Lowery 
and Van Vactor, 2009).  RhoGTPases such as RhoA and RAC1 act as signalling nodes for 
most guidance receptors, when activated they have been shown to influence both the 
polymerisation of F-actin bundles and their retrograde flow promoting forward progression of 
the growth cone.  Guanine exchange factors (GEF) activate RhoGTPases while GTPase 
activating proteins (GAP) inactivate them determining the cellular responses to guidance 
cues.  As the expression of such proteins is crucial, any environmental cue which can induce 
their expression is likely to affect axonal growth and guidance.  However, as many different 
proteins are likely to play a role in the regulation of growth cone extension, any potential link 
between their expression and extrinsic factors encountered by the axon have not been fully 
explored. 
Motor axons exit the central nervous system via the ventral roots and cranial nerves and may 
grow vast distances without branching until they reach their target tissue.  They are therefore 
likely to encounter a number of different peripheral guidance cues on route.  Repulsive 
guidance cues such as ephrins are critical for many stages of motor axon outgrowth although 
they often act in combination with attractive cues (Schmidt et al., 2009).  The initial growth  
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Figure 1.1: The Growth Cone and Neuromuscular Junction 
(a) The structure of the growth cone is critical for its role.  Microtubules enter the central 
domain (blue) from the axonal shaft.  Microtubule growth is constrained by the F-actin arcs of 
the transition zone (pink).  The peripheral domain (purple) contains pioneer microtubules and 
F-actin bundles in filopodia and the F-actin network in lamellipodia.  Adapted from (Lowery 
and Van Vactor, 2009). 
 
(b) Before contact with the extracellular substrate, filopodia do not grow; F-actin 
polymerisation at the leading edge is balanced by contraction of the Myosin II in the 
transition zone and the severing of the buckled actin filaments.  When the substrate is bound a 
complex forms coupling the receptors to the actin filaments preventing retrograde flow.  
Polymerisation of the F-actin continues and the filopodia grows.  Adapted from (Lowery and 
Van Vactor, 2009). 
 
(c) i) Neuromuscular junctions at birth have multiple inputs sharing a postsynaptic 
plaque-shaped domain.  ii) After segregation of the inputs, all but one retract from the muscle.  
iii) The nerve terminal and muscle fibres expand without changing synaptic geometry.  iv) 
Some regions of the junction are lost as the animal ages.  Adapted from (Sanes and Lichtman, 
1999). 
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from the ventral spinal cord into the periphery is driven by repulsive cues from the midline of 
the spinal cord (netrins, semaphorins, ephrins and slits) and a strong chemoattractant signal 
from Cxcl12 in the mesenchyme.  Semaphorins and ephrins also act together to ensure that 
axons fasciculate into nerve bundles preventing aberrant pathfinding choices.  Within the limb 
a combination of repulsive semaphorin, repulsive forward Ephrin-Eph (limb-axon) and 
attractant reverse Eph-Ephrin (limb-axon) signalling ensures that appropriate axons project to 
the dorsal and ventral tissue (Schmidt et al., 2009).  In addition to such classic guidance cues 
other peripherally expressed factors have been shown to influence motor axon guidance. The 
expression of the growth factor GDNF in the proximal limb is also involved in the choice 
between dorsal and ventral projection while FGF2/4/8/9 signalling through FGFR1 guides 
axons towards the axial muscles (Shirasaki et al., 2006; Schmidt et al., 2009; Bonanomi and 
Pfaff, 2010).   
A number of signalling pathways, including BMP, Wnt and Notch are involved in the 
development and maintenance of embryonic muscles (Wang et al., 2010).  Therefore, the 
ligands of these pathways expressed in the muscle are likely to be available to also bind 
receptors in the growing motor axon.  The role of such factors in determining the growth 
pattern of motor axons or in maintaining that growth for the prolonged period required to 
reach distant target muscles, has not been fully explored. 
 
1.1.2  The neuromuscular synapse 
Molecules expressed by the developing muscle are likely to be encountered by the synaptic 
connection between the neuron and muscle in addition to by the growth cone.  While axon 
growth towards the correct target tissue is critical for motor neuron connectivity, the 
development and maintenance of the neuromuscular junction (NMJ) is also essential to 
produce a functional circuitry.  Therefore, muscle derived signals have the potential to play 
multiple roles in neuronal connectivity. 
Due to its large size and the relative accessibility in the periphery the NMJ is the best 
understood of all synapses (Sanes and Lichtman, 1999).  The adult NMJ consists of three cell 
types; the presynaptic neuron, postsynaptic muscle fibres and Schwann Cells which form a 
cap over the synapse.  Synaptic vesicles containing the neurotransmitter Acetylcholine (ACh) 
cluster in dense patches (known as active zones) on the presynaptic membrane positioned 
directly opposite high concentrations of postsynaptic ACh receptors (AChR).  This structure 
allows efficient transmission by ensuring localised neurotransmitter release in a region of 
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receptor expression.  These synaptic structures are clustered into endplate bands in the centre 
of muscle fibres (Sanes and Lichtman, 1999). 
During embryonic development myogenic progenitor cells migrate from the somites to the 
periphery where they divide and differentiate into myoblasts, aligning and fusing to form 
multi-nucleated myotubes.  This migration occurs immediately prior to the growth of motor 
axons into the same region allowing the growth cone to make contact with and form synapses 
upon newly formed myotubes (Sanes and Lichtman, 1999).  Motor axons only branch once 
they have reached their target muscle; a single neuron and the many muscle fibres it 
innervates are known as a motor unit.  Synaptic transmission begins as soon as contact is 
made between the two cells, however efficacy is low as there is little neurotransmitter release 
and AChR are not yet clustered on the post-synaptic membrane.  At the point of myoblast 
fusion AChR subunits have been observed to be expressed at about 1000 per µm2, however in 
the adult, these subunits are found at >10 000 per µm2 in synaptic regions but only 10 per µm2 
a few micrometers away.  This redistribution of AChR is one of the most highly studied 
aspects of NMJ development and was found to require three processes; clustering of AChR 
into the postsynaptic membrane, transcriptional activation of AChR subunit genes in nuclei of 
this region and complimentary transcriptional repression in nonsynaptic nuclei (Sanes and 
Lichtman, 1999; Sanes and Lichtman, 2001).  Clustering of AChR occurs by trapping the 
randomly diffusing receptors rather than by active recruitment.  The neuronal heparin 
sulphate proteoglycan agrin is released into the synaptic cleft, its binding to the postsynaptic 
co-receptor LRP4 leads to dimerisation and activation of muscle specific kinase (MuSK).  
Pathways downstream of MuSK, including activation of RhoGTPases leading to cytoskeletal 
rearrangements lead to AChR (Sanes and Lichtman, 1999; Sanes and Lichtman, 2001).  
Agrin/MuSK signalling has also recently been suggested to drive the localised transcription of 
AChR subunits in the vicinity of the neurons (Jaworski and Burden, 2006).  The 
downregulation of AChR subunit transcription occurs in response to the increased cytosolic 
calcium levels which occur on depolarisation of the muscle in response to AChR activity.  
This produces the highly-localised endplate structures in which an AChR-rich synapse 
opposes the presynaptic neuron in response to neuromuscular transmission (Sanes and 
Lichtman, 1999; Sanes and Lichtman, 2001). 
A number of muscle expressed growth factors have recently been implicated in the initial 
formation of the NMJ in addition to agrin/MuSK signalling.  Wnt ligands are thought to 
interact with MuSK prior to agrin binding leading to the formation of aneural AChR clusters 
observed prior to innervation.  Also GDNF, FGF22, FGF7 and FGF10 from the muscle are 
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thought to act upon the axon in a retrograde manner to induce presynaptic differentiation 
events including synaptic vesicle clustering (Wu et al., 2010).  This evidence suggests that in 
addition to cell intrinsic factors, the formation of the presynaptic region of the NMJ is 
influenced by muscle derived factors and that the neuron can respond to such signals. 
While embryonic motorunits are capable of excitation and muscle contraction there is 
extensive postnatal development of the synapse (Sanes and Lichtman, 1999; Sanes and 
Lichtman, 2001) (Figure 1.1c).  Initially, most muscle fibres are innervated by multiple axons 
which can be observed intertwined above an elliptical uniform plaque of AChRs.  Early in 
postnatal life synaptic/input elimination occurs so that most adult fibres are innervated by 
only one axon.  This elimination occurs by retraction of all but one terminal branch from each 
muscle fibre without any change in the number of motor axons innervating the muscle as a 
whole.  In response to the elimination of inputs AChR density decreases in the corresponding 
regions of the muscle eventually leading to the pretzel like formation of AChR observed in 
the adult.  The terminal arbours of the motor axon branch in the second postnatal week in 
rodents and after this point the structure of the NMJ is maintained.  Growth of the muscle 
after this point occurs by increasing fibre size rather than number and therefore the synapse 
can grow in parallel with the muscle.  As the terminal arbours develop the postsynaptic 
membrane folds increasing the endplate area available for AChR clusters.  At this 
developmental stage the AChR subunits are also observed to change from the embryonic 
(α2βγδ) to the adult (α2βεδ) conformation and their half life in the membrane increases.   
Mature NMJ persist throughout the lifespan of healthy animals and time lapse images have 
shown most endplates to be relatively stable in mouse (Sanes and Lichtman, 1999).  However, 
more recently differences in the maintenance and stability of NMJ in young mice have been 
observed.  While all NMJ appear similar at birth, muscles can be divided between fast and 
delayed synapsing (FaSyn and DeSyn respectively), an intrinsic property dependent on the 
timing of embryonic synapse assembly (Pun et al., 2002).  The different muscle types respond 
to assault (paralysis or denervation) differently; while FaSyn NMJ are resistant, DeSyn 
muscles disassemble the current NMJ and collateral sprouts form which can develop into 
mature NMJ on removal of the stimuli.  The original NMJ on FaSyn muscle can recover 
activity if the assault is removed, however the plasticity of DeSyn muscle appears to make 
them more resilient to disease.  This plasticity gradually reduces in mice older than 6 months 
and the maintenance of all types of synapse becomes less efficient as the animal ages (Figure 
1.1c).  Partially in response to decreasing activity levels, the number of AChRs per junction is 
observed to fall, the junction branches become varicose and some retract leaving vacated 
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synaptic sites in a mechanism similar to synapse elimination (Sanes and Lichtman, 1999).  
This change in the numbers of synaptic sites in the muscle is likely to increase the 
vulnerability of old animals to degenerative diseases. 
While muscle derived factors have been shown to play roles in the embryonic development of 
the NMJ, it remains unknown whether the same factors play a role in the postnatal 
development and maintenance of the synapse.  Whether the signals and downstream 
mechanisms which control initial motor axon outgrowth are the same as those that are 
required for the development and maintenance of the NMJ has not been fully addressed. 
 
1.1.3 Motor Neuron Diseases 
The long-term maintenance of motor axons and their synapses are essential for motor 
function, loss of these connections lead to motor neuron diseases (MND).  The main symptom 
of these progressive neuropathies is muscle atrophy and weakness due to reduced motor 
innervation and stimulation of the muscle.  The outcome of the disease is dependent upon 
which muscles are most severely affected.  Diseases such as Charcot Marie Tooth (CMT) 
disease which predominantly affects the limb are non-fatal, however those that affect the 
diaphragm or intercostal muscles lead to respiratory failure.  Two of the most common fatal 
MND are Amyotrophic lateral sclerosis (ALS) and Spinal muscular atrophy (SMA); while the 
two diseases have some similarities in their symptoms and the manner of motor neuron death 
there are some key differences between them. 
ALS is the most common adult onset MND, with the lifetime risk of developing ALS 
standing at approximately 1 in 400 (Alonso et al., 2009).  Only 5-10% of cases have a familial 
aspect, sporadic cases have been linked to environmental and epigenetic causes, however 
mutations are also seen in genes linked to familial cases (Dion et al., 2009).  Nine causative 
genes have been identified and a further seven Mendelian loci have been linked to the familial 
form of the disease.  The first gene identified as causing ALS was Superoxide dismutase 1 
(SOD1), a ubiquitously expressed cytosolic enzyme which converts superoxide radicals into 
molecular oxygen and hydrogen peroxide.  125 ALS causing mutations in SOD1 have been 
identified.  Mutant SOD1 has many effects upon the motor neuron including oxidative stress 
and defects in axonal transport which lead to toxicity and cell death (Dion et al., 2009).  Many 
studies of ALS have used mutant forms of SOD1, however this gene only accounts for 1-2% 
of all ALS cases and therefore studies of ALS have expanded to encompass other genes.  
DNA/RNA binding proteins have recently been recognised as novel MND causative genes.  
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TAR DNA-binding protein 43 (TDP43) and FUS are multifunctional RNA processing 
proteins, in ALS patients they are observed to mislocate to cytoplasmic aggregates (Neumann 
et al., 2006; Kwiatkowski et al., 2009).  VapB is an ER membrane protein that plays a role in 
protein trafficking.  Mutations in the gene have recently been linked to the formation of 
ubiquitinated protein aggregates and motor neuron cell death in ALS (Chen et al., 2010).  
Additionally mutant forms of VapB have been linked to the rare late onset forms of SMA 
(Nishimura et al., 2004).  However the study of these novel genes is in the early stages and 
how their dysfunction leads to motor neuron cell death is not understood. 
SMA is predominantly childhood (prior to 3 years of age) onset and is the second most 
common form of infant mortality in the western world (1 in 6 000-10 000 live births) (Prior, 
2010).  Unlike ALS, SMA has only been linked to a single causative gene; Survival of Motor 
Neuron (SMN).  Humans have two SMN genes; SMN1 and SMN2 which differ by only five 
nucleotides.  A single C/T transition in exon 7 disrupts a splicing enhancer leading to most 
SMN2 transcripts being aberrantly spliced producing an unstable and rapidly degraded 
protein (Monani et al., 1999).  SMA patients have lost expression of SMN1, while SMN2 can 
partially compensate preventing early embryonic lethality it is unable to maintain healthy 
motor neurons.  The SMN are ubiquitously expressed shRNP assembly proteins, however the 
role RNP play in the disease is not known (Burghes and Beattie, 2009). 
ALS affects both the upper motor neurons projecting from the cortex and the lower motor 
neurons projecting from the spinal cord into the muscle while SMA only affects the lower 
motor neurons.  In addition to muscle weakness, frontotemporal dementia and dysfunction are 
observed in some ALS patients (Murray et al., 2010).  Both ALS and SMA affect the 
innervation of the limb, however the distal muscles which require long motor axons are more 
frequently affected in ALS and the proximal muscles in SMA.  However, despite these 
differences both diseases are described as distal axonopathies due to the mechanism of cell 
death.  The first observable pathologies in both diseases are synaptic abnormalities such as the 
accumulation of neurofilament and a decrease in the number of synaptic vesicles (Murray et 
al., 2010).  These abnormalities and dysfunction of the synapse lead to retraction of the motor 
neuron from the NMJ in a similar manner to postnatal synaptic elimination.  The NMJ of 
DeSyn muscles are more resilient against axon retraction in models of both ALS (Frey et al., 
2000) and SMA (Murray et al., 2008), likely due to their increased plasticity compared to 
FaSyn NMJ.  The loss of functional NMJ leads to the clinical symptoms of MND such as cell 
death in the spinal cord and atrophy of the denervated muscle.  Type I SMA is symptomatic 
from birth suggesting that it might be a developmental rather than a purely neurodegenerative 
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disease (Prior, 2010).  In SMA mouse models with a strong phenotype, accumulations of 
neurofilament and organelles are observed in embryonic axons and only half of synapses are 
occupied by motor neurons at E18.5.  Motor axons were observed to have reduced growth in 
culture however, such a phenotype was not seen in vivo (McGovern et al., 2008).  This 
suggests that motor neurons develop normally and axons grow in SMA, however 
neurodegeneration begins in the embryo. 
As MND originate at the synapse it is likely that a failure in mechanisms which maintain the 
axon and NMJ is likely to play a role in the establishment of diseases in addition to the known 
causative genes.  Therefore, future studies of signals which maintain motor axons and 
synapses as well as those that are involved in their growth and development are likely to shed 
light on the causes of MND.  Additionally, the role of known causative genes in the 
development of MND is not understood, the pathways and mechanisms both up and 
downstream of these proteins are yet to be fully examined.
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1.2 The TGF-β signalling pathway 
The transforming growth factor-β (TGF-β) signalling pathway is critical from the earliest 
stages of mammalian embryonic development.  It regulates events including formation of the 
anterior-posterior axis, cell lineage determination and bone and heart development (Derynck 
and Miyazono, 2008).  Despite the large number of known roles of the pathway, relatively 
few roles have been described in the later embryo, particularly in the nervous system. 
The pathway continues to play essential roles in the adult where it is required for the 
homeostasis of many tissues.  As a consequence, the dysfunction of the pathway has been 
linked to a wide range of diseases and manipulation of TGF-β signalling is thought to have 
therapeutic potential (Derynck and Miyazono, 2008).  Many of the key developmental roles 
of the TGF-β pathway involve the induction of different cell fates driven by the dose-
dependent effects of the pathway in combination with other signalling molecules.  For 
instance the dorsal-ventral patterning of the neural tube is driven by opposing TGF-β 
activities (ventral nodal and dorsal BMP) together with Shh and Wnt signalling (Ulloa and 
Briscoe, 2007).  As TGF-β acts in a dose-dependent manner and abnormal levels of signalling 
leads to disease, the regulation of the pathway is critical.  Many mechanisms of regulation are 
known, however it is likely that some specific regulators have not yet been examined. 
	  
1.2.1 Mechanisms of TGF-β pathway activation 
The TGF-β pathway can be divided into two branches and despite the wide range of cytokines 
that activate these branches and their divergent outcomes, they share key components and act 
by similar mechanisms. 
There are 33 TGF-β cytokines in mammals including TGF-β, Activin, Nodal, bone 
morphogenetic proteins (BMP) and growth and differentiation factors (GDF) (Derynck and 
Miyazono, 2008).  Members of the family are characterised by conserved cysteine residues; 
intermolecular disulphide bridges between these residues produce ligand dimers.  While these 
are mostly homodimers, heterodimers have been observed and in certain situations these act 
in a more potent manner.  The cytokines can be divided into two groups, depending which 
branch of the pathway they activate with the TGF-β, Activin and Nodal ligands in one group 
and the BMP and GDF in the other.  Mature ligands cross the extracellular space and bind to 
two types (type I and type II) of Serine/Threonine Kinase receptors, which form a 
heterotetramer upon ligand binding.  The majority of these TGF-β superfamily receptors are 
about 500 amino acids long, all have an amino-terminal ligand binding 3-finger toxin fold and 
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an intracellular kinase domain.  Type I receptors also have an SGSGSG sequence 
immediately amino-terminal to the kinase domain known as a GS domain.  Upon ligand 
binding the constitutively active type II receptors phosphorylate the type I GS domain, the 
phosphorylated receptor then transphosphorylates and activates target proteins (Moustakas 
and Heldin, 2009). 
In mammals there are five type II receptors; TGF-β receptor II (TβRII), BMP receptor II 
(BMPRII) and AMH receptor II (AMHRII) are specific to TGF-β, BMP and anti-Mullerian 
hormone (AMH) respectively.  Activin receptor II (ActRII) and IIB have broad specificity, 
binding BMP and Nodal in addition to Activin (Miyazawa et al., 2002).  There are seven type 
I receptors which can be divided into three structurally similar subgroups.  Activin receptor-
like kinases (Alk) 4 (also known as ActRIB) is specific for Activin and Nodal, Alk5 (TβRI) 
for TGF-β and Alk7 for Nodal, all three of these receptors activate the receptor (R-) Smad 
proteins 2 and 3.  Alk3 and 6 (BMPRIA and IB) bind to all BMP ligands and activate R-
Smads 1, 5 and 8 which are also activated by the third receptor subgroup; Alk1 binds to TGF-
β and Alk2 binds to BMP 6 and 7.  BMP-type ligands bind to type I receptors with high 
affinity, once this complex has formed it associates with the type II receptors which can then 
phosphorylate and activate the type I receptors.  In contrast, Activin and TGF-β cannot bind 
to isolated type I receptors instead binding tightly to type II receptors before the type I is 
incorporated and phosphorylated (Miyazawa et al., 2002). 
Activated receptors are internalised in clatherin coated pits and incorporated into early 
endosomes which contain membrane-bound proteins such as Smad anchor for receptor 
activation (SARA) and Endofin (Qin et al., 2002; Shi et al., 2007).  These Smad anchors 
present the R-Smads to the active type I receptors which phosphorylate the Smads at a 
conserved SSXS sequence in the C-terminal region.  This releases the phosphor-(P) Smads 
which then form heterotrimers with the Co-Smad, Smad4 (Miyazawa et al., 2002; Shi and 
Massague, 2003).  Smads continually shuttle between the cytoplasm and nucleus, however, 
phosphorylation of R-Smads and the binding of Smad4 shifts the balance towards nuclear 
Smads.  This change is possibly due to a change in the number of exposed nuclear export and 
localisation signals, however a number of other Smad nuclear entry mechanisms have been 
proposed (Moustakas and Heldin, 2009) including the use of shuttling proteins such as Taz. 
Once in the nucleus, Smad3/4 complexes bind to CG-rich regions including the CAGA motif 
in the promoters of target genes.  The most abundant form of Smad2 cannot bind DNA 
directly, however complexes of Smad2 with Smad3 or 4 have been shown to bind CAGA 
sequences and activate target genes (Shi and Massague, 2003).  Smad1, 5 and 8 do not bind 
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CAGA, instead recognising other GC-rich regions with relatively low affinity.  As the 
Smad1/5/8 binding domain is less well defined than that of Smad2/3 many fewer BMP target 
genes have been defined by the presence of binding sites in their promoters (Miyazawa et al., 
2002).  The binding of PSmads to DNA is in general very weak and DNA-binding 
transcriptional co-activators are often required to activate target genes.  PSmad2/3 interacts 
with a large number of such proteins including CBP and p300 (Derynck et al., 1998; 
Massague and Wotton, 2000; Bai and Cao, 2002). The histone acetyl transferase (HAT) 
domains of these proteins loosen nucleosomal structure, easing access of transcription 
machinery and specific transcription factors.  The level of expression of the co-activators and 
specific transcription factors modifies the target genes and role of the pathway in different cell 
types.  It has been suggested that Smad1 contains fewer charged residues than Smad3 
(Miyazawa et al., 2002) reducing the number of DNA-binding co-activators the BMP induced 
PSmads can recruit and therefore limiting its function. 
While the TGF-β pathway generally acts in a Smad dependent manner, some ligand/receptor 
combinations have also been shown to act via non-canonical pathways.  At the tight junctions 
of epithelial cells, TβRI phosphorylates the polarity complex component PAR6 in a TGF-β 
dependent manner.  Phosphorylated PAR6 recruits the E3 ubiquitin ligase Smurf1 to the small 
GTPase RhoA, the ubiquitin dependent degradation of which is critical for tight junction 
dissolution allowing epithelial to mesenchymal transition (Ozdamar et al., 2005).  BMPRII 
has a large cytoplasmic tail of 600 amino acids which is not required for Smad dependent 
signalling.  Instead, it has been shown to bind to the LIM domain of LIM kinase 1 
competitively preventing the activation of the protein.  Ligand binding to BMPRII releases 
LIMK1 and the active kinase phosphorylates targets including Cofilin, the phosphorylation of 
which prevents the depolarisation of actin (Foletta et al., 2003). 
 
1.2.2 Inhibitory regulation of the TGF-β signalling pathway 
The current model of TGF-β activity is that ligands of the pathway act as morphogens; 
concentration gradients of the ligands activate different target genes in a dose-dependent 
manner.  Changes in ligand concentration and subsequent pathway activation of as little as 2-
3 fold are thought to be sufficient to change the fate of a cell under these circumstances (Ashe 
and Briscoe, 2006).  This suggests that tight control of pathway activation is required to 
ensure that the required cell fate is produced.  Additionally, the TGF-β pathway induces 
multiple events essential for embryonic developmental in quick succession, meaning pathway 
activation must be robust yet able to change rapidly in response to a changing environment. 
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Figure 1.2: Regulation of the canonical TGF-β pathway 
(a) The two branches of the TGF-β pathway.  BMP-type ligand dimers bind type I receptors 
while Nodal/activin-type ligand dimers initially bind to type II receptors.  PSmad1/5/8-Smad4 
complexes bind to GC-rich regions in target genes promoter regions while PSmad2/3-Smad4 
binding sites are better defined. 
(b) The TGF-β pathway is regulated at a number of different points, these include: 
i) Ligand traps such as Noggin and Chordin sequester the ligand in the extracellular 
space preventing binding to receptors. 
ii) The specificity of binding can be modified by co-receptors, conversely, decoy 
receptors such as BAMBI prevent type I and II receptors forming active 
complexes (Onichtchouk et al., 1999). 
iii) Smad6 and 7 repress activation of the pathway by preventing R-Smad binding to 
type I receptors, dephosphorylating the receptors and causing their degradation via 
ubiquitination by Smurfs.  
iv) The movement of cytoplasmic Smad and PSmad is a regulated process (Moustakas 
and Heldin, 2009), MAPK mediated phosphorylation of the linker region of Smad 
proteins prevents their nuclear accumulation (Massague, 2003) and ubiquitin 
ligases including CHIP and Ecto also limit the levels of R-Smads (Itoh and ten 
Dijke, 2007). 
v) The shuttling of Smads between the cytoplasm and nucleus are regulated by post-
translational modifications of both the Smads and shuttling proteins such as Taz 
(Moustakas and Heldin, 2009). 
vi) Nuclear co-repressors such as Ski and SnoN prevent activation of target genes. 
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The TGF-β pathway has been shown to be regulated at many different levels (see Figure 
1.2b), from proproteins controlling release and activation of the ligand to post-translational 
modifications regulating Smad entry to the nucleus to the expression pattern of target genes 
(Itoh and ten Dijke, 2007; Moustakas and Heldin, 2009; Umulis et al., 2009).  Many of the 
proteins involved in these regulatory processes are themselves target genes of the TGF-β 
pathway allowing feedback loops to form (Moustakas and Heldin, 2009).  High pathway 
activity increases expression of repressive proteins in negative feedback loops, the repressive 
activity of these proteins reduces their own transcription preventing excessive inhibition.  The 
control provided by such feedback loops reduce the likelihood of extremely high or low 
activity of the pathway, keeping it within the relatively narrow boundaries of intermediate 
activity suitable for target gene activation. 
As it has been proposed that TGF-β receptor activation is dependent upon the highest ligand 
concentration encountered (Dyson and Gurdon, 1998), it seems likely that rapid 
downregulation of pathway activation requires intracellular regulation downstream of the 
receptors.  One such method of intracellular regulation is the action of the inhibitory (I-) 
Smads 6 and 7, which are themselves TGF-β target genes (Itoh and ten Dijke, 2007).  The 
best described role of I-Smads depends on their great structural similarity to R-Smads 
although they lack the SSXS domain phosphorylated by type I receptors.  Therefore, I-Smads 
bound by active type I receptors can not be phosphorylated however, their presence 
competitively prevents the binding and activation of R-Smads.  Smad7 has a broad 
specificity, it binds to all type I receptors (Mochizuki et al., 2004; Moustakas and Heldin, 
2009) while Smad6 shows the highest specificity for the BMP type I receptors BMPRIA and 
IB (Goto et al., 2007; Moustakas and Heldin, 2009).  In addition to competitive repression, I-
Smads have also been shown to inactivate and induce the destruction of the receptor 
complexes, thereby reducing phosphorylation of R-Smads and pathway activation.  Smad7 
recruits the phosphatases GADD34/PP1c to TβRI and PP1α to Alk1, these inactivate the 
receptor complex preventing activation of Smads (Shi et al., 2004; Valdimarsdottir et al., 
2006).  The HECT ubiquitin ligases Smurfs (Smad ubiquitylation regulatory factors) form 
complexes with I-Smads and are targeted to lipid-raft vesicles containing endocytosed active 
receptor complexes.  The I-Smads associate with the receptors leading to Smurf mediated 
proteosomal degradation of both the I-Smads and receptors reducing pathway activity 
(Kavsak et al., 2000).  I-Smads have also been shown to directly bind R-Smads preventing 
recruitment of Smad4 (Hata et al., 1998; Murakami et al., 2003) and to block target gene 
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activation by limiting R-Smad binding to DNA (Zhang et al., 2007) or by recruiting 
transcriptional co-repressors (Bai and Cao, 2002; Lin et al., 2003). 
The Ski family of nuclear oncoproteins have also been shown to downregulate the TGF-β 
transcriptional response.  This family consists of four members; Ski, Ski novel protein (SnoN) 
and two more distantly related proteins; Functional Smad suppressing element on 
chromosomes 15 and 18 (Fussel 15 and 18) (Deheuninck and Luo, 2009).  Unlike the Fussels, 
which are specifically expressed in neurons, Ski and SnoN are found at low levels throughout 
both embryos and adults, although Ski expression peaks occur at specific developmental 
stages.  Although these proteins have no endogenous catalytic activity and cannot directly 
bind DNA, they do form complexes with a number of transcription factors including Smads 
and Gli3 as well as transcriptional co-repressors such as N-CoR and mSin3A (Deheuninck 
and Luo, 2009).  Both Ski and SnoN can repress the Smad2/3 branch (Akiyoshi et al., 1999; 
Stroschein et al., 1999) but Smad1/5/8 signalling is predominantly repressed by Ski (Wang et 
al., 2000).  Ski binds to both PSmad2/3 and Smad4 disrupting the interaction between the two 
Smads (Wu et al., 2002).  This complex is thought to stably bind to target gene promoters, 
however transcriptional co-activators are not recruited, instead co-repressors such as Sin3A 
act to further prevent TGF-β target gene activation (Akiyoshi et al., 1999).  In a similar 
manner to I-Smads, SnoN although not Ski, is itself a target gene of the pathway (Itoh and ten 
Dijke, 2007; Deheuninck and Luo, 2009), therefore the presence of SnoN produces a second 
layer of negative feedback to control the activation of target genes. 
 
Despite the many layers of intracellular regulation, extracellular regulation of the TGF-β 
pathway also plays a role in regulating the transcriptional response and has in fact been 
proposed to be crucial for the production of morphogen gradients.  Computer modelling 
suggests that physiological concentrations of TGF-β ligands should saturate available 
receptors (Umulis et al., 2009).  However, measurements of actual receptor occupancy have 
shown that only 2-6% of available receptors close to the ligand source are bound (Dyson and 
Gurdon, 1998).  This indicates that ligand binding to receptors is regulated, ensuring that the 
majority of ligands do not bind to the first receptors encountered but instead spread through 
the tissue to produce a gradient.  One mechanism that maintains the interactions between 
ligand and receptor within a physiologically-relevant range is extracellular ligand binding 
proteins (traps) such as Noggin and Chordin (Harrison et al., 2005; Gazzerro and Canalis, 
2006; Umulis et al., 2009).  These prevent ligand binding to receptors producing a gentler 
diffusion curve and lowering activation of the pathway close to the ligand source (O'Connor 
et al., 2006).  The ligand is released by binding traps due to cleavage by metalloproteases 
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such as BMP1 or in response to low ligand concentration (Umulis et al., 2009; Zakin and De 
Robertis, 2010).  The activation of the TGF-β signalling pathway and the transcriptional 
responses produced are therefore modified by concentration gradients, not only of the ligand 
but also of ligand binding traps and metalloproteases.  Expression of such proteins close to 
sources of ligand are likely to produce a highly complex pattern of PSmad activity within a 
tissue. 
1.2.3 Positive regulation of the TGF-β pathway 
While feedback loop regulation of the TGF-β pathway is critical to prevent excessive 
activation of the pathway, there are also some circumstances when a cell might require an 
increased response of the pathway.  Some mechanisms of TGF-β pathway enhancement act 
independently of other regulatory mechanisms; for instance Glycosylphosphatidylinositol 
anchored repulsive guidance molecules have been shown to act as co-receptors for BMP2 and 
4 allowing them to activate ActRIIa in addition to BMPRII (Xia et al., 2007).  However, other 
mechanisms act directly to counteract negative feedback loops allowing the cell to maintain 
high levels of pathway activation.  The E3 ubiquitin ligase Arkadia (Akd) plays such a role, 
enhancing target gene expression by decreasing pathway repression. 
Arkadia is a ubiquitously expressed protein, first studied as a factor required for the formation 
of head structures and turning in the early embryo.  Without these key developmental events 
Arkadia null (Akd-/-) embryos die at mid-gestation (Episkopou et al., 2001).  This phenotype 
was observed to be similar to that produced by loss of Nodal.  A genetic decrease in 
embryonic Nodal expression enhances the Akd-/- phenotype (Episkopou et al., 2001) and 
Arkadia enhances Nodal driven mesendoderm differentiation in Xenopus (Niederlander et al., 
2001).  Therefore, it was concluded that Arkadia either directly interacts with or acts in 
parallel to the Nodal signalling pathway.  Loss of Arkadia expression was found to reduce the 
activity of Smad2/3 dependent reporter genes such as CAGA-12, suggesting that as observed 
in the embryo, Arkadia enhances signalling specifically through the Smad2/3 branch of the 
TGF-β pathway (Levy et al., 2007; Mavrakis et al., 2007).  Conversely, levels of PSmad2/3 
were found to be higher in the nuclei of Akd-/- ES cells and embryos than in wildtype cells 
(Mavrakis et al., 2007), suggesting that loss of Arkadia expression should increase the activity 
of Smad2/3 dependent reporters rather than decreasing it.  Together this data indicates that 
Arkadia acts in a complex manner. 
Arkadia has been shown to enhance pathway activity by mediating the degradation of  
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Figure 1.3: Arkadia activates Smad2/3 signalling by derepression 
(a) I-Smads inhibit signalling by a number of mechanisms including recruitment of the Smurf 
ubiquitin ligases to receptor complexes leading to their degradation.  Binding of I-Smads and 
Arkadia to the Axin scaffold complex leads to ubiquitination and degradation of I-Smads 
without any other removal of signalling pathway components.  Removal of I-Smads increases 
the active receptor complexes increasing signalling levels.	  
(b) SnoN prevents activation of Smad2/3 target genes by recruiting transcriptional co-
repressors such as Sin3A.  Arkadia recognises the repressed complex and causes 
ubiquitination of the entire complex.  The complex is recognised by the proteosome and 
degraded allowing fresh active PSmad-Smad4 complexes to bind and activate target gene 
expression. 
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cytoplasmic and nuclear I-Smad6/7 (Koinuma et al., 2003).  The scaffold protein Axin binds 
to Arkadia and sequesters it in the cytoplasm independent of TGF-β pathway activation, as 
Axin also binds Smads, it acts to enhance the interaction between Arkadia and Smad7 leading 
to Smad7 ubiquitination and degradation (Liu et al., 2006) (Figure 1.3b).  Arkadia does not 
appear to ubiquitinate any other proteins in complex with Smad7 and therefore acts purely to 
remove a functional repressor of the TGF-β pathway and increase the levels of PSmad.  
However, while this activity would explain the observed luciferase result it does not account 
for the levels of PSmad2/3 observed in Akd-/- ES cells. 
Arkadia has additionally been shown to bind to both PSmad2/3 (Mavrakis et al., 2007) and to 
the nuclear TGF-β repressors SnoN and Ski (Levy et al., 2007; Nagano et al., 2007), leading 
to their poly-ubiquitination and degradation by the proteosome.  These data lead to a proposed 
model (V. Episkopou, personal communication) in which inactive SnoN/Ski-PSmad2/3 
complexes form on promoter sequences in the absence of Arkadia expression, preventing 
transcription but producing high levels of nuclear PSmad2/3.  Where Arkadia is expressed, 
this complex is cleared from the promoter allowing fresh, active PSmad2/3 to bind and 
activate target genes enhancing the transcriptional response. 
Studies of the structure of the Arkadia protein have shown that the carboxyl-terminal region 
contains the ubiquitin ligase RING-H2 zinc finger domain and a motif known to act as an 
NLS.  Additionally, there is a conserved region just amino-terminal to the RING sequence 
known as the NRG domain (Figure 1.4b) (Mavrakis et al., 2007).  While the RING domain is 
required for the ubiquitination activity of Arkadia (Koinuma et al., 2003), the NRG domain is 
required for binding to the R-Smads, I-Smads, SnoN and Ski and is therefore also essential 
for Arkadia’s activity (Mavrakis et al., 2007; Nagano et al., 2007).  The long (988aa) amino-
terminal of Arkadia is less well understood although it contains two serine rich domains and a 
further 2 nuclear localisation signals.  This region has been shown to bind both Ski and 
Smad7 (Nagano et al., 2007).  The domains located in both terminal regions were found to be 
conserved in Arkadia proteins, not just in mouse and humans but also in invertebrates, 
including Drosophila melanogaster and Caenorhabditis elegans suggesting Arkadia has an 
essential conserved function through evolution (Dixon, 2006). 
While Arkadia acts upon repressors that target both branches of the TGF-β pathway (I-Smads, 
SnoN/Ski), it enhances only the Smad2/3 mediated branch.  This specificity despite the 
similarities between the two branches raised the possibility that a second Arkadia like protein 
exists that acts upon the Smad1/5/8 mediated branch. 
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1.2.4 A second Arkadia protein 
To investigate the possibility that a second Arkadia-like protein exists that can regulate BMP 
signalling a homology search was previously carried out using BLAST (Ensembl Release 35, 
November 2005).  Two regions on mouse chromosome 3 which resemble the cDNA of 
Arkadia were found, however, as these contain frame shift and nonsense mutations they were 
designated as pseudogenes (Figure 1.4a green arrowheads) (Dixon, 2006).  Additionally a 
large genomic region (260kb in mouse) with homology to both the amino and carboxyl 
terminal regions of Arkadia was found on chromosome 18 in mouse (Figure 1.4a, red 
arrowhead) and human.  This locus was named Arkadia2 and found to contain two CpG-
islands which are active promoters, P1, and a further 146kb upstream, the internal P2.  The 
locus is highly complex with many expressed sequence tags (ESTs) (Ensembl Release 57, 
March 2010, some shown Figure 1.4b), 3 polyadenylation (pA) sites and alternative splicing 
between the exons (Dixon, 2006).  Amino-terminal transcripts (Arkadia2N) are produced 
from P1 and end at either pA1 or 2, however no transcripts homologous to full length Arkadia 
ending at pA3, were observed.  Carboxyl-terminal (Arkadia2C) transcripts are produced from 
P2 and contain the E3 RING domain, an NLS and the substrate specificity NRG domain 
found in the carboxyl-terminal of Arkadia (Figure 1.4c).  Arkadia2C transcripts correspond to 
the previously identified RNF165. 
Despite the high similarity in the amino acid sequences of the RING and NRG-TIER domains 
in Arkadia and Arkadia2C, it was found that Arkadia2C could not rescue the Smad2/3 
signalling response (measured by CAGA-12 luciferase activity) in Akd-/- mouse embryonic 
fibroblasts (Figure 1.4d).  This raised the question of whether Arkadia2C acted in the 
Smad1/5/8 mediated branch of TGF-β signalling or functions in a manner unrelated to that of 
Arkadia.  Moreover, as Arkadia plays a critical role in the early embryo, it was proposed that 
Arkadia2C may also have an essential function in vivo. 
 
1.2.5 The TGF-β pathway in axon growth and synapse formation 
In addition to their known roles in the patterning of the nervous system there is increasing 
evidence of a role for the TGF-β ligands in neuronal connectivity.  For instance, non-
canonical TGF-β signalling mediated by the phosphorylation of Par6 has been shown to play 
a role in initial neurite specification and axon outgrowth in cortical neurons (Yi et al., 2010).  
However both the canonical and non-canonical pathways have also been implicated in the 
later stages of axonal growth/guidance and synaptic growth and maintenance. 
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Figure 1.4: Arkadia2  
(a) Ideogram showing significant alignments of the mouse Arkadia cDNA (blue arrow) 
sequence in the mouse genome using BLAST.  Two alignments on chromosome 3 (green 
arrows) are Arkadia-like pseudogenes.  Arkadia2 (red arrow) is located on chromosome 18.  
(b) The Arkadia2 locus (Chromosome 18:E3) showing two promoters (P1 and P2) and a 
number of ESTs including:  8030462N17Rik-202 (1), 8030462N17Rik-201 (2), Rnf165-201 
(3) and ENSMSESTG00000001475 (4) (Ensembl release 57, March 2010). 
(c) Domains of Arkadia are found throughout Arkadia2: serine rich domains (yellow), nuclear 
localization signals (black), Arkadia homology domains (red), NRG-TIER domain (blue) and 
a RING domain (green).  Conservation as indicated. 
(d) CAGA12-luciferase activity in Arkadia-null mouse embryonic fibroblasts transfected with 
GFP, GFP-Akd (GAkd) or GFP-Akd2C (GAkd2C).  Error bars represent ±SEM. N=4 for all. 
**, P<0.001. 
	   37	  
 
 
	   38	  
In addition to the initial patterning of neuron types within the spinal cord the BMP, Shh and 
Wnt ligands also determine the growth of axons from the dorsal commissural neurons 
(dI1).The cell bodies of dI1 are located close to the roofplate, however, their axons grow 
towards the ventral floorplate where they cross the midline and then extend in a rostral 
direction.  Heterodimers of BMP7 and GDF7 produced by the roofplate have been shown to 
act as chemorepulsive cues for commissural axons at much lower concentrations than is 
required to specify cell fate (Butler and Dodd, 2003).  These ligands act through BMPRIB 
(Yamauchi et al., 2008) to both guide the axons in a ventral direction and to slow their growth 
(Phan et al., 2010).  It is thought that the reduced growth rate of these axons ensures that 
growth cones do not reach the position of further guidance cues at a time before the signal is 
fully established as the increased growth rate in response to reduced BMP leads to later 
misdirection.  The pathway downstream of the BMP receptor that determines the route of the 
axons is unknown, however, axonal growth rate is reduced by the non-canonical activation of 
LIMK by BMPRII leading to Cofilin inactivation.  As the axons extend ventrally the effect of 
BMP lessens, although the growth cones are in a region of lower BMP concentration the cell 
bodies remain close to the ligand source, suggesting that BMP receptors remain active in 
these cells.  Phan et al therefore proposed that the cells become desensitised to BMP or that 
the combination of BMP and later guidance cues affects axonal growth in a different manner.  
If this is the case then dI1 neurons change their response to BMP ligands twice over only one 
and a half developmental days.  The GDF7 expression that induces dI1 formation begins in 
the roofplate at E9 (Lee et al., 1998), however by E10.5 some axons have not only grown in a 
ventral direction under the influence of GDF7:BMP7 but have also crossed the midline at the 
floorplate (Helms and Johnson, 1998) and have therefore stopped responding.  This dynamic 
ability of neurons to switch their responses to ligand stimulation over a relatively short time 
allows for pathways which have an inhibitory role early in a neuron’s life to play a different 
role later in development. 
Components and target genes of the canonical TGF-β pathway have also been implicated in 
axonal growth.  The nuclear transcriptional repressor SnoN, itself a TGF-β target gene, was 
found to enhance the growth rate along the entire length of the axon in cerebellar granule cells 
both in vitro and in vivo (Stegmuller et al., 2006).  The complex of SnoN with PSmad2 
appears to act to recruit the E3 ubiquitin ligase Cdh1-APC which ubiquitinates SnoN, leading 
to its degradation and a decrease in axon growth in response to TGF-β pathway activation 
(Stegmuller et al., 2006; Stegmuller et al., 2008).  As binding of SnoN to Smad2 acts to 
repress the TGF-β pathway, it was assumed that SnoN enhanced axonal growth by reducing 
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expression of genes that inhibit axon growth.  However, Ikeuchi et al (Ikeuchi et al., 2009) 
suggest that in neurons SnoN acts as a transcriptional activator recruiting p300 to TGF-β 
responsive target genes.  The actin-binding protein Ccd1, which activates JNK is a “SnoN 
target gene” which may cause the observed increase in axonal growth.  The Inhibitors of 
DNA-binding/Differentiation (Id) genes are direct PSmad1/5/8 target genes (Korchynskyi and 
ten Dijke, 2002; Miyazono and Miyazawa, 2002).  Id1, 2 and 4 all contain a D-box motif 
suggesting that as in the case of SnoN, they are targets of Cdh1-APC.  If Id2 is not degraded it 
induces unrestricted axon growth in cerebellar granule neurons in vitro and in vivo (Lasorella 
et al., 2006) .  It was therefore proposed that a balance of Id2 expression and degradation 
maintains the level of Id mediated inhibition of basic helix-loop-helix transcription factors 
required for axonal growth.  As BMP signalling drives Id expression, it appears that both 
branches of the TGF-β pathway can influence the length of cerebellar granule cell axons.  
Despite the continued study of the roles of TGF-β ligands in axon growth/guidance, they have 
not previously been shown to influence the growth of some of the longest axons in the body 
including the peripheral motor axons. 
While BMP signalling has not been shown to influence motor axon growth, there is evidence 
that it plays a critical role in the growth and maintenance of the Drosophila NMJ.  This role 
of the BMP pathway was first uncovered when it was found that mutations in the BMPRII 
homologue Wishful thinking (Wit) lead to the formation of small NMJ with increased spacing 
between the boutons and impaired synaptic function (Aberle et al., 2002; Marques et al., 
2002).  Further experiments have shown that the precise levels of pathway activation have a 
critical effect on the growth of the NMJ; mutations which reduce activity lead to small 
synapses (Aberle et al., 2002; Marques et al., 2002), while removal of the repressive ubiquitin 
ligase Highwire produces large synapses (McCabe et al., 2004).  The BMP ligand Glass 
bottomed boat (Gbb) from the muscle was shown to activate presynaptic receptors including 
Wit in a retrograde manner leading to Mad phosphorylation (Marques et al., 2002; McCabe et 
al., 2004).  PMad is transported to the nucleus (McCabe et al., 2004) where it can activate its 
target genes including the guanine exchange factor (GEF) Trio.  Trio is the first target gene 
which has been shown to influence actin cytoskeletal dynamics in the synapse by activating 
the Rho GTPase Rac (Ball et al., 2010).  As Rac has prominent roles in axonal growth, 
branching and guidance in addition to synaptic growth, it seems likely that BMP activation of 
Trio might also influence motor neuron development prior to synaptogenesis.  In addition to 
the canonical role of BMP signalling in the development of the synapse, Gbb ligands from the 
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muscle have been shown to be required for NMJ stability acting through the non-canonical 
DLIMK pathway (Eaton and Davis, 2005).   
Whether BMP signalling is required for the growth and maintenance of the mammalian NMJ 
has not been studied.  In particular conservation of mechanisms such as the retrograde 
signalling from the muscle and activation of RhoGTPases would validate the use of 
Drosophila as a model system to study motor neuron development, function and degeneration. 
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1.3 This study: The Role of Arkadia2C and the BMP signalling pathway in motor 
neuron development 
Regulation of the TGF-β pathway is essential to ensure that the appropriate levels of 
signalling response are produced.  The E3 ubiquitin ligase Arkadia activates the Smad2/3 
mediated branch of the pathway by derepression, however a similar regulatory mechanism 
had not previously been described for the Smad1/5/8 branch of the pathway.  Both branches 
of the pathway have been implicated in determining axon growth in the CNS and the 
Drosophila BMP pathway is critical for NMJ development, however the role of Smad1/5/8 
signalling in the mammalian motor neuron remained unknown. 
This project utilised a mouse line in which the ROSAfary genetrap is inserted into the first 
intron of the Arkadia2C gene (Figure 4.1a) in order to study the molecular and functional 
characteristics of the Arkadia homologue.  It was found that Arkadia2C functioned 
specifically in the nervous system, with molecular studies suggesting that it acted to enhance 
BMP signalling.  This was conformed in vivo using genetic interactions.  Arkadia2C null mice 
were found to complete gestation but mostly die prior to weaning (postnatal day 21).  
Examination of the surviving adults showed that they had a motor defect in the forelimb and 
mild hypoxia.  Studies of Arkadia2C null embryos showed there to be reduced motor axon 
growth in the forelimb and diaphragm, the likely cause of the adult phenotype.  Arkadia2C 
adults also showed signs of NMJ degeneration in a similar manner to mouse models of motor 
neuron disease.  PSmad1/5/8 was found in the motor neurons that innervate the limb and 
study of the developing limb suggested that the mesenchyme acts as a potential BMP ligand 
source.  
These data suggest that the Arkadia homologue Arkadia2C acts to derepress signalling 
through the Smad1/5/8 branch of the TGF- β pathway in the mammalian nervous system.  It 
also indicates that such signalling is required for motor axon growth and NMJ maintenance 
and that the system of BMP signalling within the motor neurons is strikingly similar to that 
previously described in Drosophila. 
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2 Materials and Methods 
 
All chemicals were obtained from Sigma-Aldrich unless otherwise stated. 
 
 
2.1 Mice and procedures 
 
2.1.1 Mouse strains 
All mice used in this investigation were maintained in the Central Biomedical Services Units, 
Hammersmith Hospital, Imperial College, UK under the Home Office’s Animals (Scientific 
Procedures) Act 1986. 
Arkadia2C/P9-3f mice were previously produced in-house by the Jonathon Goodwin of the 
MRC Clinical Sciences Centre Transgenic Facility by injection of ES cell lines containing the 
P9-3f genetrap (Fred Hutchinson Cancer Research Center, USA) into 129SVcc blastocysts.  
Other transgenic lines were received as kind gifts. 
 
2.1.2 Transgenic lines 
The Arkadia2C/P9-3f line carry the ROSAFARY genetrap vector inserted into the first intron 
of Arkadia2C to create two fusion transcripts.  The expression of the β-geo transgene, a fusion 
of bacterial β-galactosidase and the neomycin resistance gene, is driven by the endogenous 
Arkadia2C promoter.  These mice were crossed to produce homozygous mice on 129SVcc, 
CD1 and C57BL/6 backgrounds. 
Mice carrying the Hb9-eGFP reporter in a FVB genetic background (Liem et al., 2009) 
express GFP in the cell bodies, axons and dendrites of motor neurons.  These mice were used 
to visualise motor neuron axon growth throughout embryonic development in both Arkadia2C 
mice and offspring of genetic interactions. 
6 further lines were bred with Arkadia2C mice in genetic interaction studies.   Nodal-LacZ 
mice have the β-geo transgene in place of the second exon, leaving all regulatory elements 
intact (Collignon et al., 1996).  The Smad8-LacZ mice contain a β-galactosidase-polyA 
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cassette in the ATG-containing exon 2 (Arnold et al., 2006).  Homozygous Smad8-LacZ mice 
appear normal and are fertile, therefore mice were maintained as homozygotes.  A lacZ gene 
containing a nuclear localization signal was fused in frame to the start codon of the β-catenin 
gene, replacing sequences encoding the NH2-terminal domain and armadillo repeats 1–4 
(Huelsken et al., 2000) to create the β-cateninlacZ mice used.  The ATG-containing exon 1 of 
Smad4 was removed by gene targeting (Chu et al., 2004) to create mice heterozygous for a 
Smad4 null allele.  SnoN mutant mice were created using the ES cell line RRH119 from 
BayGenomics, the genetrap vector pGT0Lxf was inserted into intron1 of SnoN.  Homozygous 
RRH119 mice are viable and fertile, therefore mice were maintained as homozygotes.  Exons 
4 and 5 of BMPRII, which encode the transmembrane domain and the amino-terminal region 
of the kinase domain, was replaced with a construct of SA IRES/LacZ/loxP/pgk neo/lox 
(Beppu et al., 2000) to create a BMPRII null allele.  The first two exons of BMPRIa were 
replaced with a neomycin-resistance expression cassette (Mishina et al., 1995; Mishina et al., 
2002) to create a BMPRIa null allele. 
 
2.1.3 Scoring of phenotypes in offspring from genetic interactions 
Pups were counted less than 24 hours after birth and scored for the presence of a clenched 
paw phenotype, the increasing severity of the phenotype prior to weaning was also recorded.  
Dead pups were genotyped, any that were counted at birth but not found on a later day were 
scored as “missing”.  At least 100 pups from each cross were genotyped and data was 





2.2.1 Embryo recovery 
Mice were maintained on a 12 hour light, 12 hour dark cycle.  Mice were mated and noon of 
finding a vaginal plug was designated as Embryonic Day (E) 0.5.  Pregnant females were 
sacrificed on the day required for the procedure, the uterus was removed and embryos were 
dissected in cold PBS.  Embryos were processed according to the appropriate protocol. 
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2.2.2 X-gal staining  
2.2.2.1 X-gal stain of wholemount embryos and sections to examine Arkadia2C 
expression 
Tissue was fixed on ice for between 10 (E6.5 embryos) and 60 minutes (adult brain) in X-gal 
Fixative (0.2% glutaraldehyde, 2% formaldehyde, 5mM EGTA, 2mM MgCl2 in 0.1M sodium 
phosphate buffer (pH7.3)). 
Tissue to be sectioned was washed in PBS, embedded in 4% (w/v) agarose in PBS and 
vibratome sections of between 80 and 250µm were made. 
Both sections and whole embryos were rinsed in X-gal Rinse (0.2% Igepal CA-630, 0.1% 
Sodium Deoxycholate, 2mM Mg Cl2 in 0.1M sodium phosphate buffer (pH7.3)) before 
staining to a dark blue in X-gal Stain (1mg/ml X-gal (5-bromo-4-chloro-3-indolyl-β-D-
galactosidase), 5mm K4Fe(CN)6-3H2O, 5mM K3Fe(CN)6 in X-gal Rinse).  Tissue was then 
briefly rinsed and post-fixed overnight at 4 ºC.  Tissue was washed in PBS and cleared 
through a glycerol series (25, 50 and 80% in PBS) prior to imaging. 
 
2.2.2.2 X-gal stain and immunohistochemistry to examine Smad8 expression 
Embryos were fixed at room temperature for 10 minutes in X-gal Fixative.  Embryos were 
washed thoroughly in X-gal Rinse before staining overnight at room temperature in X-gal 
Stain.  Stained embryos were washed and post-fixed at room temperature for 30 minutes 
before embedding in 4% (w/v) agarose, vibratome sections of 100µm were made. 
Sections were rinsed in H2O and endogenous peroxidase activity was quenched by incubation 
in 1%H2O2 for 20 minutes, after washes in H2O and TBS (8mg/ml NaCl, 200µg/ml KCl, 
25mM Tris Cl (pH7.5) in water) the sections were blocked for 30 minutes in 5% Albumin 
from bovine serum (BSA) in TBS, 0.1% Triton X-100 (TBSTX).  Sections were incubated in 
antibodies in the blocking media at 4ºC overnight.  Rabbit anti-FoxP1 was used at 1:32000, 
Rabbit anti-Isl1 at 1:4000 (gifts from T. Jessell) and Rabbit anti P-Smad1/5/8 (Cell Signaling) 
at 1:500. 
The antibody was detected using the Ultra Sensitive ABC Peroxidase Kit (Thermo Scientific).  
Sections were washed in TBS and incubated in biotinylated secondary antibody in 1% 
Normal Goat Serum (NGS) or BSA in TBSTX for 30 minutes at room temperature.  
Biotinylated Goat anti-Rabbit (Thermo Scientific) was used at 7µg/ml.  Sections were washed 
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in TBS, incubated for 30 minutes in ABC reagent, washed and developed in 1X Metal 
Enhanced DAB Substrate (Thermo Scientific) for approximately 10 minutes until staining 
was visible.  Sections were rinsed in H2O and cleared through a glycerol series before 
mounting with Glycerol Gelatin (Sigma Aldrich). 
 
2.2.3 Wholemount in situ Hybridisation  
2.2.3.1 Embryo fixation and processing 
All steps for E6.5-8.5 embryos were carried out in Transwell netwells with a 12µm mesh in 
12 well plates (Corning Inc.).  Embryos were fixed overnight in fresh 4% paraformaldehyde 
(PFA), washed three times in PBS, 0.1% Tween-20 (PBT) and dehydrated through a MeOH 
series (25, 50, 75 and 100% in PBT).  Embryos were stored for up to two months at -20 ºC.  
Embryos were rehydrated through a reversed MeOH series, washed in PBT and bleached for 
1 hour at room temperature in 6% H2O2.  Embryos were washed three times in PBT and 
incubated in 10µg/ml proteinase K for the following times: 10 minutes for E6.5 and E7.5, 15 
minutes for E9.5, 30 minutes for E11.5, 37 minutes for E12.5 and 45 minutes for E13.5.  The 
proteinase K was inactivated in 2mg/ml glycine in PBT for 5 (E9.5 and younger) or 10 
minutes at room temperature and embryos were washed twice in PBT.  Embryos were post-
fixed for 20 minutes in 4% PFA+0.1% glutaraldehyde in PBT and washed twice in PBT for 5 
minutes. 
 
2.2.3.2 Hybridisation of riboprobe and incubation with anti-DIG antibody for E6.5-9.5 
embryos 
Embryos were pre-hybridised in Prehyb buffer (50% Formamide, 5xSSC, 0.1% Tween-20, 
50µg/ml Heparin in water) at 70 ºC for 5 hours. 0.2µg/ml of probe was added to pre-warmed 
Hyb buffer (8µg/ml tRNA, 8µg/ml herring sperm in Prehyb buffer) and denatured at 70 ºC for 
10 minutes prior to adding to the embryos.  Hybridisation was carried out at 70 ºC overnight 
on a rocking platform. 
The following day embryos were washed twice for 30 minutes at 70 ºC in Solution I (50% 
formamide, 4xSSC, 1%SDS in water) , once for 10 minutes at 70 ºC in SolutionI:SolutionII 
(500mM NaCl, 10mM Tris Cl (pH7.5), 0.1% Tween-20 in water) and three times for 5 
minutes at room temperature.  The embryos were then washed twice in Solution III (50% 
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formamide, 2XSSC in water) at 65ºC for 30 minutes and three times in TBS, 0.1% Tween-20 
(TBST) for 5 minutes.  Embryos were blocked in 10% heat–inactivated sheep serum in TBST 
at room temperature and incubated in 1:2000 anti-DIG FAB (Roche Diagnostics) in 1% heat–
inactivated sheep serum in TBST overnight at 4ºC.  The following day embryos were washed 
for 1 hour at room temperature 6 times and then overnight at 4 ºC. 
 
2.2.3.3 Hybridisation of riboprobe and incubation with anti-DIG antibody for E11.5-
13.5 embryos 
Embryos were rinsed once in 1:1 PBT:Hybridisation Buffer (50% formamide, 1.3XSSC, 
5mM EDTA, 50µg/ml Yeast RNA, 0.2% Tween-20, 0.5% CHAPS, 100µg/ml Heparin in 
H2O) until they settled, rinsed in pre-warmed Hybridisation Buffer until they settled and then 
pre-hybridised in Hybridisation Buffer for 5 hours at 70ºC.  This was replaced with fresh pre-
warmed Hybridisation Buffer containing 0.1-0.2µg/ml probe and embryos were rocked at 70 
ºC overnight. 
The following day embryos were washed twice in pre-warmed Hybridisation Buffer for 30 
minutes at 70ºC, once for 20 minutes at 70ºC in 1:1 Hybridisation Buffer:TBST.  The 
embryos were then rinsed twice and washed twice for 30 minutes in TBST at room 
temperature before rinsing twice with MABT (100mM Maleic acid, 150mM NaCl, 1% 
Tween-20).  Embryos were blocked in 10% heat–inactivated sheep serum in MABT for 1 
hour at room temperature and incubated in 1:2000 anti-DIG FAB (Roche Diagnostics) in 
fresh 10% heat–inactivated sheep serum in MABT overnight at 4ºC.  The following day 
embryos were washed for 1 hour at room temperature 6 times and then overnight at 4 ºC. 
 
2.2.3.4 Signal detection 
Embryos were washed for 10 minutes three times in NTMT (100mM NaCl, 100mM Tris Cl 
(pH9.5), 50mm MgCl2, 0.1% Tween-20 in H2O) and then incubated in the dark in BM Purple 
(Roche Diagnostics) + 0.1% Tween-20 until the colour had developed. 
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2.2.4 Immunofluorescence 
2.2.4.1 Whole-mount antibody staining of forelimb innervation  
E11.5-13.5 Hb9-eGFP embryos were recovered, eviscerated and pinned ventral side down on 
Sylgard 184 Silicone Elastomer (Dow Corning) plate.  Tissue was taken for genotyping and 
skin was removed from the forelimbs of E13.5 embryos.  Embryos were fixed in 4% PFA 
overnight at 4ºC, washed three times in PBS and bleached overnight at 4ºC in Dent’s Bleach 
(5 parts 37% H2O2: 2 parts DMSO: 8 parts MeOH).  Embryos were washed five times in 
MeOH and fixed overnight at 4ºC in Dent’s Fix (1 part DMSO: 4 parts MeOH), some 
embryos were stored in Dent’s Fix at 4ºC for up to 14 days. 
Embryos were rinsed and washed a minimum of 3 hours in PBS.  Primary antibodies were 
diluted in blocking serum (5% heat inactivated normal goat serum, 75% PBS, 20% DMSO): 
1:500 rabbit anti-GFP (Invitrogen, A11122) and 1:500 mouse anti-my-32 myosin (Sigma, 
M4276).  Embryos were incubated in primary antibody at room temperature for 3 days. 
Embryos were rinsed and washed in PBS for 5 hours. Secondary antibodies were diluted in 
blocking serum: 1:500 Alexa-488 anti-rabbit and 1:500 Alexa-568 anti-mouse (Invitrogen).  
Embryos were incubated in secondary antibody in the dark at room temperature overnight. 
Embryos were rinsed and washed in PBS for 5 hours, for 5 minutes in 1:1 PBS:MeOH and for 
three 20 minute periods in MeOH.  The embryos were rinsed in 1:1 MeOH:BABB (1 part 
benzyl alcohol: 2 parts benzyl benzoate), cleared in BABB and stored at 4ºC. 
 
2.2.4.2 Whole-mount antibody staining of diaphragm innervation 
Diaphragms from E16.5-P18 pups were dissected, excessive connective tissue and bone 
removed and tissue taken for genotyping.  The diaphragms were gently stretched, pinned out 
on a Sylgard 184 plate and fixed in 0.1% PFA at 4ºC overnight followed by fixation in 1% 
PFA at room temperature for 90 minutes.  Tissue was washed twice for 10 minutes in PBS 
and excess aldehyde was quenched in 0.1M glycine for 15 minutes at room temperature. 
The diaphragms were returned to PBS and all connective tissue was carefully removed.  
Tissue was blocked for 1 hour at room temperature in Blocking Solution (2% BSA, 4% NGS 
in PBT), primary antibody was diluted in Blocking Serum: 1:1000 rabbit anti-neurofilament 
(Chemicon) and 1:100 anti-synaptophysin (Zymed/Invitrogen) and tissue was incubated in 
antibody for 2 hours at room temperature followed by an overnight incubation at 4ºC. 
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The diaphragms were washed for 3 hours in PBT.  Tissue was incubated in the dark overnight 
at 4 ºC in 1:250 Alexa-568 anti-rabbit and 1:250 Alexa-488 α-Bungarotoxin in Blocking 
Serum.  The diaphragms were washed for 3 hours in PBT before rinsing in PBS and post-
fixed in 1% PFA for 10 minutes at room temperature.  The tissue was again washed in PBS 
before all remaining bone was removed and the diaphragms were mounted on Superfrost 
slides (BDH) using Vectashield (Vector labs). 
 
2.2.4.3 Antibody staining of spinal cord sections 
E11.5-13.5 embryos were recovered, eviscerated and fixed in fresh 4% PFA for 2 hours on 
ice.  The ventral vertebrae in the brachial and thoracic regions were removed from E13.5 
embryos to increase penetration of the fixative.  Embryos were extensively washed in PBS 
and cryoprotected in 30% sucrose in PBS overnight at 4ºC before being embedded in Tissue 
Freezing medium (Jung) and stored at -80ºC. 
14µm cryosections were cut and mounted on Polysine slides (VWR).  After air-drying slides 
were rehydrated in PBS and blocked using 1% BSA in 0.1% Tween-20 in PBS for 10 
minutes.  Primary antibody was diluted in 0.1% BSA in PBT, slides were incubated overnight 
at 4 ºC.  Rabbit anti-FoxP1 was used at 1:32000, Guinea pig anti-FoxP1 at 1:16000, Rabbit 
anti-Isl1 at 1:4000, Guinea pig anti-Hb9 at 1:16000 and Rabbit Lim3 at 1:4000 (all gifts from 
T. Jessell).  Rabbit Pea3 was used at a concentration of 1:5000 (gift from S. Arber), rabbit anti 
P-Smad1/5/8 (Cell Signaling) at 1:500, goat anti-nNos (Abcam) at 1:500.  
Slides were washed in PBS and blocked for 1 hour at room temperature in 1% normal goat 
serum or, in the case of a goat primary antibody, 1% BSA in PBT.  Appropriate Alexa Flur 
secondary antibodies (Invitrogen) were added to the blocking medium and slides were 
incubated in the dark at room temperature for 1 hour.  Slides were washed in PBS before 
mounting with Vectashield with DAPI (Vector labs). 
 
2.2.4.4 Confocal acquisition  
Confocal images of diaphragm innervation were captured on a Leica SP1 inverted microscope 
through either a 10x/0.3NA dry or a 63x/1.32-0.6NA objective.  For 10x images stacks were 
taken at 2µm intervals while 63x images have stacks at 10µm intervals.  Stacks were 
reconstructed using the downloadable package ImageJ. 
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Confocal images of forelimb innervation and spinal cord sections were captured on a Leica 
SP5 inverted confocal microscope through either a 10x/0.4NA dry, 20x/0.7NA dry or a 
40x/1.25-0.75 oil objective.  Image stacks of the forelimb were taken at 5µm intervals, 
multiple stacks overlapping in the XY plane were taken of limbs at E13.5 and stacks were 
stitched together using Xuv Tools or, latterly, Leica LAS AF software.  Stacks were then 
reconstructed using ImageJ. 
Image stacks were taken at a ventral location within the diaphragm muscle to prevent 
secondary nerve branches complicating measurements.  Stacks were flattened and axons were 
traced from the edge of the phrenic nerve to synapses towards the outer edge of the endplate 
chosen at random using Neuron J.  15 terminal branches were measured per image stack (1 wt 
and 2 Akd2C-/- diaphragms at E17.5, 2 wt and 2 Akd2C-/- diaphragms at P17). 
 
2.2.5 Recovery of tissue for RNA extraction 
2.2.5.1 E11.5 brain 
E11.5 embryos were recovered and tissue taken for genotyping.  The brain was removed and 
washed in cold PBS before addition of 350µl of buffer RLT (Qiagen RNeasy kit) and 
homogenisation using a 27g needle.  Samples were snap frozen on dry ice and stored at -80ºC 
until genotyping was complete. 
2.2.5.2 E13.5 ventral brachial spinal cord 
E13.5 Hb9-eGFP embryos were recovered, eviscerated in cold PBS and tissue taken for 
genotyping.  The spinal cord was dissected from the hindbrain to the caudal end of the 
thoracic region and the dorsal root ganglia and meninges were removed.  The tissue was 
flattened to create an open book preparation and observed under a fluorescence microscope.  
GFP expression in motor neurons was visible throughout the ventral spinal cord, however the 
brachial LMC was visible as a thickening of the GFP expressing domain.  The LMC 
containing region was removed from flanking rostral and caudal tissue and the dorsal region 
which did not express GFP.  The brachial motor pools and the corresponding dorsal region 
were then each added to 350µl of buffer RLT and vortexed for 30 seconds before snap 
freezing. 
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2.2.5.3 E15.5 diaphragm muscles 
E15.5 embryos were recovered and tissue taken for genotyping.  The skin and internal organs 
were removed leaving the ribs intact before the diaphragm was removed from the bone.  The 
diaphragm was washed in cold PBS, added to 350µl of buffer RLT and homogenised using a 
27g needle before snap freezing. 
 
2.2.5.4 Embryoid bodies 
Embryonic stem cells were differentiated towards a motor neuron cell fate using a protocol 
adapted from (Wichterle and Peljto, 2008)  (Efstathia Thymiakou and Vasso Episkopou).  
After exposure to BMP4, Noggin (R&D Systems) or Dorsomorphin (Calbiochem) for the 
required period, embryoid bodies were collected, washed in PBS and snap frozen in buffer 
RLT (350µl of buffer per dense 96mm plate). 
 
2.3 Analysis of post-natal phenotypes 
 
2.3.1 Test for hypoxia 
Mice (older than 17 days) were placed in a warming box set to 39ºC for 15 minutes, animals 
were not otherwised stressed or made to exercise.  Tails were cut approximately 0.75cm from 
the tip after aneathisisation and blood allowed to flow into an eppendorf.  Samples were spun 
for 15 minutes at 4000rpm at room temperature.  The clear plasma layer was removed and 
stored at -20ºC. 
L(+)-lactate levels in the blood plasma were measured using a Lactate Colorimetric Assay Kit 
(Abcam), the resulting colour was detected by spectrophotometry at OD = 450 nm.  Blood 
plasma was diluted 1/10 in lactate assay buffer to produce concentrations within the range of 
the standard provided. 
 
2.3.2 Tests of grip and strength 
2.3.2.1 Cage lid test 
The protocol was adapted from (Papaioannou and Behringer, 2005).  An adult mouse was 
placed on the wire cage lid.  Once the mouse had gripped the bars the lid was inverted and 
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held over the cage at about 25 cm, it was gently rotated so that the mouse always had its belly 
to the sky.  The time taken for the mouse to fall was measured starting as the cage lid was 
inverted and ending when the mouse landed, with a cut-off time of 60 seconds.  If the mouse 
fell within the first 10 seconds it was assumed not to have gripped the cage lid and the test 
was repeated, if the second time was also within 10 seconds an average time was recorded, if 
10 seconds was exceeded the longer time was recorded.  The timing of the test was subjective 
and therefore no other researcher carried out the test.  Two tests were carried out 30 minutes 
apart; this was repeated at weekly intervals at least three times.   
Results are shown as mean hang time for each individual mouse ± standard error mean.  To 
check for increasing phenotype severity as Akd2C/Smad8 animals aged the protocol was 
carried out weekly for 6 months. 
 
2.3.2.2 Grip strength meter 
The protocol was adapted from The Jackson Laboratory Website.  Forelimb grip strength was 
measured using a horizontal Grip Strength Meter (Ugo Basile).  Mice were not trained prior to 
a single test of 5 consecutive trials with a 60 second rest period between each trial.  Adult 
mice were held by the tail and lowered towards the apparatus until they grasped the parallel 
bar with both forepaws.  Mice were then pulled backwards in the horizontal plane and the 
force applied to the bar (g) at the moment of grasp release was recorded by the machine.  The 
force excerted to pull the mouse backwards and the point chosen for the start of this force 
(once the mouse had gripped the bar) were subjective and therefore no other researcher 
carried out the test.  The mice were weighed and the force exerted normalised to the mass of 
each individual.  The minimum, mean and maximum forces exerted by each individual mouse 
were analysed. 
 
2.3.3 Tests of balance and motor co-ordination 
2.3.3.1 Rotarod 
The protocol was adapted from Chao et al., 2010.  Adult mice were acclimatised to the 
rotarod apparatus (Harvard Apparatus) for approximately 15 minutes each day of testing.  Six 
trials were carried out over two days one week apart with a 30 minute rest interval between 
trials.  Each trial lasted for a maximum of 5 minutes, during which the rod accelerated linearly 
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from 4 to 40 rpm.  The number of seconds the mouse balanced on the rod before falling was 
recorded.  Results are shown as mean time on the rod for each individual animal ± standard 
error mean. 
 
2.3.4 Tests of gait and posture 
2.3.4.1 Pawprint analysis 
The fore or hindpaws of the mouse were painted with black food colouring and the mouse 
was placed in an enclosed path of 30cm ending in an enclosed dark space with a paper floor.  
Animals that produced clear prints were tested once, animals that moved abnormally slowly 
or fast or with an abnormal gait were tested a second time to check for sustained behaviour. 
The resulting pawprints were then analysed using some of the parameters described in 
Klapdor et al., 1997: stride length, stride width, foot length, toe spread and the spread of their 
inner toes. 
 
2.3.5 Study of muscle size, atrophy and innervation 
2.3.5.1 Recovery of muscles from adult mice 
Mice were exsanguinated with 5ml  PBS and perfused with 20ml fresh 4% PFA under 
terminal anaesthetic (1:1:3 by volume Hypnorm(VetaPharma):Midazolan(Hameln):H2O).  
Excessive fat and connective tissue were removed and individual forelimb extensor muscles 
were dissected out.  The muscles were washed in PBS, photographed, cryoprotected in 30% 
sucrose in PBS overnight at 4ºC and embedded in Tissue Freezing medium (Jung) prior to 
storage at -80ºC. 
 
2.3.5.2 Haematoxylin and Eosin staining 
25µm transverse cryosections of muscle were rinsed in distilled H2O and stained for 5 
minutes in 1X Gill’s Haematoxylin (Biostain Ready Reagents).  Slides were rinsed in tap 
water until it ran clear, dunked 2-3 times in Acid Alcohol (1%HCl in 70% EtOH), rinsed in 
tap water then slowly dunked in Ammonia Water (0.1% NH4OH).  Slides were further 
washed in tap water and counterstained with 1% aqueous Eosin Y (Biostain Ready Reagents) 
for 1 minute, rinsed again in tap water and dehydrated through steps of 95% and 100% EtOH.  
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Sections were cleared in xylene and mounted using VectaMount (Vector Laboratories).  
Images were taken on a stereomicroscope (Leica) and all cells scored.  Cells were counted as 
containing central nuclei if the dark nucleus was observed to not be touching the darkly 
stained cell membrane. 
 
2.3.5.3 Antibody staining of synapse innervation in adult muscle 
25µm longitudinal cryosections of muscle were blocked for 90 minutes in 4% BSA, 2% NGS 
in PBS, 1% Triton X-100 and incubated at 4ºC overnight in 1:1000 rabbit anti-neurofilament 
(Chemicon) and 1:100 anti-synaptophysin (Zymed/Invitrogen).  The following day the slides 
were washed in PBS and incubated for 1 hour at room temperature in 1:1000 Alexa-488 anti-
rabbit and 1:500 Alexa-555 α-Bungarotoxin.  The slides were washed in PBS and mounted 
using Vectashield with DAPI (Vector Laboratories).  Consecutive sections were imaged using 
the SP5 confocal and the density of synapses within them counted. 
 
2.4 Molecular biology 
 
2.4.1 Genotyping of transgenic mouse lines by PCR 
2.4.1.1 The standard PCR reaction 
Tissue was digested in 1mg/ml Fungal Proteinase K (Invitrogen) in GNK buffer (10mM Tris 
HCl, 1.5mN MgCl2, 50mMKCl, 0.01% Gelatin, 0.45% Igepal CA-630, 0.45% Tween 20) 
overnight at 52ºC.  The proteinase was inactivated for 10 min at 95ºC and samples were 
stored at -20ºC. 
PCR reactions were set up using the GoTaq Flexi DNA Polymerase kit (Promega), 1µl DNA 
was added to a total volume of 20µl (4µl 5X GoTaq Flexi Buffer, 1 mM MgCl2, 0.5µM each 
primer (Sigma-Genosys, see Table 2.1), 60 µM of each dNTP (Promega)). 
PCR was performed using a Peltier Thermal Cycler (MJ Research), most primer sets used the 
following reaction: initial denaturation at 94°C  for 5 minutes, followed by 39 cycles of 94°C 
for 30 seconds, 58°C for 60 seconds and 72°C for 90 seconds with a final elongation step of 5 
minutes at 72°C.  The BMPRII reaction was modified to have 35 cycles of 45 seconds at each 
of 94°C, 62°C and 72°C.  
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The resulting PCR products were size-fractionated by electrophoresis in 1.5% (bands larger 
than 250bp) or 2% (bands smaller than 250bp) agarose gels containing ethidium bromide and 
visualised under UV light. 
 
2.4.2 Quantitative and semi-quantitative PCR 
2.4.2.1 RNA production 
RNA was produced using the RNeasy mini and micro kits with on column DNase digestion 
(Qiagen) as per the manufacturers instructions.  Briefly, frozen samples in RLT buffer were 
defrosted at 37 °C and vortexed for 30 seconds.  Samples diluted in 70% ethanol were added 
to the RNeasy column and washed in buffer RW1 prior to 15 minutes on column RNase-free 
DNase digestion.  Columns were further washed in buffers RW1 and RPE, with an additional 
80% RNase-free ethanol wash in the case of micro-RNeasy columns, prior to air-drying.  The 
RNA was resuspended in RNase-free water, concentration was measured using a NanoDrop 
1000 Spectrophotometer (Thermo Scientific) and samples were stored at -80°C. 
 
2.4.2.2 cDNA production 
cDNA was produced from RNA using the SuperScript III First Strand Synthesis System for 
RT-PCR (Invitrogen) as per the manufacturer’s instructions.  Briefly, to denature 1µg RNA, 
125ng of random hexamers and 1mM of dNTP in a total volume of 25µl was incubated at 
65°C for 5 minutes.  1x RT buffer, 5mM MgCl2, 10mM DTT, 100U RNase OUT and 500U 
SuperScript III RT were added and the mix was incubated at 25°C for 10 minutes to allow 
annealing of the random hexamers, cDNA synthesis was carried out at 50°C for 75 minutes 
and the reaction was terminated at 85°C for 5 minutes.  5U of E. coli RNase H was added to 
each sample and the RNA was digested at 37°C for 20 minutes.  cDNA was stored at -20°C. 
2.4.2.3 Semi-quantitative PCR 
PCR reactions were set up using the GoTaq Flexi DNA Polymerase kit (Promega) as 
described in 2.4.1.1 and PCR was performed using a Peltier Thermal Cycler (MJ Research).  
The standard reaction was 94°C for 5 minutes followed by 21-33 cycles (see Table 2.2) of 
94°C for 30 seconds, 58°C for 60 seconds and 72°C for 90 seconds, all reactions had a final 
elongation step of 72°C for 10 minutes.  
 
	   55	  
Table 2.1: Primers for genotyping PCRs  
 
All samples were precisely loaded onto a 2% gel and run in fresh 1X TAE.  The intensity of 
bands was estimated using GeneTools software (Syngene) and samples were approximately 
normalised using GAPDH levels prior to the study of other genes.  The intensity of GAPDH 






Product size Sequence 














β-catenin 287bp (wildtype) 













Smad8 192bp (wildtype) 




Smad4 625bp (wildtype) 
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Table 2.2: Primers for semi-quantitative PCR 




GAPDH Forward AACTTTGGCATTGTGGAAGG 
GAPDH Reverse ACACATTGGGGGTAGGAACA 
21 223 
BMP4 Forward GCTGGGCCGCAAGAAGTTCG 
BMP4 Reverse GTTCCTCCACGGCTTCTTCGTGA 
27 278 
BMP4 Forward TGAGGGATCTTTACCGGCTCCA 
BMP4 Reverse GATCACCTCATTCTCTGGGATGC 
27 215 
BMP5 Forward CCACATGGAGAAGCAGTGSCAGCAG 
BMP5 Reverse TTTACATTGATGGCTGCGGCCATCCC 
27 189 
BMP6 Forward GCTGCTGAGTTCCGCGTCT 
BMP6 Reverse GACGTGGAGTCCATCCCGAGTC 
27 261 
BMP7 Forward AGCACTCAGGCAGGGAGTCGGA 
BMP7 Reverse CTTGGAGCGATTCTGGCTGCG 
27 317 
 
2.4.2.4 SYBR-green Quantitative-PCR  
A reaction mix of 1X QuantiTect SYBR Green PCR Master Mix (Qiagen), 300nM of each 
primer (see Table 2.3) and DNA in a total volume of 30µl per well was used.  PCR 
amplification was carried out on a CFX Real time system (BioRad) and analysed using 
BioRad CFX Manager.  The reaction was: 95°C for 15 minutes followed by 46 cycles of 94°C 
for 15 seconds, 55°C for 30 seconds and 72°C for 30 seconds with a full plate read of DNA 
concentration after each cycle.  This was followed by a melt curve from 55-94°C with 
increments of 0.3°C. 
 
2.4.2.5 Taqman Quantitative-PCR  
A reaction mix of 1X Taqman Universal PCR Master Mix, 1X Taqman probe (both Applied 
Biosystems, see Table 2.4) and cDNA in a total volume of 30µl. PCR amplification was 
carried out on a CFX Real time system (BioRad) and analysed using BioRad CFX Manager.  
The reaction was: 50°C for 2 minutes and 95°C for 10 minutes followed by 42 cycles of 95°C 
for 15 seconds, 55°C for 60 seconds, and a plate read.   
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Table 2.3: Primers for quantitative PCR 
Primer name Sequence 
GAPDH Forward AACTTTGGCATTGTGGAAGG 
GAPDH Reverse ACACATTGGGGGTAGGAACA 
YWHAZ Forward GTATTGAGCAGAAGACGGAA 
YWHAZ Reverse ATAGAAGACTTTCCTTTCTGGTT 
Akd2C Exon 1-2 Forward TCTCGTGCTTCCAGTGTTTG  
Akd2C Exon 1-2  Reverse GGTCAGCGACTGGTGCAG 
Akd2C Exon 3-3 Forward TCTCGCATCCCAGGCGGAAT 
Akd2C Exon 2-3 Reverse GGGCTGAGGTGTCTGCAGTTG 
Akd2C Exon 7-8 Forward GGAAGATGTGAGACGCCTACC 
Akd2C Exon 7-8 Reverse TCAGCTGTCGGCTCCTAGC 
Smad8 Exon 1-2 Forward CTCGGACAGAGTAAGCTGGCTCCA 
Smad8 Exon 1-2 Reverse GGCGGCAAGTACCTGTCCACG 
Smad8 Exon 5-6 Forward TTTGTGAAGGGCTGGGGAGCAGAGT 
Smad8 Exon 5-6 Reverse GCAACGTGGCTGACGACGTGAC 
Kalirin Forward GGGTCAACACGGAGGATAACAAG 
Kalirin Reverse CACAGGTAGGTCTCCAAGCACTC 
Trio Forward TTCTTCCGATCCGGGTTTCG 
Trio Reverse GCTGCGGGCTGGAAATGTTAA 
 
 
Table 2.4: Taqman probes for quantitative PCR 
Gene Probe Probe sequence 
YWHAZ Mm01158416_g1 CTTCCTGCAGCCAGAAGCGTTTGAC 
Kalirin Mm00616605_m1 ACATAAAGCCCGAAAACCTGCTCAT 
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2.4.3 Production of riboprobes for wholemount RNA in situ hybridization 
 
Table 2.5: Probes for in situ hybridisation 
 
2.4.3.1 Construction of Akd2C probe 
The Akd2C probe maps to a 739bp region in the 3’UTR of the gene and was designed for use 
in the Allen Brain Atlas (http://www.brain-map.org/, gene name Gm96).  Primers stated on 
the website were used to amplify the probe region from adult brain cDNA (Shinya Tanaka), 
the resulting product was run on a 1% agarose gel and extracted using the QIAquick Gel 
Extraction Kit (Qiagen).  Briefly, the gel fragment was excised from the gel and dissolved at 
50 ºC for 10 minutes in 3:1 Buffer QG to gel, 1 gel volume of isopropanol was added and the 
DNA was bound to a QIAquick column by centrifugation.  The column was washed in 
Buffers QG and PE and air-dried before the DNA was eluted using Buffer EB. 
The probe sequence was cloned into the alpha-peptide coding region of the beta-galactosidase 
within the pGEM-T vector (Promega) by adding 100ng of DNA to 33ng pGEM, 1x Rapid 
Ligation Buffer and 3U T4 DNA Ligase (all Promega) in a total volume of 10µl and 
incubating at room temperature for 1 hour.  JM109 High Efficiency Competent Cells 
(Promega) were transformed with the resulting vector by heatshock and colonies were 
selected from an Ampicillin/X-gal/IPTG plates.  Plasmids were sequenced to confirm the 
probe region only recognised the 3’UTR of Akd2C and stored at -20ºC.  
 
Probe Source Enzyme Polymerase 
Akd2C anti-sense http://mouse.brain-map.org/brain/Gm96.htm  SacI T7 
Akd2C sense http://mouse.brain-map.org/brain/Gm96.htm ApaI SP6 
BMP2 anti-sense (Dickinson et al., 1990) XbaI T3 
BMP2 sense (Dickinson et al., 1990) XhoI T7 
BMP4 anti-sense (Jones et al., 1991) Accl T7 
BMP4 sense (Jones et al., 1991) EcoRV SP6 
BMP7 anti-sense (Hofmann et al., 1996) XbaI T7 
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2.4.3.2 Probe synthesis 
3µg of plasmid was linearised in a total volume of 90µl using enzymes (New England 
Biolabs) (see Table 5), linearization was confirmed by running a small volume on a gel and 
the remainder of the digest was cleaned using the QIAquick  PCR purification kit (Qiagen).  
Briefly, DNA was diluted 1:5 in Buffer PB and bound to a QIAquick column by 
centrifugation. The column was washed using Buffer PE and air-dried, DNA was eluted in 
30µl RNase-free water.  Labelled RNA was produced in a 2 hour reaction at 37ºC, a total 
volume of 40µl contained 1µg linear DNA, 16.08U RNA Guard (Amersham Biosciences), 1X 
Transcription Buffer, 1X DIG RNA labelling mix and 40U of the appropriate RNA 
polymerase (See Table 5) (all from Roche Diagnostics).  RNA was diluted in 100µl RNase-
free water, 300µl cold EtOH and NaOAc to a final concentration of 100mM and precipitated 
at -20ºC overnight. RNA was pelleted at 4ºC and washed twice with 75%EtOH before air-
drying and resuspension in 200µl RNase-free water. 
 
2.4.4 Luciferase assays  
2.4.4.1 Electroporation of chick neural tube  
Fertile eggs were stored at 16-20°C for a maximum of 5 days prior to use.  Eggs were 
incubated horizontally in humid conditions at 37°C for approximately 20 hours and removed 
from the incubator when sampled eggs were found to be at Hamburger Hamilton stage 
(HH)10-11. DNA mixes comprised of 1µg/µl luciferase reporter construct, 1µg/µl 
experimental construct (containing 0. 1µg/µl of ligand when used), 0.1µg/µl renilla luciferase 
(pRL-SV40).  0.5µl of fast green dye was added per 5µl of DNA mix. DNA mix was injected 
into the neural tubes of HH10-11embryos and an electric current was passed through parallel 
electrodes flanking the neural tube.  L-shaped Genetrodes (BTX) were used in combination 
with an Electro Cell Manipulator 2001 (BTX) which produced four 50ms pulses of 20V. 
Eggs were sealed using parafilm and returned to the incubator for 22 hours. 
The spinal cords of live embryos (selected by visible beating hearts) were washed in PBS, 
added to 100µl cold 1X Passive Lysis Buffer (Dual Luciferase Reporter Assay, Promega) and 
stored at -20°C. 
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2.4.4.2 Measurement of luciferase activity 
Luciferase reporter activity was measured using the Dual Luciferase Reporter Kit (Promega) 
and a Centro LB960 (Berthold Technologies) with MikroWin software.  Samples were 
defrosted, shaken for 10 minutes at room temperature and spun down.  10µl of the samples 
were added to wells on a white 96-well luminometer plate.  50µl Luciferase Assay Reagent II 
was added per well, there was a 2 second delay before the firefly (reporter construct) 
luminescence was measured for 10 seconds, this was then repeated with Stop and Glo 
Reagent to measure the renilla luminescence.  The firefly/renilla luciferase ratio was 
calculated for each well and a mean and standard error of the mean calculated for each 
condition.  Different conditions were normalised against the GFP control and two-tailed 
homoscedastic Student’s T-tests were carried out to give the probability that any two 
populations are identical. 
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3 Arkadia2C is specifically expressed in the nervous system and enhances 
BMP signalling in a neuronal context 
 
3.1 Introduction 
Arkadia enhances the transcriptional response of the Smad2/3 branch of TGF-β pathway by 
degrading repressor proteins.  The homologous protein Arkadia2C contains many of the key 
functional domains of Arkadia suggesting that it functions in a similar manner.  A series of 
biochemical experiments, carried out by E. Thymiakou, show that Arkadia2C degrades the 
same repressor proteins when they act in the Smad1/5/8 branch of the signalling pathway.  To 
address the role of Arkadia2C and enhancement of BMP transcriptional responses in 
development and disease the location of Arkadia2C expression and its function there were 
examined. 
 
3.1.1 Molecular studies show that Arkadia2C derepresses BMP-Smad1/5/8 signalling 
responses 
Arkadia interacts with and mediates the degradation of PSmad2/3-SnoN/Ski complexes and 
also the I-Smad6/7 (Levy et al., 2007; Mavrakis et al., 2007; Nagano et al., 2007).  
Immunoprecipitation assays in HEK293T stably expressing GFP-Arkadia2C showed that 
Arkadia2C interacts with endogenous PSmad1/5/8 (Figure 3.1a) but not with PSmad2/3 
(Figure 3.1b).  As Arkadia2C does not interact with PSmad2/3 and does not rescue Smad2/3 
transcriptional responses in Akd-/- cells (Shinya Tanaka, Figure 1.4) it appears that the two 
Arkadia proteins are not functionally redundant.  The interaction between Arkadia2C and 
PSmad1/5/8 is enhanced by the overexpression of SnoN or Ski suggesting that like Arkadia, 
Arkadia2C recognises repressed effector complexes (Figure 3.1a).  This interaction between 
Arkadia2C, Ski and PSmad1/5/8 was confirmed in situ using Proximity Ligation Assay 
(PLA), a technique that detects protein-protein interactions (Figure 3.1c).  It was also shown 
that Arkadia2C interacts with I-Smad6/7 by immunoprecipitation.  The interaction between 
Arkadia2C and these repressive factors was shown to lead to the ubiquitination of Ski, Smad6 
and Smad7 in a ubiquitin ligase RING domain dependent manner (Figure 3.1d-f) and in the 
presence of BMP these proteins are degraded (Figure 3.1g-h).  This suggests that in a similar 
manner to Arkadia, Arkadia2C acts to ubiquitinate and degrade proteins which repress BMP-
Smad1/5/8 signalling.  However, whether this degradation of repressors enhances the 
Smad1/5/8 transcriptional response had not been assayed. 
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Figure 3.1: Arkadia2C interacts with components of the BMP signalling pathway and 
degrades the intracellular repressors Smad6/7 and Ski 
 
(a-b) Immunoprecipitation (IP) in HEK293T-GAkd2C cells after 1 hour treatment with (a) 
dorsomorphin or BMP4; (b) SB 431542, an inhibitor of the TGF-b/Activin pathway, or 
Activin.  IB, immunoblot; TL, total lysate; arrow, PSmad1/5/8 specific band; *, non-specific 
band. 
(c) Proximity Ligation assay (PLA) in HEK293T cells transfected with FLAG-Akd2C and 
treated for 1 hour as indicated showing interaction of Arkadia2C with endogenous 
pSmad1/5/8 or Ski.  Red spots, PLA signal; blue, DAPI-nucleus (Thymiakou and Episkopou, 
2011). 
(d-f) Immunoprecipitation showing the ubiquitination of (d) mycSki, (e) mycSmad6 and (f) 
mycSmad7 in HEK293T cells transfected as indicated.  
(g-h) Immunoblot showing Smad6/7 (g) and Ski, SnoN (h) in HEK293T and HEK293T-
GAkd2C cells treated with dorsomorphin (DM), an inhibitor of the BMP pathway, or BMP4. 
Protein levels of Smad6/7 and Ski were quantified and normalized to PCNA as shown in the 
histographs. Untr, untreated; Arrows indicate the bands used for quantification. 
 
All work by Efstathia Thymiakou. 
	   63	  
 
 
	   64	  
3.1.2 Expression of BMP pathway components limits their function 
BMP signalling is required for many developmental events (Derynck and Miyazono, 2008), 
and knockout of many of the key components of this pathway produce strong null embryonic 
phenotypes.  Variation in these phenotypes is in part determined by levels of functional 
redundancy between proteins; loss of BMP4 reduces gastrulation and mesoderm formation 
(Winnier et al., 1995), yet due to redundancy between Smad1 and Smad5, embryos null for a 
single Smad protein knockouts survive to midgestation (Chang et al., 1999; Lechleider et al., 
2001).  Other components of the pathway, such as Smad8, are not required for embryonic 
development or survival and null mice appear normal (Arnold et al., 2006).  The strength of a 
null phenotype is likely not only to reflect how many proteins play a redundant role but also 
whether the protein plays a role in a limited number of tissues or in a ubiquitous manner. 
Smad1 and 5 are ubiquitously expressed in the embryo while Smad8 is specifically expressed 
in the extra embryonic regions at E7.5 (Arnold et al., 2006).  As the embryo develops Smad8 
maintains a highly restricted expression pattern including in the heart tube and cartilage 
primordium (Arnold et al., 2006).  Therefore, the relatively mild phenotype of Smad8 null 
mice likely reflects its limited expression pattern in addition to its functional redundancy with 
the ubiquitously expressed Smad 1/5.  In a similar manner a study of the expression pattern of 
Arkadia2C will identify where it functions to enhance BMP transcriptional responses in vivo 
and how wide a role it plays in development and disease. 
This chapter will address where Arkadia2C is expressed using two techniques, in addition 
luciferase assays were carried out after the electroporation of chick embryos to confirm 
Arkadia2C’s role in BMP signalling in vivo.  The results show that Arkadia2C is expressed 
specifically in the nervous system in both the embryo and adult and that in the chick neural 
tube it enhances BMP transcriptional responses in a RING domain dependent manner.  This 
suggests that Arkadia2C functions to enhance BMP signalling responses in the embryonic and 
adult nervous system. 
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3.2 Results 
 
3.2.1 Arkadia2C expression in the embryo 
Two techniques were used in order to examine the expression pattern of Arkaida2C in the 
embryo.  Arkadia2C expression in a wildtype context was examined using wholemount in situ 
hybridisation with a probe designed against the 3’UTR of the gene.  In addition, the P9-3f line 
of mice carry a ROSAfary genetrap insertion in the first intron of Arkadia2C. The expression 
of the ROSAfary’s β-geo transcript under the control of the endogenous Arkadia2C promoter 
(Figure 4.1a) allows examination of the endogenous Arkadia2C expression domain by X-gal 
staining. 
Both techniques showed that Arkadia2C was not expressed at E5.5 or E6.0, however by E6.5 
expression was observed throughout the epiblast with slightly stronger staining indicating 
higher expression in the presumptive nervous system in the anterior region (Figure 3.2a and 
b).  Expression continued throughout embryonic development, however by E9.5 strong 
staining was highly restricted to the developing neural tube (Figure 3.2a) and at E11.5 
Arkadia2C was observed not only in the spinal cord and brain but also in the sympathetic 
ganglia, part of the peripheral nervous system.  Peripheral expression is also observed at 
E16.5 when X-gal staining is present in the dorsal root ganglia adjacent to the spinal cord 
(Figure 3.2c) and in the gastrointestinal tract (Figure 3.2d).  The gastrointestinal tract is 
innervated by the enteric nervous system; in order to show whether these neurons express 
Arkadia2C sections of the stained intestine were made (Figure 3.2d insert).  These showed the 
staining to be confined to a specific layer within the musculature which corresponds to the 
location of the enteric nervous system (Heanue and Pachnis, 2007 and personal 
communication with A. Canty)  Therefore, Arkadia2C is specifically expressed throughout 
both the central and peripheral nervous systems from early in development. 
 
3.2.2 Arkadia2C expression in the adult 
The observation that Arkadia2C is most highly expressed in the developing nervous system 
correlated with previous RT-PCR studies which showed Arkadia2C to be expressed most 
highly in the brain and testes of the adult mouse, with low to non-existent expression in other 
tissues.  To confirm that Arkadia2C expression in the adult is predominantly neuronal, and to 
examine whether it is localised to specific neuron types within the brain and spinal cord, X- 
gal staining was carried out on sections of tissue.  No staining was observed in non-neural 
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Figure 3.2: Arkadia2C is expressed in the developing nervous system	   
 
(a) Wholemount RNA in situ hybridisation for Arkadia2C in early embryonic development.  
Purple, Arkadia2C expression; HF, headfold; E7.5 shown as frontal view showing headfold; 
scale bars=100µm (E6.5, E7.5) and 500µm (E9.5). 
(b-d) X-gal staining (blue) showing expression of the Arkadia2C/β-geo transcript in the 
embryo. (b) Wholemount staining of the early embryo; (c) Sections of the E16.5 spinal cord; 
(d) Wholemount staining of the E16.5 gut.  White arrow, expression in the sympathetic 
ganglia; DRG, dorsal root ganglia; ENS, enteric nervous system; scale bars=100µm (b E7.5) 
and 500µm (b-d). 
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tissue with the exception of the testes (Figure 3.3a), suggesting that the faint bands produced 
by other tissue in RT-PCR (data not shown) are due to excessive amplification of expression 
in a very low level of neuronal contamination of the samples.  Arkadia2C expression was seen 
throughout the grey matter of the adult spinal cord (Figure 3.3b) in a similar manner to at 
E13.5 (data not shown) and E16.5 (Figure 3.2c).  Staining appeared of similar intensity 
throughout the spinal cord suggesting Arkadia2C is not specifically found in one cell type.  
Staining in the adult brain, however, is observed to be more localised (Figure 3.3b).  Highest 
expression was seen in the cerebral cortex and hippocampus, staining was also observed in a 
specific layer of the cerebellum.  The precise cell layers in both the cerebral cortex and 
cerebellum in which Arkadia2C is expressed is yet to be explored, however the location of 
staining within the cerebellum suggests that Arkadia2C is expressed by Purkinje cells and 
certain cells within the granule cell layer.  This implies that throughout life, Arkadia2C 
expression, and therefore function, is highly restricted to the nervous system. 
 
3.2.3 Arkadia2C enhances BMP signalling in the chick neural tube 
In order to examine whether degradation of pathway repressors by Arkadia2C enhances the 
activation of BMP transcriptional responses the BRE2-luciferase reporter was used.  BRE2-
luciferase contains two copies of the BMP responsive element from the promoter of the BMP 
target gene Id1 and induces transcription of firefly luciferase in response to PSmad1/5/8 
binding (Korchynskyi and ten Dijke, 2002).  Initial experiments were carried out by 
transfecting Akd2C+/+ and Akd2C-/- embryonic stem cells and the neuroblastoma cell line 
Neuro2A (Klebe and Ruddle, 1969).  No difference was observed in the BMP transcriptional 
response in the presence of Arkadia2C in either cell line although both showed increased BRE 
activity in the presence of BMP4 (data not shown).  It is possible that these cell lines do not 
contain the repressor proteins Arkadia2C acts upon and therefore do not provide the correct 
context to study the function of the protein. 
In order to increase the likelihood that Arkadia2C would function to enhance the BMP 
transcriptional response, a neural tissue in which components of the signalling pathway are 
known to be present was required.  BMP signalling is known to occur in the chick embryo 
neural tube between Hamburger-Hamilton stage (HH) 10 and 18 (Liem et al., 1995; Liem et 
al., 1997).  Therefore, to examine the enhancement of BMP transcriptional responses by 
Arkadia2C, BRE2-luciferase assays were carried out in the chick neural tube at HH stages 11-
12.  GFP-tagged constructs were co-electroporated with the relevant luciferase reporters and 
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Figure 3.3: Arkadia2C is expressed in the adult nervous system  
 
(a-b) X-gal staining (blue) showing expression of the Arkadia2C/β-geo transcript in adult 
non-neural (a) and neural (b) tissue.  Cor, cortex; Cer, cerebellum; Hipp, hippocampus; ML, 
molecular layer; PC, Purkinje cell layer; GC, granule cell layer; WM, white matter. 
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 individual neural tubes were collected 22 hours later.  Each experiment was repeated at least 
three times (maximum of 24 embryos per condition per repeat) with at least two different 
preparations of each construct used over the repeats.  The GFP tag should have allowed the 
level of electroporation of each embryo to be gauged, however GFP-tagged mouse 
Arkadia2C, mouse Arkadia and Drosophila Arkadia were all observed to only produce weak 
fluorescence compared to that of GFP and GFP-tagged Arkadia2C ΔRING in which the E3 
ubiquitin ligase RING domain has been removed (data not shown).  This is likely to be due to 
the fact that the RING domain of Arkadia proteins have been suggested to mediate their own 
ubiquitination (Mavrakis et al., 2007) and degradation, therefore proteins in which the RING 
domain is present are inherently unstable and do not accumulate sufficiently to produce a 
strong GFP signal. 
Comparison of BRE2-luciferase activity found that 1µg/µl BMP4 increases activity by 6-fold 
compared to an inactive GFP plasmid.  In the presence of exclusively endogenous BMP, it 
was found that 1µg/µl GFP-tagged Arkadia2C also increased activity of the luciferase reporter 
by two-fold compared to GFP alone.  However, for N of approximately 20 this result was not 
significant (P=0.29) and the result only became significant when the number of embryos used 
was increased (P= 4.1x10-5 for data shown in Figure 3.4a).  The experiment was therefore 
repeated with the addition of exogenous BMP4 (0.1µg/µl BMP4: 0.9µg/µl plasmid of interest) 
to enhance both BMP signalling and response to Arkadia2C.  It was found that the activity of 
BRE-luciferase was again increased by two-fold by GFP-Arkadia2C compared to GFP alone 
(P=0.018, Figure 3.4b, for raw data see Appendix I).  To examine whether signal 
enhancement by Arkadia2C is dependent upon its ubiquitin ligase activity, the enzymatically 
inactive ΔRING construct was used.  It was found that without ubiquitination activity 
Arkadia2C could not increase BRE2-luciferase activity above the level observed with GFP in 
the presence of exogenous BMP4 (Figure 3.4b, for raw data see Appendix I).  Therefore, as 
suggested by the biochemical data (Figure 4.1), Arkadia2C enhances BMP signalling by 
ubiquitinating target proteins via its RING domain. 
In addition to examining enhancement of BMP signalling by Arkadia2C, the possibility of 
redundancy between the Arkadia proteins was studied.  Previously Arkadia was shown to not 
enhance Smad1/5/8 signalling in the context of NIH3T3 cells (Levy et al., 2007); to examine 
whether this was also the case in the context of the chick neural tube, the activity of BRE-
luciferase in the presence of GFP-Arkadia was measured.  It was found that 1µg/µl Arkadia  
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Figure 3.4: Arakdia2C enhances Smad1/5/8, but not Smad2/3, signalling in the chick 
spinal cord via its RING domain  
 
(a) BRE2-luciferase in HH11 + 22hours chick spinal cord.  GFP, pTriEx-GFP; mAkd2C, 
pTriEx-GFPmouseAkadia2C; BMP4, pTriEx-BMP4.  Error bars represent ±SEM; **, 
P<0.01; N, number of embryos. 
(b) BRE2-luciferase in HH11 + 22hours chick spinal cord with addition of exogenous BMP4.  
mAkd, pTriEx-GFPmouseArkadia; dAkd, pTriEx-GFPdrosophilaArkadia; ∆RING, pTriEx-
GFPhumanArkadia2C∆RING; *, P<0.05.   
(c) CAGA12-luciferase in HH11 + 22hours chick spinal cord with addition of exogenous 
activin.  Activin, pTriEx-Activin. 
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did not enhance BRE-luciferase activity compared to GFP alone (Figure 3.4b), confirming 
theprevious result.  In addition Arkadia2C was previously shown not to enhance Smad2/3 
signalling in the absence of Arkadia (Figure 1.4d).  To show whether this is also the case in 
the chick neural tube the Smad2/3 responsive CAGA12-luciferase construct was used in 
combination with expression of exogenous activin, a ligand capable of stimulating CAGA-12 
(Figure 3.4c).  It was found that while 1µg/µl GFP-Arkadia can increase CAGA-12 activity by 
approximately three-fold compared to GFP alone without Activin stimulation (Figure 3.4c), 
0.9µg/µl GFP-Arkadia2C does not enhance CAGA-12 even in the presence of 0.1µg/µl 
exogenous Activin (Figure 3.4d).  Together this data suggests that in all contexts studied to 
date Arkadia specifically enhances Smad2/3 mediated transcriptional responses while 
Arkadia2C is specific to Smad1/5/8 mediated responses. 
In Drosophila there is only one Arkadia gene (dArkadia), which has previously been shown 
to enhance Smad2/3 mediated signalling responses (Dixon, 2006).  As there is no Arkadia2 
gene to enhance Smad1/5/8 mediated responses in Drosophila it seemed possible that the 
single dArkadia acted on both branches of the pathway.  The ability of dArkadia to enhance 
BRE-luciferase activity in the chick neural tube was measured and it was found that GFP-
dArkadia did not enhance activity compared to GFP alone independent of  exogenous BMP4 
(Figure 3.4 a and b).  Therefore dArkadia only has a homologous function to mammalian 
Arkadia, not Arkadia2C. 
Overall, the measurements of luciferase activity in the chick neural tube suggest that 
Arkadia2C specifically boosts Smad1/5/8 and not Smad2/3 mediated signalling responses in 
this context and that this occurs via the E3 ubiquitin ligase RING domain.  This activity is 
complementary to that of Arkadia which is specific to Smad2/3 mediated signalling response. 
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3.3  Discussion 
Arkadia2C was known to contain many of the protein domains critical for Arkadia function, 
leading to the prediction that it acts in a similar manner to Arkadia but is specific to the 
Smad1/5/8 branch of the TGF-β pathway.  This chapter presents a body of evidence to 
support this hypothesis.  In addition, the expression pattern of Arkadia2C was examined; this 
suggested that Arkadia2C function resides within the nervous system both during embryonic 
development and in the adult. 
 
Study of the expression pattern of Arkadia2C was used to gain insight into its function.  
Detailed X-gal staining of the genetrap reporters shows that, with a few exceptions such as the 
testes, Arkadia2C is not expressed in tissues outside the nervous system.  In highly innervated 
tissues, such as the gut, Arkadia2C expression is confined to the neuronal compartment.  
Furthermore, the neuronal specificity of Arkadia2C is indicated by the fact that it enhances 
the BRE-luciferase reporter in the neuronal context provided by the chick neural tube but not 
in a number of cell lines.  This specificity may rely on the presence and activity of the 
repressor proteins which are targeted for degradation by Arkadia2C.  Alternatively, unknown 
factors that repress activity in a non-neuronal context or enhance activity in the nervous 
system may determine the observed specificity of Arkadia2C. 
 
The chick neural tube functional reporter assays also showed that Arkadia could not replace 
Arkadia2C function and enhance Smad1/5/8 transcriptional responses.  Therefore despite the 
fact that Arkadia is ubiquitously expressed, including in the nervous system, it seems unlikely 
that the two factors act in a redundant manner, instead complementing each other in the 
different branches of the TGF-β pathway.  The unique function of Arkadia2C is a strong 
indicator that loss of its expression will produce a phenotype; as Arkadia2C enhances BMP 
signalling responses any phenotype is expected to be associated with regions of the nervous 
system which require such enhanced signalling. 
 
BMP signalling has been shown to play many roles in embryonic and adult neurons (Derynck 
and Miyazono, 2008) but the levels of signalling required for specific events remain elusive.   
Arkadia has been shown to enhance only a subset of Nodal dependent events in the early 
embryo in a context dependent manner (Episkopou et al., 2001).  Specifically Arkadia is 
required for anterior/head structure formation, an event which occurs on the opposite side of 
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the embryo from Nodal expression in a region which is known to express the Nodal 
antagonists Lefty2 and Cerberus.  This is consistent with a model in which Arkadia acts to 
boost signalling intracellularly to compensate for reduced ligand availability.  Similarly the in 
vivo function of Arkadia2C is likely to shed light on regions of the nervous system which 
require intracellular boosting of the BMP pathway for their development or function. 
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The expression studies and functional experiments shown in Chapter 3 suggest that 
Arkadia2C enhances BMP activity specifically in the nervous system, however the neuronal 
role of Arkadia2C in the context of the whole animal remained unknown.  In the following 
two chapters the phenotype produced by the loss of Arkadia2C function in mice is addressed 
using the P9-3f line of mice in which a genetrap is inserted into the gene.  Arkadia2C null 
mice have symptoms that resemble motor neuron diseases leading to the majority dying 
before weaning.  In addition, both null and heterozygous adult mice exhibit behavioural and 
anatomical defects consistent with finding in the literature that Arkadia2C is a candidate for 
bipolar disorder (Pickard et al 2005). 
 
4.1.1 Motor neuron disease-like phenotypes in mice 
Knowledge of the different genes associated with motor neuron diseases in humans has been 
used to generate mouse models of the diseases.  The study of such models increases our 
understanding not only of the pathology and progression of these diseases but also the 
underlying mechanisms.  Mouse models of adult-onset ALS produces age dependent deficits 
in motor co-ordination and gait due to progressive loss of neurons and muscle weakness 
(Swarup and Julien, 2010).  In general these mice do not display symptoms in the first few 
months of life, however certain models have been observed to have early co-ordination 
abnormalities (Durand et al., 2006).  Other diseases such as SMA and Charcot-Marie-Tooth 
disease are infant onset in both humans and mouse models.  These mice display muscle loss 
during postnatal development and therefore, do not grow at the same rate as littermates 
(Hsieh-Li et al., 2000; Detmer et al., 2008; Michaud et al., 2010).  Chronic necrosis of 
peripheral tissues such as the ears and tails due to atrophy of muscles and chronic hypoxia is 
also common to many of the models of early onset diseases. 
At a cellular level there are greater similarities between the phenotypes of models of early and 
late onset motor neuron diseases.  Counts of neurons in the ventral horn of the spinal cord 
show mice with disease models to have fewer motor neurons due to cell death (Detmer et al., 
2008; Michaud et al., 2010).  The loss of motor neurons can also be visualised using 
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antibodies in the target muscle where axons can been seen to be degenerating leaving empty 
post-synaptic structures (Michaud et al., 2010; Park et al., 2010).  Subsequent atrophy of 
denervated muscle is observed, measurable by the number of muscle fibres (Hsieh-Li et al., 
2000), muscle fibre diameter (Michaud et al., 2010) and a slight increase in the number of 
internal nuclei (Park et al., 2010).  Such atrophy, coupled with a potential reduced ability to 
eat, is likely to cause the decrease in body mass or inability to increase body mass in pups 
observed in the animal as a whole.  
Motor co-ordination loss is often first observed in the limbs of human motor neuron disease 
patients and mouse models also have obvious defects here.  Models of SMA have been 
observed to have decreased righting ability in young pups and weak grip strength (Michaud et 
al., 2010).  Charcot-Marie-Tooth disease animals survive to adulthood yet have persistent gait 
abnormalities in the hindlimb and hold their hindpaws in fists (Detmer et al., 2008). 
The cause of death in SMA and ALS in both humans and mouse models is often a decreased 
ability to breathe or swallow, both of which are necessary for independent life.  SMA has 
traditionally been thought to decrease oxygen intake predominantly due to weakened 
intercostal muscles which produce a characteristic bell shaped trunk (Monani et al., 2000) and 
laboured breathing, however recent studies have also shown that innervation of the diaphragm 
is abnormal in both mouse models and human SMA patients (Kariya et al., 2008; Michaud et 
al., 2010).  Diaphragmatic denervation is a common feature in human patients with ALS and 
has been also been observed in some rodent models of the disease (Llado et al., 2006). 
Despite the large number of genes that have been associated with different forms of motor 
neuron disease and the production of mouse models, relatively little is known about the 
pathways that link known genes to the phenotypic outcome. 
 
4.1.2 Bipolar Disorder-like phenotypes in mice 
Arkadia2C has previously been linked to Bipolar disorder in a human family (Pickard et al., 
2005).  A pericentric inversion of chromosome 18 in the family was shown to be located close 
to five genes including Arkadia2N and 2C; as Arkadia2C was the only one that was expressed 
specifically in the nervous system Pickard et al suggested it as a strong candidate gene.  
Complex psychiatric illnesses including Bipolar Disorder are notoriously difficult to model in 
mice, however a number of models which share certain features of the disease are commonly 
used in its research (Martinowich et al., 2009).  Most of these animals only model one aspect 
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of the disease , responding to behavioural tests in a manner indicative of anxiety, depression 
or hyperactivity (Martinowich et al., 2009). 
 
This chapter examines the role of neuronal Arkadia2C in the adult and compares the 
phenotype of Arkadia2C mutant mice with those of known disease models.  Homozygous 
individuals from this line were shown to be null for Arkadia2C and surviving adults have a 
defect in motor function, especially in the forelimb.  Heterozygous mice also exhibit 
abnormalities in the CNS.  These data suggest that in the adult Arkadia2C is required for 
maintenance of motor innervation and loss of Arkadia2C produces a motor neuron disease 
like phenotype.  Therefore, these data show for the first time that the BMP signalling pathway 
plays a role in the development of motor neuron disease in mammals. 
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4.2 Results 
	  
4.2.1 The ROSAfary genetrap insertion disrupts Arkadia2C expression 
To examine the role of Arkadia2C in mice it was first necessary to ascertain whether the 
ROSAfary genetrap insertion produced a null mutation or a hypomorph.  The genetrap vector 
was inserted into the first intron of Arkadia2C producing two hypothetical fusion proteins 
(Figure 4.1a, see Figure 1.4b for scale).  To compare the level of Arkadia2C expression in 
homozygous mutants (Akd2C-/-) and wildtype (Akd2C+/+) mice, quantitative (Q-) PCR of 
cDNA from embryonic brain, a tissue which normally expresses high levels of Arkadia2C, 
was used.   
To detect any potential splicing around the genetrap insertion a primer pair was designed to 
span intron 1.  A PCR product will only be produced from this primer pair if the transcript 
contains adjacent exons1 and 2, a situation that exists in the wildtype but not after genetrap 
insertion.  It was found almost no exon1-2 product was made from samples homozygous for 
the genetrap insertion (Figure 4.1b, 0.18% of wildtype expression, 3 Akd2C+/+ and 2 Akd2C-/- 
embryos, N=4 for each).  The majority of the Arkadia2C sequence, including the C-terminal 
NRG-TIER and RING domains, are located after the genetrap insertion site and may be 
expressed under the control of the constitutive ROSAfary phosphoglycerate kinase (PGK) 
promoter (Figure 4.1a).  To detect the expression of Arkadia2C sequences downstream of the 
genetrap insertion site two sets of primers were used; the first immediately downstream of the 
genetrap insertion site spanning intron 2 and the second spanning intron 7 and amplifying 
much of exon 8 which contains the functional domains.  Again, neither of these primer sets 
detect transcript above minimal levels (Figure 4.1b, 3.46% and 1.84% of wildtype expression 
respectively) suggesting that expression from the PGK promoter does not produce significant 
transcripts and no fusion proteins with active ubiquitin ligase activity should be present in 
Akd2C-/- individuals.  Overall the Q-PCR showed that mice homozygous for the P9-3f 
genetrap insertion are null for Arkadia2C.  
 
4.2.2 The Arkadia2C null phenotype 
It was previously found that Akd2C-/- embryos comprise the expected 25% of the total counted 
at E18.5, immediately prior to birth (Shinya Tanaka).  Approximately 10% of Akd2C-/- mice 
were found dead in the first 24 hours after birth suggesting that these individuals are not 
capable of independent life and have impaired feeding or breathing.  On an inbred genetic  
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Figure 4.1: Arkadia2C null mice are of reduced size with a clenched paw phenotype  
 
(a) Schematic showing insertion of the ROSAfary genetrap into intron 1 of Arkadia2C and 
resulting transcripts. 
(b) Quantitative PCR of Arkadia2C transcripts from embryonic brain in Akd2C+/+ and Akd2C-
/- animals. 
(c) Akd2C-/- null pups and littermates at P3 and P17.  Red arrows show affected limbs. 
(d) Dot plot showing mean plasma lactate concentration ±SD for each individual mouse. 
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background (129SVcc) all Akd2C-/- mice died in the first 25 postnatal days, prior to weaning, 
however the phenotype has variable penetrance and with nurturing, the life span of 
homozygotes can be extended.  In an outbred/mixed background, provided by the 
Smad8/CD1 line, the symptoms stabilise fully in some individuals (approximately 50% of 
Akd2C-/- from this cross, 2% of all Akd2C-/-produced) and they survived to adulthood. 
In order to more fully understand the Akd2C-/- phenotype and why the animals died, they were 
closely examined throughout their lives.  Live null pups are initially indistinguishable from 
their littermates during the first two postnatal days (Figure 4.1c, panel1), all pups are of 
similar size and have milk in their stomachs.  Closer examination showed that all 
homozygous animals hold their forepaws in a relaxed fist due to a reduced ability to dorsiflex 
and extend their digits (Figure 4.1c, indicated by red arrows).  This phenotype was not found 
in any Akd2C+/+ or heterozygous littermates making it characteristic of the Akd2C-/- genotype.  
The phenotype was restricted to the forelimbs in >98% of homozygotes, however, on 
occasion animals with extended hindlimbs and reduced dorsiflexion in the hindpaw were 
found (Figure 4.1c panel 3, blue arrow). 
Akd2C-/- animals did not suffer from chronic necrosis of peripheral tissues due to localised 
hypoxia as is observed in a number of mouse models of early onset motor neuron disease 
(Hsieh-Li et al., 2000; Detmer et al., 2008; Michaud et al., 2010).  However, hypoxia was 
suspected due to the dark colouration of blood in the muscles of pre-weaning Akd2C-/- 
animals. Lactate is a waste product of anaerobic glycolysis (Berg et al., 2002) and blood 
plasma lactate levels are found to be elevated in response to exercise or reduced oxygen 
perfusion of tissue (Pittman, 2011).  Therefore, whether Akd2C-/- pups and adults were 
hypoxic was ascertained by colourmetric analysis of blood plasma lactate.  While there was a 
wide range of lactate concentrations in  the blood of Akd2C-/- animals, it was generally found 
to be elevated compared to wildtype (mean of 6.11mM v 8.08mM, 0.05>P>0.01; Figure 
4.1d).  This increased blood plasma lactate concentration suggests an increased incidence of 
anaerobic respiration in Akd2C-/- animals due to a reduced breathing efficiency.  Additionally, 
after postnatal days 2-4 homozygous animals are notably smaller than their littermates (Figure 
4.1c panels 2 and 3) with the differential increasing as the animals age.  The small animals 
have reduced skin turgor suggesting dehydration (Figure 4.1c, panel 1) and while Akd2C-/- 
pups have milk in their stomachs, older pups have notably less food in their stomachs than 
littermates.  All homozygous mice suckle throughout their lives and appear hungry, it is 
therefore possible that they are physically incapable of consuming sufficient food as they age 
and it is this aspect of their phenotype that leads to death in most individuals. 
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The few animals that survive to adulthood remain smaller than their littermates as young 
adults (1-4 months) and the forepaw extension phenotype persists throughout life.  
Approximately 50% of these adult animals are fertile (both sexes), however Akd2C-/- females 
fail to care for their pups resulting in only 10% of those born from Akd2C-/- X Akd2C-/- 
crosses surviving to weaning.  While Arkadia2C is expressed in the testes (Figure 3.3) and 
can therefore potentially directly affect the fertility of males, the reduced fertility of the 
females and their inability to care for pups suggests that Akd2C-/- animals have behavioural 
abnormalities. 
 
4.2.3 Arkadia2C null mice have reduced fore and hindpaw extension 
The Akd2C-/- animals which survived to adulthood provided a cohort suitable to study the 
observed clenched forepaw phenotype.  The posture of the paws and the gait of Akd2C-/- and 
Akd2C+/+ animals when walking were observed by analysing their footprints, the parameters  
measured are shown in Figure 4.2a.  As no adult Akd2C-/- had been observed to hold their 
hindlimbs in an extended position (as shown in Figure 4.1c), the prints produced by the 
forelimbs were initially studied (Figure 4.2b; for raw data see Appendix II).  It was found that 
Akd2C-/- mice have a reduced forelimb mean stride length compared to Akd2C+/+ (57.28mm 
compared to 41.75mm, P=0.03) predominantly due to a decreased minimum stride length 
(53mm compared to 31mm, P=0.02) rather than a decreased maximum stride length (63mm 
compared to 55mm, P=0.06).  No significant difference was observed in the mean stride 
width between Akd2C-/- and Akd2C+/+ mice suggesting that Akd2C-/- mice have a normal 
forelimb gait.  The mean foot length of Akd2C-/- mice was only 6.2mm compared to 8.06mm 
in Akd2C+/+ (P=0.002).  This reduction in length is due to the paw being held in a fist, 
observed in the footprints as a lack of toes; 6.5% of Akd2C-/- footprints have clear toes 
compared to 100% of Akd2C+/+ prints (P=1.95x10-5; Figure 4.2c-d ).  The prints were 
examined more closely and it was found that in 50% of Akd2C-/- prints with visible toes the 
middle two toes were touching, a feature not observed in Akd2C+/+ prints.  This suggests that 
not only do Akd2C-/- adults have impaired expansion of their digits from the fist position they 
also suffer from a decreased ability to spread their digits.  The Akd2C-/- footprints which show 
clear toes were produced by the same paws which produced “toeless prints”; this suggests that 
in the adult the forepaws are held in a fist the majority of the time.  However, occasionally 
they can be opened either by the action of the mouse itself or by pressure produced as the 
animal walks.  This suggests that the flexor muscles which act to produce a fist are not 
hypercontracted, rather the extensor muscles which act to spread the digits have  
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Figure 4.2: Arkadia2C null adult mice have reduced distal forelimb extension  
 
(a) Measurements of footprint trails to analyse stance and gait of mice. Mean, maximum and 
minimum stride length and width were calculated for each mouse. 
(b) Histograms presenting measurements of footprint trails of Akd2C+/+ and Akd2C-/- fore and 
hindlimbs shown as average of genotype population±SD. Akd2C+/+ , N = 4; Akd2C-/- , N = 2; 
*, 0.05>P>0.01; **, P<0.01. 
(c) Fore and hindpaw prints from Akd2C+/+ and Akd2C-/- mice.  Least and most affected 
Arkadia2C null prints shown. Red arrowhead, no toes visible; blue arrowhead, toes touching. 
(d) Histograms presenting percentage of footprints with all toes visible, all toes not touching 
and being of normal appearance shown as average of genotype population±SD.  Akd2C+/+ , N 
= 4; Akd2C-/- , N = 2;  **, P<0.01. 
(e) Maximum grip strength achieved by each individual mouse.  Akd2C+/+ N = 8, Akd2C-/- N = 
4. 
(f) Dot plot showing mean hang time on inverted cagelid ±SEM for each mouse and 
box/whisker plot showing variations within hangtime of each genotype.  Akd2C+/+ N = 7, 
Akd2C-/-  
N = 8. 
(g) Mean time spent on accelerating rotarod by each mouse; Akd2C+/+ N = 8, Akd2C-/- N = 2. 
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reduced contraction activity or strength. 
 
A strong hindlimb phenotype is present in a small number of Akd2C-/- mice, however it was 
hypothesized that other animals have a mild hindlimb phenotype which cannot be observed 
grossly.  Therefore, the pawprints produced from the hindlimb were also analysed for 
abnormal hindlimb gait (Figure 4.2b) or paw posture (Figure 4.2c-d) in Akd2C-/- adults.  No 
significant difference was observed in the stride length and width or the average foot length 
between Akd2C+/+ and Akd2C-/- animals.  However, it was found that the spread of both the 
inner (4.35mm compared to 6.11mm, P=0.02) and outer (7.18mm compared to 9.58mm, 
P=0.01) toes was reduced in Akd2C-/- animals suggesting that they suffer from an inability to 
spread the digits of the hindlimb in addition to those of the forelimb.  Also clenched paws 
were observed in some prints leading to only 37.2% of Akd2C-/- hindlimb footprints appearing 
“normal” compared to 84.5% of Akd2C+/+ prints (P=0.06).  The hindlimb prints of only two 
Akd2C-/- animals were studied reducing the significance of the test.  Of these, one animal 
produced prints which all showed clear toes (100% compared to an average of 95.6% amongst 
Akd2C+/+) while the second animal only produced visible toes in 36.8% of prints.  Whether 
one of these phenotypes is predominant in Akd2C-/- mice or the observed 50:50 split is 
representative can not be ascertained without a greater number of surviving Akd2C-/- adults.  
Despite this fact, it is clear that there is reduced extension of both the fore and hindlimb digits 
in Akd2C-/- adults although the phenotype is stronger in the forelimb.  
 
In order to ascertain whether the observed reduced extension of digits in Akd2C-/- mice 
affected the animals’ motor performance, their grip strength and balance was measured.  Two 
tests were used to measure forelimb strength; in the first a grip strength meter was used, in the 
second the time that the mouse could suspend itself from an inverted cage lid was measured 
(Papaioannou and Behringer, 2005).  The grip strength meter requires the animal to grab a 
bar, the experimenter then gently pulls the mouse away from the bar maintaining an even 
pressure both throughout the test of an individual mouse and also between individuals.  Each 
mouse was tested five times and the results normalised as a function of their mass. This test 
measures the function of flexor muscles to maintain a grip against pressure. The Akd2C-/- 
mice had difficulty with the initial task of grasping the bar and as pressure was occasionally 
excerted before the bar was gripped sufficiently the mean score of Akd2C-/- mice was lower 
than that of Akd2C+/+ controls (Data not shown; N=8 (Akd2C+/+ ) and 4 (Akd2C-/- ); average 
of mean score for each mouse±SD; Akd2C+/+ , 2.4±0.7 x mouse mass; Akd2C-/-, 1.5±1.4 x 
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mouse mass; P=0.05).  To overcome the bias introduced by failure of the Akd2C-/- mice to 
grasp the bar in all tests the maximum grip strength achieved by each mouse was studied.  It 
was found that there was no significant difference between the force excerted by the different 
genotypes after the bar had initially been grasped (Figure 4.2e; average of maximum score for 
each mouse; Akd2C+/+, 3.1±0.7 x mouse mass; Akd2C-/-, 3.0±1.8 x mouse mass; P=0.89, not 
significantly different).  This suggests that while Akd2C-/- adult mice have difficulty co-
ordinating their grip, once this is achieved forelimb flexor muscle function is relatively 
normal.  
The cage lid test measures the time (ending at 60 seconds) that a mouse can suspend itself on 
an inverted cage lid.  As most animals move around the lid during the test it requires repeated 
gripping and releasing of the bars and therefore measures the function of both the extensor 
and flexor muscles of fore and hindlimbs over a prolonged period of time.  Each animal was 
tested at least six times, spread over three weeks.  In this test Akd2C-/- mice performed 
exceedingly poorly compared to Akd2C+/+ controls (Figure 4.2f; N=7 (Akd2C+/+) and 8 
(Akd2C-/-); average of mean score for each mouse±SD; Akd2C+/+ , 56.9±3.0 seconds; Akd2C-/-
, 5.3±3.0 seconds; P=5.8x10-14).  Often the Akd2C-/- mice failed to grasp the cage bars when 
they first tried to move after the start of the test and Akd2C-/- animals that did not move or 
suspended themselves using their hindlimbs maintained their grasp for longer.  As seen in the 
grip strength test this suggests that while flexor muscles can excert force to maintain a grip, 
the act of extending and flexing the digits is weak in Akd2C-/- mice.  This reflects the 
phenotype seen in the pawprint analysis where Akd2C-/- animals often fail to extend their 
digits. 
As mouse models of motor neuron disease often show decreased balance on a rotating rod 
(Knippenberg et al., 2010), the ability of a limited number of Akd2C-/- mice to balance on an 
accelerating rotarod was measured.  There was wide variation in the ability/desire of 
Akd2C+/+ mice to complete this test and the scores of the two homozygotes fell within the 
wildtype range with one individual producing the highest mean time (Figure 4.2g; average of 
mean score for each mouse±SD; Akd2C+/+ , 72.6±60.0 seconds; Akd2C-/-, 117.0±76.4 
seconds; P=0.41).  While the low numbers of mice used (N=8 and 2) and the wide variation in 
scores make it hard to draw a conclusion from these results, it appears that the inability of 
Akd2C-/- mice to extend their digits fully does not adversely affect their balance. 
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4.2.4 Atrophy of the forelimb extensor muscles of Arkadia2C null mice is likely due to 
reduced innervation 
The above behavioural tests show Akd2C-/- mice to have inefficient extensor function in the 
forelimb.  As Arkadia2C is expressed specifically in the nervous system this defect must be 
caused by a neuronal deficit affecting muscle control.  Therefore, the muscles of the forelimb 
were examined to find the cause of the functional deficiency.  Two muscles that control the 
extension of the wrist joint; the extensor carpi radialis longus (ECRL) and the extensor carpi 
radialis brevis (ECRB) and two that control extension of the digits; the extensor digitorum 
communis (EDC) and the extensor digiti quinti (EDQ) (Figure 4.3a) were studied in greater 
depth. 
These extensor muscles of the forelimb were first compared at E13.5, a point at which the 
primary myogenesis is nearing completion (Wang et al., 2010); the myofibres have condensed 
into discernable muscle masses and innervating motor axons are entering their targets.  
Visualization with anti-myosin32 showed that muscles develop and are of normal size and 
structure in E13.5 Akd2C-/- embryos (Figure 4.3b; blue arrowhead indicates extensor 
muscles).  However, upon dissection and examination of the same muscles from Akd2C-/- 
adults it was found that, while the tendons were the same length, the muscles were regularly 
smaller in size than those from approximate age and size-matched Akd2C+/+ animals (Figure 
4.3c).  This difference was most pronounced in the extensor digiti muscles in the majority 
(13/15) of animals studied although a further 2 animals showed a greater reduction in extensor 
carpi muscles.  It was often found that the muscle fibres were replaced with fatty tissue; some 
EDC and EDQ muscles displayed such atrophy that no muscle tissue remained (data not 
shown).  No difference was seen in the size of ventral flexor muscles between Akd2C+/+ and 
Akd2C-/- mice (data not shown). 
The small extensor muscle size of Akd2C-/- mice may be due to reduced growth after E13.5, 
previous atrophy or ongoing atrophy.  The multiple nuclei of mature muscle fibres are 
normally located at the periphery (Sanes and Lichtman, 1999), however in cells undergoing 
atrophy they are observed to migrate to a more central location (Park et al., 2010).  To study 
whether forelimb muscle from Akd2C-/- mice showed increased numbers of internal nuclei 
H&E staining was carried out on cross-sections of ECRL and EDC muscles.  Preliminary 
experiments showed no significant difference in the mean number of cells with internal nuclei 
between Akd2C+/+ and Akd2C-/- ECRL (Figure 4.3c; two central sections from six different 
muscles examined, all cells counted per section; 0.97±0.31% of cells compared to  
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Figure 4.3: Muscle degeneration and innervation in adult Arkadia2C null mice 
 
(a) Diagram showing muscles of the dorsal forelimb. Extensor carpi radialis longus (ECRL), 
extensor carpi radialis brevis (ECRB), extensor digitorum communis (EDC), extensor digiti 
quinti (EDQ). 
(b) Whole-mount immunofluorescence showing developing forelimb extensor muscle at 
E13.5. Blue arrowhead, extensor carpi and digiti muscles; proximal limb to the left; scale bars 
= 250 µm. 
(c) Muscles from size matched Akd2C+/+ and Akd2C-/- mice, each picture shows left and right 
limb from a single animal.  Scale bars = 1mm. 
(d) Haematoxylin and Eosin stain of extensor carpi radialis longus muscles. Blue arrowheads, 
internal nuclei; scale bars = 50µm.  
(e) Innervation of synapses within the extensor digitorum communis. Red, α-Bungarotoxin 
(AChRs); Green, neurofilament & synaptophysin and background staining/autofluorescence 
of muscle fibres; blue arrowhead, innervated synapse; yellow arrowhead, denervated synapse; 
scale bars = 50µm. 
(f) Degenerating synapseless Akd2C-/- extensor digitorum communis.  Red, α-Bungarotoxin 
(AChRs) and autofluorescence of fatty tissue; Green, neurofilament & synaptophysin and 
background staining/autofluorescence of muscle fibres; white arrowhead, fatty tissue; scale 
bars = 100µm. 
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1.77±0.57%; P=0.23, not significantly different) and EDC (0.31±0.13% of cells compared to 
0.40±0.21%; P=0.72, not significantly different) muscles.  However, the sections with the 
highest percentage of cells with internal nuclei were Akd2C-/- in both cases (ECRL: 8.11% 
compared to a maximum of 3.3% in Akd2C+/+; EDC: 5.5% compared to 3.3%).  Decreased 
numbers of muscle fibres and fibre diameter are also associated with ongoing muscle atrophy 
but unfortunately, due to the preparation method, these could not be analysed.  As no 
siginificant difference was found in markers of atrophy between Akd2C+/+ and Akd2C-/- 
forelimb muscles it seems likely that the observed difference in size (Figure 4.3c) is due to 
previous atrophy at an earlier age than studied (6-8 months), or reduced muscle growth as the 
animal aged. However due to the limitations of this study ongoing atrophy can not be ruled 
out and further studies including younger animals are required to establish the exact time 
point of the largest decrease in muscle size. 
Muscle atrophy resulting in decreased muscle size frequently follows motor axon denervation 
in motor neuron disease models.  Therefore, any current muscle atrophy in Akd2C-/- mice 
should be accompanied by denervation.  Longitudinal sections of EDC muscle from Akd2C+/+ 
and Akd2C-/- animals were examined using antibodies against the presynaptic markers 
neurofilament and synaptophysin and fluorescent α-Bungarotoxin to visualize the 
postsynaptic NMJ structures.  Sections from throughout the muscle were examined for the 
presence of synapses; the percentage of synapses occupied by axons and the density of 
synapses were counted to measure the extent of early and late stage denervation.  In regions 
containing synapses, the density was similar in Akd2C+/+ and Akd2C-/- mice (Figure 4.3e; 
4.63, 3.35 synapses/mm2 respectively; P=0.49).  However, a greater number of Akd2C-/- 
sections examined contained no synapses (1/15 Akd2C+/+ sections examined and 5/15 Akd2C-
/- sections) and in these sections muscle fibres were often found to have disintegrated into 
fatty tissue (Figure 4.3f, fatty tissue indicated by white arrowhead).  This suggests that 
innervation has been lost from specific regions of the muscle previous to the study and muscle 
fibres have atrophied.  Examination of all motor synapses present in Akd2C-/- muscles showed 
increased denervation, on average 78% of synapses per muscle were observed to be occupied 
by axons compared to 93% of all motor synapses in Akd2C+/+ muscle (Figure 4.3e, P=0.007).  
Despite the denervation of these synapses, the postsynaptic structures have not yet 
disintegrated, however as adult postsynaptic structures remain stable in muscle for a number 
of weeks after denervation (Sanes and Lichtman, 2001) the timing of denervation can not be 
concluded from this result.   
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Figure 4.4: Brain structure in mice with reduced Arkadia2C expression 
 
(a) Adult Akd2C-/- animal showing the stereotypical neck wound. 
(b) Sections of adult brain showing the location of the corpus callosum.  Purple arrowheads 
indicate the position of the corpus callosum; scale bars, 1000 and 500µm. Akd2C+/+ brains are 
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Overall, this data shows that NMJ form in at least a subset of Akd2C-/- extensor muscles, 
however these synapses become denervated leading to muscle atrophy and the observed 
weakness in extensor function, a motor neuron disease-like phenotype.  This suggests that 
Arkadia2C is required for the maintenance of the neuromuscular synapse in these muscles.   
 
4.2.5 Arkadia2C null mice also suffer from symptoms in the CNS  
Arkadia2C is widely expressed in the nervous system, raising the possibility that its loss 
might affect neurons other than those motor neurons which innervate the forelimb.  A full 
behavioural analysis of Akd2C+/- animals is currently being carried out to examine the 
possibility that reduction in Arkadia2C expression affects behaviour and that Arkadia2C plays 
a role in brain function (George Panagis, University of Crete).  However, while a full analysis 
has not been carried out there is tantalising evidence that Akd2C-/- animals might suffer from a 
psychiatric disorder as well as a motor neuron one.  Observation of a small number of Akd2C-
/- mice shows them to be more active than their littermates despite their abnormal paw 
posture.  Akd2C-/- mice were often found to develop wounds on their back, in particular at the 
level of their neck (Figure 4.4a).  Wounds on the lower back appeared to be indicative of 
aggressive behaviour as they healed when mice were housed individually, however those on 
the neck remained suggesting they were caused by excessive grooming or itching.  
Additionally, while Akd2C+/- exhibit no motor defect, preliminary study of the structure of 
adult and immature brains of both Akd2C+/- and Akd2C-/- animals suggest that the majority of 
individuals on 129SVcc and 50% CD1 genetic backgrounds lack the corpus callosum (Figure 
4.4b).   However, studies of Akd2C+/- and Akd2C-/- animals on a 50% C57/Black6 genetic 
background found that the corpus callosum was present.  Further studies into the role of 
genetic background on the loss of the corpus callosum is required to fully understand this 
phenotype. 
Hyperactivity is a symptom of Bipolar Disorder in humans and is found in a number of 
genetic mouse models of the disease (Martinowich et al., 2009) while abnormal length and 
shape of the corpus callosum has been found in human patients (Brambilla et al., 2009).  
Arkadia2C has been suggested as a candidate gene in a family with Bipolar Disorder (Pickard 
et al., 2005), the analysis of Akd2C-/- animals presented here supports the conclusion that 
Arkadia2C is the gene that produces the phenotype in this family. 
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4.3  Discussion 
	  
Arkadia2C is a neuronal protein that has been shown to enhance BMP signalling in ovo, 
however its function in the murine nervous system was not known.  Here it was shown that 
insertion of the P9-3f genetrap created an Arkadia2C null line of mice.  Akd2C-/- animals are 
born but the majority die within the first three weeks of life, most likely due to reduced food 
intake and difficulty breathing typical of motor neuron diseases.  All Akd2C-/- mice, 
independent of their lifespan, show a clear phenotype in the forepaws which are held as loose 
fists.  Surviving Akd2C-/- adults showed reduced forelimb extensor motor function due to 
decreased muscle size and denervation of remaining muscles.  As the extensor function of 
Akd2C-/- mice does not appear to deteriorate after weaning, it seems likely that degeneration 
of the motor neuron and forelimb muscle occurs either in the embryo or during postnatal 
growth.  Early postnatal growth is the stage where the majority of Akd2C-/- mice waste and 
thin suggesting that this might also be the stage of degeneration in surviving mice and that the 
Arkadia2C null phenotype is an early-onset postnatal motor neuron disease.  Loss of 
Arkdia2C expression also produces a behavioural defect thought to be caused, in part, by the 
absence of the corpus callosum structure.   
 
Arkadia2C null adults and pups share many gross features with mouse models of motor 
neuron diseases (see Table 4.1); the most obvious of which being a size differential to 
littermates, reduced movement of the forepaw and to a lesser extent the hindpaw.  Unlike 
ALS, SMA is an infant onset motor neuron disease and a number of severe mouse models 
show a phenotype from birth (Hsieh-Li et al., 2000; Monani et al., 2000).  Variation in the 
genetic background and SMN2 copy number of smn-/-SMN2 “SMA mice” produces 
individuals with a life expectancy of between 0 days and that of a wildtype animal. A similar 
effect in observed in Akd2C-/- mice which show a variation in life expectancy on different 
genetic backgrounds.  All SMA model mice show decreased size compared to littermates in 
the days prior to death due to reduced food intake as is seen in Akd2C-/- pups.  In addition, the 
health of both Akd2C-/- mice and SMA models can deteriorate sharply from pups appearing 
relatively normal to the point of death in only 2-3 days. 
Mouse models of SMA only have mild symptoms in the limb, the most severe of which being 
paralysis of hind limb (Hsieh-Li et al., 2000).  This closely models human SMA patients  
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Table 4.1: Similarities and differences between Arkadia2C null mice and murine models 
of motor neuron diseases 
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where the proximal muscles are most severely affected (Munsat and Davies, 1992) and 
therefore the distal limbs are rarely affected.  However, human ALS and CMT disease 
patients have acute symptoms in the distal limb including the hands and feet (Kuncl et al., 
1988; Dyck et al., 1993).  In Akd2C-/- mice, a clear phenotype is present in the paw and 
analysis of the muscle shows that loss of innervation is limited to the most distal extensor 
muscles which extend the digits.  This phenotype is similar to that seen in mice used as a 
model of CMT type 2a, these animals have limp hindpaws as pups due to an inability to 
dorsiflex and therefore drag their hindlimb behind their body.  In the adult the hindlimb 
extensor muscles are significantly reduced in size leading to animals holding their hindpaw as 
a fist (Detmer et al., 2008).  While the symptoms of Akd2C-/- animals are predominantly in 
their forepaws, rare individuals that survive past the immediate postnatal stage have strong 
hindlimb defects (Figure 4.1c, Blue arrow) that present as remarkably similar to the CMT 
mice.  In addition, the phenotype seen in the Akd2C-/- forelimb is reduced dorsiflexion and 
extensor muscle size, identical to the CMT defect.  This suggests that both Akd2C-/- and CMT 
mice, in addition to human patients, have denervation and muscle atrophy specifically in the 
extensor muscles of affected limbs although the reason for this specificity is unknown. 
Both ALS and SMA have recently been described as distal neuropathies, the first 
abnormalities/events of the disease occur in the axon and synaptic structures prior to any 
clinical symptoms (Murray et al., 2010).  One of the later distal events is the denervation of 
synapses due to degeneration of the axon, this leaves visible postsynaptic structures on the 
muscle which lack innervation.  Such “empty synapses” are observed in the extensor muscles 
from Akd2C-/- adults although the time at which innervation is lost is unknown.  Denervated 
postsynaptic structures can be maintained for a number of weeks in adults although they 
degrade very rapidly in the first three postnatal weeks (Sanes and Lichtman, 2001).  The 
empty synaptic structures observed in Akd2C-/- muscle (Figure 4.2d) have the characteristic 
pretzel shape of mature synapses that have undergone synapse/input elimination rather than 
simple AChR clusters suggesting denervation.  Therefore, it appears that these muscles were 
innervated for at least the first two post-natal weeks and that there is subsequent denervation 
in the adult as in mouse models of ALS. 
In addition to the limb phenotype, Akd2C-/- mice have a number of other potential motor 
defects which have not fully been explored.  Akd2C-/- pups are observed to have slightly 
increased levels of blood plasma lactate suggestive of hypoxia.  Hypoxia is observed in 
models of both SMA and ALS due to reduced motor innervation of the diaphragm and 
intercostal muscles (Monani et al., 2000; Llado et al., 2006) and is a contributing factor to the 
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death of the animals.  It is likely that Akd2C-/- pups also suffer from motor innervation defects 
in one of these groups of muscles.  The major contributing factor to the death of Akd2C-/- pups 
which do not survive past weaning appears to be an inability to eat to a sufficient degree to 
meet the needs of a growing animal.  Arkadia2C is expressed in the ENS which innervates the 
gut (Chapter3) suggesting that it be required to allow movement of food through the gut and 
removal of nutrients.  Although this can not be ruled out, reduced volumes of food are 
observed in the stomach suggesting that the defect is upstream of this point.  The wasting 
observed in mouse models of ALS and SMA has been linked to low food intake, however it is 
unclear if this is due to a reduced ability to swallow or if respiratory defects lead to a failure to 
co-ordinate swallowing and breathing (Michaud et al., 2010).  The reduced food intake 
observed in Akd2C-/- pups is likely to share a common cause with these models and warrants 
further investigation. 
Overall, Arkadia2C null mice seem to share many symptoms with mouse models of motor 
neuron diseases including ALS, SMA and CMT, although there are also differences between 
the phenotypes (see Table 4.1).  It therefore appears likely that not only is Arkadia2C required 
for NMJ maintenance but that it might control a previously described pathway or function that 
leads to motor neuron disease.  Arkadia2C acts to enhance BMP transcriptional responses; 
however while BMP signalling has linked to motor neuron disease in studies in Drosophila, 
no such link has previously been shown in mammals.  This raises the question of whether the 
motor neuron disease-like phenotype produced in Arkadia2C null animals is due to decreased 
activation of BMP target genes or if Arkadia2C has a function independent of the BMP 
pathway.  Additionally, as the Arkadia2C null clenched paw phenotype is visible from birth it 
suggests that an aspect of this motor neuron disease is developmental rather than 
degenerative.  The implication of BMP signalling in motor neuron disease by the Akd2C-/- 
mice presents a good case for future study into the role of this pathway in such diseases.  In 
particular an understanding of whether Arkadia2C acts up or downstream of proteins known 
to be linked to motor neuron disease will determine whether manipulation of the BMP is a 
potential method of therapy. 
 
In addition to the motor axon phenotype, there is emerging evidence that reduced Arkadia2C 
expression affects the long axons of the corpus callosum in the brain and also the function of 
central neurons leading to a behavioural defect.  In both Akd2C+/- and Akd2C-/- mice complete 
loss of the corpus callosum have been observed in some adults and pups. The corpus callosum 
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contains the axons which join the left and right hemispheres of the brain and are therefore 
longer than many other axons.  This seems to imply that full expression of Arkadia2C is 
required for the formation/growth of long axons in the brain.   
Understanding the role of Arkadia2C in corpus callosum formation is, however, complicated 
by the fact that the phenotype varies dependent upon genetic background.  Loss of corpus 
callosum was most commonly seen in animals on a 129SVcc background reflecting published 
data that 129 mice commonly have callosal defects (Balogh et al., 1999).  However, Akd2C+/+ 
littermates on a 129SVcc background do not have a defect suggesting that both genetic 
background and level of Arkadia2C expression affect the formation and/or maintenance of the 
corpus callosum.  This theory is supported by the fact that loss of corpus callosum has never 
been reported in animals on a Black6 background (Akd2C data not shown and Baloghet al., 
1999), while animals on an outbred CD1 backgroundonly exhibit the defect upon reduction of 
Arkadia2C expression (Akd2C data not shown and Mendes et al., 2006).  Interestingly, the 
variations in callosal defect do not reflect variations in other aspects of the Akd2C-/- 
phenotype.  For instance, while animals on a 129SVcc background have complete loss of the 
corpus callosum, Akd2C-/- pups on this background survive for longer than those on a CD1 or 
Black6 background. 
The central phenotype in Arkadia2C mice adds further evidence to the proposal that central 
connectivity defects result in psychiatric illnesses including Bipolar Disorder.  Whether the 
observed central axon and motor axon defects observed in the same mice have a similar cause 
is unknown, as is whether the central defects are developmental or neurodegenerative. 
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5 Loss of Arkadia2C leads to defects in motor neuron development 
 
In previous chapters it has been shown that the loss of Arkadia2C disrupts the maintenance of 
neuromuscular junctions and null mice show degenerative symptoms similar to those found in 
motor neuron disease models and patients.  However Arkadia2C is also expressed in the 
nervous system throughout embryonic development and newborn Arkadia2C null pups have a 
clear phenotype in their paws unlike in the majority of motor neuron disease models.  This 
suggests that Arkadia2C also has an embryonic role in motor neurons either in their initial 
development or their prenatal maintenance. 
 
5.1.1 Motor innervation of the forelimb 
The lower motor neurons are found in the ventral region of the spinal cord; they project axons 
to the periphery and use ACh as their primary neurotransmitter (Dasen and Jessell, 2009).  
Dependent on their target muscles, motor neurons can be subdivided into four groups, the cell 
bodies of which are located in columns within the spinal cord (Figure 5.1a).  The medial 
motor column (MMC) is found throughout the length of the spinal cord and innervates dorsal 
axial muscles.  The preganglionic column (PGC) and the hypaxial motor column (HMC) are 
found specifically in the thoracic region; they innervate ganglia of the sympathetic chain and 
body wall muscles respectively.  The motor neurons that innervate the limb are located in the 
lateral motor column (LMC) which is found specifically in the brachial (forelimb) and lumbar 
(hindlimb) spinal cord (Dasen and Jessell, 2009). 
The predominant motor neurons affected in the Akd2C-/- adult are in the forelimb which is 
innervated by the brachial LMC.  The adult LMC is split into two divisions (Figure 5.1b); 
axons from cell bodies within the lateral LMC (LMCl) project to the dorsal limb mesenchyme 
which predominantly consists of extensor muscles while axons from the medial LMC 
(LMCm) project to the ventral mesenchyme which produces many flexor muscles 
(Landmesser, 1978; Dasen and Jessell, 2009).  Groups of cells known as motor pools are 
found at distinct positions within these divisions.  Each motor pool projects to a single target 
muscle within the limb.  The vertebrate limb contains more than fifty muscle groups (Dasen 
and Jessell, 2009) suggesting that there must be fifty unique motor pools within the LMC for 
each limb.  Each motor pool has a unique transcriptional signature of genes including Hox 
accessory proteins (Dasen et al., 2008), LIM homeodomain proteins (Tsuchida et al., 1994) 
and ETS factors (Lin et al., 1998).  The expression of these factors would allow the molecular 
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Figure 5.1: Divisions of motor innervation	   
 
(a) Diagram showing the motor columns at different rostral-caudal levels of the spinal cord.  
LMC, lateral motor column; MMC, medial motor column; HMC, hypaxial motor column; 
PGC, preganglionic column; fl, forelimb; hl, hindlimb; sg, sympathetic ganglia; bw, 
bodywall.  Adapted from (Dasen et al., 2008). 
(b) Diagram showing brachial motor columns and summarizing the expression of molecular 
markers within motor pools innervating the forelimb and diaphragm. Adapted from (Rousso 
et al., 2008). 
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identification of each individual motor pool, however a map of these factors is not yet 
complete.  While both the fore and hindlimb LMC have medial and lateral divisions, there are 
differences in motor pool organisation and the genes expressed (Landmesser, 1978; Dasen 
and Jessell, 2009).  However, some generalisations can be made, including that the number of 
cells in a motor pool reflects the size of the muscle it innervates; muscles in the proximal limb 
are innervated by more rostral motor pools and the most rostral fibres within a muscle are 
innervated by cells at the most rostral edge of the motor pool (Dasen and Jessell, 2009). 
 
5.1.2 The development of forelimb innervation 
A ventral-dorsal gradient of Shh from the floorplate determines the position of the five 
subtypes of neural progenitors in the ventral neural tube.  Shh levels induce expression of 
transcription factors which cross-repress each other to produce defined boundaries between 
the five domains.  The penultimate ventral domain expresses Olig2, Pax6, Nkx6.1 and Nkx6.2 
and forms motor neuron progenitors (Briscoe et al., 2000; Dasen and Jessell, 2009).  These 
cells exit the cell cycle at about E9.5 in mice and begin to express motor neuron specific 
transcription factors.  A rostral-caudal (R-C) pattern of Hox gene expression induced by 
opposing gradients of FGF8 (C-R) and retinoic acid (R-C) plays a critical role in patterning of 
motor neurons.  Hox genes not only determine the extent of the different motor columns but 
also the position of the motor pools within that column, interactions between different Hox 
genes have been shown to define the different motor pools (up to ten) at a single R-C level 
(Dasen and Jessell, 2009).  A dynamic pattern of expression of intermediate intrinsic 
transcription factors (used as markers for motor pool subsets) is induced downstream of Hox 
proteins and determines some aspects of motor pool specification.  One example is that 
RALDH2-dependent synthesis of retinoids specifies the LMCl by inducing Lhx1 which 
regulates EphA4 expression preventing axons from entering the ventral mesenchyme (Kania 
et al., 2000; Kania and Jessell, 2003). 
After exiting the spinal cord and entering the peripheral limb target tissue, axons from LMC 
neurons are exposed to permissive neurotrophic factors such as GDNF.  The subset of motor 
neurons which can respond to this signal begin to express the ETS motor pool specific factor 
Pea3 (Haase et al., 2002).  Pea3 determines later steps of motor pool specification including 
clustering of cells into pools, muscle specific innervation and the connectivity between 
sensory and motor systems (Vrieseling and Arber, 2006).  Although the GDNF signal has a 
peripheral source, the ability to respond to it is an intrinsic property of the neurons likely 
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induced in certain cells downstream of Hox proteins.  While Pea3 is the best understood 
example of this peripheral input, the ETS factor ER81 is induced by a peripheral factor in 
certain hindlimb motor pools (Lin et al., 1998) and it is likely that other peripheral signals 
drive later steps of motor pool specification. 
 
All the axons which innervate the forelimb coalesce at the brachial plexus at E10.5 shortly 
after leaving the spinal cord (Huber et al., 2005), however, immediately after entering the 
limb they bifurcate into dorsal and ventral nerves following their LMCl/m identity.  As the 
limb grows and muscle masses start to form the nerves grow out, and axons defasiculate at 
various point in order to head towards their target muscles.  Once the axon has reached its 
target muscles (E13-14.5) immature synapse form, however the nerves in the limb continue to 
grow during embryonic and postnatal life as the limb expands (Landmesser, 1978; Hollyday, 
1980).   
 
5.1.3 Innervation of the diaphragm 
As Akd2C-/- pups exhibit symptoms of hypoxia it seems likely that they have motor deficits in 
the muscles that control breathing; the diaphragm and intercostal muscles.  The diaphragm 
muscle of mammals is located between the thoracic and abdominal cavities and in conjunction 
with the intercostal muscles is used to expand the lungs during breathing.  While the 
diaphragm is essential for breathing in the postnatal period its functions diversify as the 
animal matures to include roles in sneezing, vocalisation and weightlifting, amongst others, 
and in most adult mammals it plays a minimal role in breathing at rest (Mantilla and Sieck, 
2008).  The motor innervation of the diaphragm originates in the lateral region of the brachial 
MMC (Rousso et al., 2008) adjacent to the LMC motor pools which innervate the forelimb.  
However, the diaphragm is much simpler than the limb, the domed structure consists of 
peripheral skeletal muscle which is innervated and a single central tendon which is attached to 
the liver (Ackerman and Greer, 2007).  As the diaphragm is a single muscle it is innervated by 
one motor pool consisting of only about 220 neurons, the axons of which form the phrenic 
nerve (Greer et al., 1999).  In a similar manner to the cells of the LMC there is somatotropic 
patterning of diaphragm innervation; the neurons that are located more rostrally within the 
spinal cord innervate the more ventral regions of the diaphragm (Mantilla and Sieck, 2008).  
However, unlike the cells of the LMC which are under voluntary control and therefore receive 
input from the upper motor neurons of the cortex (Kandel et al., 2000) the cells of the phrenic 
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pool receive rhythmic input from the premotor neurons of the medulla (Mantilla and Sieck, 
2008). 
The development of the diaphragm muscle and its innervation coincides with that of the 
forelimb.  The phrenic axons exit the spinal cord and coalesce with those from LMC neurons 
in the brachial plexus at E10.5, however instead of growing laterally towards the limb they 
grow ventrally towards a protrusion of the body wall known as the pleuroperitoneal fold 
(Greer et al., 1999) currently thought of as the predominant diaphragm primordium (Mantilla 
and Sieck, 2008).  The phrenic nerve and pleuroperitoneal fold descend together in a caudal 
manner towards the mature location of the diaphragm and myoblasts migrate from the 
brachial somites to radiate over the diaphragm structure (Mantilla and Sieck, 2008).  At about 
E12.5 the phrenic nerve starts to form intramuscular branches within the diaphragm muscle 
and it is thought that electrical excitability of theses branches is required for the terminal 
differentiation of the myoblasts into myotubes.  Subsequent to this point the synapses form 
and mature along with the muscle fibres.  While the diaphragm is capable of respiratory 
movements as early as E15.5 when the myotubules and axons have reached the most ventral 
regions (Greer et al., 1999) postnatal maturation of both the synapses and the muscle fibres 
allows the increased repertoire of roles in the adult. 
 
This chapter will examine the embryonic phenotype of Arkadia2C null mice in particular the 
specification of motor neurons, the outgrowth of motor axons and the formation of the 
neuromuscular junctions in the forelimb and diaphragm.  It was found that while motor 
specification and synaptogenesis were normal Arkadia2C null mice suffer from reduced 
motor axon extension.  This suggests that Arkadia2C is required for embryonic development 
of motor neurons in addition to the maintenance of motor neurons in the adult. 
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5.2 Results 
 
5.2.1 Forelimb motor pools are correctly specified between the dorsal and ventral limb 
in Arkadia2C null embryos 
In order to ascertain whether misspecification of motor neurons is a factor in the Akd2C-/- 
phenotype the expression of transcription factors which mark the brachial motorpools that 
innervate the forelimb was examined.  In particular as the adult Akd2C-/- phenotype is specific 
to the dorsal extensor muscles which are innervated by the LMCl, the relative sizes of the 
medial and lateral divisions of the LMC were measured at E13.5.  The LMC was present at 
the correct rostral-caudal position in the Akd2C-/- spinal cord relative to the position of nNos 
expressed by the PGC (data not shown).  The number of LMCm cells co-expressing the 
intrinsic factors FoxP1 and Isl1 was found to be similar in Akd2C+/+ and Akd2C-/- spinal cords 
(47.8% compared to 47.6%, P=0.93) as was the number of LMCl cells expressing FoxP1 and 
high levels of Hb9 (51.9% compared to 52.6%, P=0.89, 13 embryos from each genotype; 
Figure 5.2a).  Therefore, the loss of dorsal axonal innervation in the absence of Arkadia2C is 
not due to a loss of all LMCl neurons and subsequent increase in numbers. 
While the both the LMCl and LMCm are present in the Akd2C-/- spinal cord, this study does 
not exclude the possibility that individual motor pools within the divisions are misspecified.  
As the precise combination of transcription factors expressed by the motor pools which 
innervate the extensor carpi and digiti muscles (affected in Akd2C-/- adults) have not been 
mapped, the presence of these motor pools could not be examined.  However, the ETS factor, 
Pea3 is known to be expressed in response to GDNF signalling predominantly (~95%) in the 
LMCm (Livet et al., 2002).  If misspecification of motor pools in Akd2C-/- embryos lead to a 
greater number of axons encountering GDNF, the number of cells expressing Pea3 should 
increase.  Therefore, the size of the Pea3 positive pool within the LMC was measured in 
Akd2C+/+ and Akd2C-/- spinal cords.  There was found to be no difference in the size of the 
Pea3 positive pool between the two genotypes (20.2% of FoxP1 expressing cells compared to 
19.7%, P=0.84; Figure 5.2b) suggesting that the number of cells exposed to GDNF sources 
within the motor column is not changed by loss of Arkadia2C expression. 
Together these data show that many of the factors that mark specific motor neuron pools in 
the brachial spinal cord are expressed in a normal manner in Akd2C-/- embryos.  This suggests 
that motor neurons are correctly specified in the absence of Arkadia2C and that if there is a 
developmental aspect to the Akd2C-/- phenotype it occurs at a later time point in motor neuron 
development. 
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Figure 5.2: Forelimb motorpools are normally specified in Arkadia2C null embryos 
 
(a) Immunofluorescence showing motor pool marker expression in the brachial spinal cord at 
E13.5. Percentages show number of FoxP1 expressing cells (LMC) that also express Isl1 
(LMCm) or high Hb9 (LMCl). 
(b) Immunofluorescence showing expression of the motor pool marker Pea3 at E13.5. 
Percentages show number of FoxP1 expressing cells that also express Pea3. 
Scale bars = 50μm. 
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5.2.2 Axons innervating the forelimb do not extend fully in Arkadia2C mutant 
embryos 
To examine the development and maintenance of motor axons in Akd2C-/- embryos, the 
Arkadia2C line was bred with mice carrying the motor neuron specific transgene HB9-eGFP 
(Liem et al., 2009).  The growth of eGFP expressing neurons and the muscles they innervated 
was then examined between E11.5, when the nerve has bifurcated to innervate the dorsal and 
ventral limb, and E13.5 when axons have grown to each individual muscle.  The phenotype of 
the limbs was scored against an arbitary scale where 0 was complete loss of dorsal 
innervation; 1 was loss of distal and thining of proximal dorsal innervation; 2 was loss of 
distal dorsal innervation; 3 was thinning of distal dorsal innervation and 4 was normal dorsal 
innervation (examples of phenotype shown in Appendix III).   
Wildtype forelimbs of all ages appeared normal and were scored as 4 (N=17, 18 and 6 for 
E11.5, 12.5 and 13.5 respectively; Figure 5.3c).  At E11.5 Akd2C-/- the majority (9/13) of 
forelimbs were scored as 4, they do not exhibit any obvious motor innervation abnormalities, 
the nerve exits the spinal cord and bifurcates (represented in Figure 5.3a, blue arrow indicates 
the radial nerve innervating the dorsal limb).  3 of 13 forelimbs scored 3 and 1 scored 2 
suggesting that a small number of E11.5 embryos have a mild dorsal forelimb phenotype.  By 
E12.5 a clear innervation defect had developed in the majority (21/24) of forelimbs with 
axons failing to extend into the developing dorsal forelimb muscles (Figure 5.3a,c). These 
phenotypes varied from finer nerve fibres in the distal dorsal limb due to reduced axon 
numbers (score of 3, 7/24 forelimbs), through complete loss of distal dorsal innervation (score 
of 2, 13/24 forelimbs) to finer proximal dorsal innervation in addition to loss of distal 
innervation (score of 1; 1/24 forelimbs).  At E13.5 the phenotype is even more pronounced, 
only 2 out of 24 forelimbs examined did not have an obvious phenotype (score of 4) and 4 out 
of 24 forelimbs scored 3.  A complete loss of innervation to the distal dorsal forelimb was 
observed in the majority of embryos (Figure 5.3a; blue arrow; score of 2, 8/24).  In 10/24 
forelimbs reduced innervation was also observed in the proximal dorsal muscles (score of 4; 
yellow arrows).   
Despite the observed neural deficit, the extensor muscles of the forelimb appear to be of 
normal size at E13.5.  Overlay of the anti-myosin32 and GFP images (Figure 5.3b) show that 
the innervation of the extensor muscles that control the wrist and digits of the forelimb is 
reduced or lost in Akd2C-/- embryos suggesting that the function of these muscles is likely to 
be significantly reduced resulting in the clenched paw phenotype observed in newborn 
Akd2C-/- pups. 
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Figure 5.3: Forelimb muscles develop normally in Arkadia2C null embryos but distal 
extensor muscles lack innervation 
 
(a) Whole-mount immunofluorescence with anti-GFP showing forelimb innervation in HB9-
eGFP transgenic embryos. Blue arrows, distal dorsal limb innervation; yellow arrows, 
proximal dorsal limb innervation. 
(b) Overlay of anti-myosin (red) and anti-GFP (green) at E13.5. 
Scale bars = 250µm. 
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5.2.3 Terminal branches of Arkadia2C null phrenic nerve show reduced growth 
Due to reduced axon growth into the dorsal region of the forelimb, NMJ do not form in this 
region, therefore a different tissue is required to study synaptogenesis and maturation.  In 
addition to the obvious forelimb posture defects, Arkadia2C null mice exhibit mild hypoxia 
suggesting reduced breathing efficiency and a minor defect in innervation of muscles 
involved in breathing.  Therefore, innervation of the diaphragm by the phrenic nerve was 
studied using anti-neurofilament/synaptophysin to examine presynaptic structures and α-
Bungarotoxin to visualise the postsynaptic AChR.  The phrenic nerve extends throughout the 
Akd2C-/- diaphragm at P0 innervating even the ventral-most regions and forms synapses at all 
positions (Figure 5.4a).  However, these synapses are clustered together around the 
intramuscular nerve fibre producing a narrower endplate band both in 17 day old pups (P17) 
where Akd2C-/- individuals are smaller than their littermates and at E18.5, before a size 
difference which might affect the diaphragm is present (Figure 5.4b).  More detailed analysis 
of the terminal branches between the phrenic nerve and the neuromuscular synapses in the 
ventral diaphragm (purple box in Figure 5.4a) was carried out.  This showed that the mean 
length of terminal branches in E17.5 Ark2C-/- diaphragms was 72.25% that of wt (mean length 
of 117.30µm and 84.75 µm, P<0.01) and at P17 64.57% of wt (mean length of 193.61µm and 
125.02µm, P<0.01).  These synapses were found to form normally and in the postnatal animal 
form the stereotypical pretzel shape (Figure 5.4c) indicative of normal levels of synapse 
elimination.  As live Akd2C-/- animals are only mildly hypoxic it seems likely that these 
synapses and the diaphragm they innervate are functional. 
Overall, analysis of the diaphragm shows that axon guidance to the muscle, synaptogenesis 
and postnatal synapse development occur normally in the absence of Arkadia2C expression.  
However, the growth of terminal branches of the axons after they enter the muscle is 
significantly reduced. 
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Figure 5.4: Terminal branches of the phrenic nerve are short in Arkadia2C null mice 
 
(a) Immunofluorescence showing synapse formation throughout the diaphragm muscle at P0. 
Scale bars = 1mm.  
(b) Immunofluorescence showing terminal branch length at E18.5 and P17. 
(c) Immunofluorescence showing gross structure of the neuromuscular junction at P17.  Scale 
bars = 10µm. 
Green, α-Bungarotoxin (AChRs); red, neurofilament & synaptophysin. 
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5.3 Discussion 
	  
In chapter 4 it was shown that Arkadia2C is required for the maintenance of motor neurons 
and their synapses in adults, however the early phenotype in the paws of newborns suggested 
a developmental involvement in the phenotype.  Here examination of embryonic motor pools 
indicated that the brachial LMC is correctly specified in the absence of Arkadia2C expression, 
however axons do not extend into the distal dorsal forelimb.  The increasing proximal-distal 
severity of the limb phenotype indicates that axons that need to grow the greatest distance 
from the spinal cord are most severly affected.  Study of the innervation of the diaphragm 
showed that axon guidance and synaptogenesis were normal in Akd2C-/- animals, however the 
terminal branches were short indicating a defect in axon extension.  The innervation defects 
observed in both the limb and diaphragm suggest a common underlying deficiency in axon 
extension. 
 
The defects observed in the motor neuron development in Akd2C-/- embryos are unlike those 
previously reported in mouse models; the Akd2C-/- phenotype appears to affect the outgrowth 
of motor axons and no other step of motor connectivity.  Additionally, a specific subset of 
motor neurons display a substantial phenotype in the absence of Arkadia2C expression.  This 
is especially evident in the forelimb where the distal dorsal innervation is lost while the 
ventral innervation appears grossly normal although it can not be ruled out that a mild Akd2C-
/- innervation defect forms in the ventral region  Mouse models used to study motor neuron 
development have been produced in which the patterns of axons in the limb are abnormal 
(loss of Hoxc8, (Tiret et al., 1998)) or innervation to specific muscles is lost (loss of Hoxc9, 
(Jung et al., 2010)).  However, in such cases disorganisation of the motor pools within the 
spinal cord is observed in addition to abnormal pattern of motor axon growth and guidance 
within the limb.  The study of motor pool marker expression suggested that such 
disorganisation of the motor columns does not occur in the Akd2C-/- spinal cord, in addition 
the fact that axons are seen entering the dorsal limb at E11.5-E12.5 and the diaphragm is 
correctly innervated suggest that motor axon guidance is normal in the absence of Arkadia2C 
expression.  Instead it appears that motor axon extension is a process independent of 
specification and guidance of the motor axon and that Arkadia2C is required for this.   
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Akd2C-/- mice are born with clenched paws and develop symptoms of hypoxia and reduced 
food intake that are reminiscent of models of motor neuron disease.  This suggests that the 
reduced axonal growth of motor neurons in the forelimb and diaphragm contributes to the 
disability seen in the pups.  It is also possible that a deficit in axon growth is the underlying 
cause of axon degeneration after birth due to an inability to elongate in response to the 
postnatal growth of the animal.  The symptoms of human SMA and CMT disease patients can 
manifest within the first few years of life (Prior, 2010; Patzko and Shy, 2011) and mouse 
models of these diseases are often born with strong phenotypes (Monani et al., 2000; Detmer 
et al., 2008) in a similar manner to Akd2C-/- mice.  There have been very few studies of 
whether motor neuron development plays a role in such early onset motor neuron disease 
phenotypes, however one study suggested that mice with an early onset of SMA like 
symptoms have normal axon growth to the target muscle but fail to maintain the NMJ 
(McGovern et al., 2008).  This suggests that the murine model of motor neuron disease 
provided by the Akd2C-/- mice is the first to clearly link an embryonic motor neuron defect 
with later motor axon degeneration. 
 
In this chapter Arkadia2C has been shown to play a role in the embryonic growth of motor 
axons in addition to their postnatal maintenance.  Arkadia2C enhances BMP signalling, 
however the BMP pathway has not previously been linked to the embryonic development, in 
particular axon growth, of motor neurons in mammals.  It is therefore unknown how loss of 
Arkadia2C mediates the observed phenotype.  In particular it remains to be explained why 
loss of Arkadia2C expression produces a stronger axonal growth phenotype in the axons 
which innervate the diaphragm and dorsal forelimb than in other motor neurons. 
6 Arkadia2C functions within the Smad mediated BMP signalling 




Biochemical and in ovo evidence suggest that Arkadia2C enhances signalling through the 
canonical BMP pathway (See Chapter 3).  Loss of Arkadia2C expression produces a neural 
phenotype in both the adult and embryo, the most striking aspects of which are defective 
motor axon elongation in the embryo and degeneration of NMJ in the adult.  This implies that 
enhancement of canonical BMP signalling by Arkadia2C is required for growth and 
maintenance of motor axons despite such roles not having been previously attributed to the 
BMP pathway.  To test the molecular function of Arkadia2C in vivo, genetic interaction 
experiments with mice carrying mutations in components of the BMP pathway were used.  As 
Arkadia2C enhances BMP signalling responses, it is possible that a genetic reduction of a 
component of the pathway could recapitulate aspects of the motor neuron phenotype in 
Arkadia2C heterozygous mice which otherwise do not exhibit motor neuron defects. 
 
6.1.1 Genetic interaction experiments 
The crossing of mouse lines carrying mutations in two different genes and examination of the 
resulting phenotype has been used to determine the in vivo action of a gene.  The phenotype 
of compound mutants produced by these crosses can be much more severe than that produced 
by either individual mutation.  This phenomenon, which defines genetic interaction, reveals a 
functional relationship between the two genes and the pathways they act in.  In addition to 
identifying two genes which act towards the same functional outcome, genetic interaction 
experiments can show the relative positions of different genes within a single pathway.  Loss 
of a gene that acts upstream in a linear pathway cannot affect the phenotype produced by a 
downstream gene as the pathway is already fully blocked.  Genetic interaction experiments 
can also address redundancy between two proteins; for instance Nodal expression must be 
repressed in the anterior epiblast to allow normal gastrulation, however embryos that are null 
for either of the unrelated Nodal agonists Cerberus-like or Lefty1 complete gastrulation 
(Perea-Gomez et al., 2001).  This suggests that the two proteins act in a redundant manner, a 
hypothesis confirmed by the production of compound Cerberus-like/Lefty1 mutants which 
displayed patterning defects as early as E6.5 (Perea-Gomez et al., 2002). 
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 Figure 6.1: Developmental outcomes of Arkadia/Nodal compound mutants 
	  
Graph showing relative amounts of Arkadia enhanced Nodal signalling present in embryos of 
different genotypes.  Approximate threshold levels required for different developmental 
events are shown, genotypes which do not reach the appropriate threshold fail to undergo the 
event and present with the relevant phenotype. 
 
Adapted from (Andrew, 2003). 
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Genetic interaction experiments between genes within the same pathway, including those that 
have functional redundancy can also be used to assess the level of pathway activation required 
for a specific event.  Signalling pathways which act in a morphogenic manner are thought to 
activate different target genes at different thresholds of pathway activity; if activity is even 
marginally below the threshold the target gene will not be activated.  Genetic interactions 
allow the manipulation of the activity of signalling pathways in relatively small increments 
and study of the phenotype of each compound mutant allows a scale of signalling to be 
concluded for different events (see Figure 6.1).  
6.1.2 Genetic interaction experiments using the Arkadia proteins 
Genetic interaction experiments were first used to show the role of Arkadia in Smad2/3-
mediated signalling (Episkopou et al., 2001), a function later confirmed using biochemical 
experiments.  While mice heterozygous for either Nodal (Collignon et al., 1996) or Arkadia 
are born at expected rates, some double heterozygous Akd+/-:Nodal+/- embryos exhibit anterior 
truncation with 10% of embryos having a phenotype equivalent to Akd-/- embryos.  Further 
experiments using the Nodal hypomorph (Lowe et al., 2001) in addition to the Nodal and 
Arkadia lines allowed the levels of Smad2/3 mediated signalling to be manipulated and a 
hierarchy of signalling thresholds required for early developmental events to be established 
(Figure 6.1, (Andrew, 2003)). Genetic interactions between Arkadia and Nodal were 
consistent with the molecular function of Arkadia, and biochemical data showed that 
Arkadia2C acted in a similar manner to enhance the BMP signalling response.  It was 
therefore concluded that genetic interaction experiments between BMP pathway components 
and Arkadia2C would be a suitable means by which to examine whether Arkadia2C acted in 
this pathway in motor neurons.  As in the experiments using Arkadia, these were expected to 
produce an Akd2C-/--like phenotype in Akd2C+/- mice that had reduced expression of a 
component of the BMP signalling pathway.   
6.1.3 Interaction between Arkadia proteins and other signalling pathways 
The scaffold protein Axin has been shown to bind to Smad7 and Arkadia enhancing the 
ubiquitination and subsequent degradation of Smad7 by Arkadia.  Axin binds to many 
proteins and has been shown interact with components of the MAP kinase signalling cascade 
in addition to Smad3 (Yasuda et al., 1999; Furuhashi et al., 2001), however it also plays a 
critical role in the canonical Wnt signalling pathway.  Axin acts as a scaffold for a group of 
proteins including adenomatous polyposis coli (APC) and glycogen synthase kinase 3β 
(GSK3 β); the kinase component phosphorylates β-catenin leading to its ubiquitination and 
degradation.  When Wnt ligands bind the Frizzled/Ryk receptor complex, Dishevelled is 
	   120	  
activated blocking the phosphorylation of β-catenin.  The subsequent accumulation of β-
catenin allows it to enter the nucleus and activate target genes together with TCF/LEF (Hur 
and Zhou, 2010). 
While Arkadia has not been shown to directly interact with any component of the Wnt 
pathway other than Axin, the fact that multiple pathways utilise the scaffold may allow Wnt 
signalling to influence Arkadia-mediated TGF-β signalling and vice-versa.  Indeed it was 
found that increased activation of the Frizzled receptors leads to degradation of Axin and 
therefore represses the degradation of Smad6/7 by Arkadia leading to reduced activation of 
TGF-β target genes (Liu et al., 2006). 
 
This chapter examines the role of Arkadia2C in vivo by the means of genetic interaction 
experiments.  The results show a genetic interaction between Arkadia2C and BMPRII or 
Smad8, producing a phenotype similar to that seen in Arkadia2C null mice.  These data 
therefore confirm Arkadia2C enhances the BMP signalling response in vivo. 
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6.2 Results 
	  
6.2.1 Arkadia2C function does not overlap with that of Arkadia in the regulation of 
Smad2/3 signalling  
To examine whether there is cross-talk between Arkadia mediated enhancement of Smad2/3 
signalling responses and Arkadia2C in vivo, a series of genetic interaction experiments were 
carried out.  If Arkadia2C functioned in this pathway then a reduction in the expression of any 
pathway component would be expected to increase the severity of the Akd2C-/- phenotype and 
produce a similar phenotype in Akd2C+/- pups.  In order to assess changes in phenotype 
severity, offspring from the genetic interaction crosses were counted less than 24 hours after 
birth and any dead pups were collected.  At this age live pups were also scored for the 
presence of an Akd2C-/--like phenotype observed as holding the forepaws in loose fists.  Litters 
were followed until weaning age and as many pups as possible were collected if they died.  
Dead pups were genotyped using the appropriate PCR, all other mice were genotyped after 
weaning at postnatal day 21. 
It had previously been shown that loss of Arkadia2C expression did not alter the Akd-/- 
phenotype and vice-versa (work carried out by Shinya Tanaka) suggesting that the two 
Arkadia proteins do not have a redundant function in vivo.  However, this did not address the 
potential role of Smad2/3 dependent signalling in the neuronal Akd2C-/- phenotype; to do so 
the P9-3f Arkadia2C line was crossed with lines carrying mutations in Nodal (Collignon et 
al., 1996) and the nuclear co-repressor SnoN, a major substrate of Arkadia (BayGenomics ES 
cell line RRH119, International Gene Trap Consortium).  As mice null for Nodal die prior to 
the formation of the Akd2C-/- limb innervation defect at E12.5 (Zhou et al., 1993), an Akd2C+/-
:Nodal+/- X Akd2C+/- cross was used to examine whether a phenotype was present in double 
heterozygotes and whether the Akd2C-/- phenotype was more severe when the Nodal 
expression was reduced  The SnoN mutant line produces hypomorphs which are viable and 
fertile as homozygotes; therefore Akd2C+/-:SnoN-/- mice were examined for a phenotype and 
the phenotypes of Akd2C-/-:SnoN-/- and Akd2C-/-:SnoN+/+ were compared (For crosses and 
expected offspring see Appendix IV). 
Akd2C+/-:Nodal+/- mice do not exhibit a visible paw phenotype and reduced Nodal expression 
does not decrease the birth rate of Akd2C-/- mice, implying that the phenotype severity does 
not change (Raw data in Appendix VIa).  If Arkadia2C acts in a similar manner to Arkadia to 
enhance Smad signalling via degradation of SnoN, loss of SnoN expression should rescue the 
Akd2C-/- phenotype.  However, Akd2C-/-:SnoN-/- mice were born at lower than expected 
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frequencies and the majority died prior to weaning (Raw data in Appendix VIa); this 
phenotype was not notably different to that of Akd2C-/- pups and suggests that SnoN is not a 
substrate of Arkadia2C.  These genetic results match the biochemical data showing that 
Arkadia2C does not bind PSmad2/3, enhance the CAGA-luciferase reporter or degrade SnoN 
(Figure 3.1, 3.4) and therefore confirms in vivo that Arkadia2C does not act in the Smad2/3 
mediated branch of TGF-β signalling. 
 
6.2.2 Arkadia2C functions in the BMP pathway in vivo 
A similar strategy was used to examine whether Arkadia2C acts upon the BMP pathway in 
vivo.  The P9-3f Arkadia2C was crossed with lines carrying mutations in the receptors 
BMPRII (Beppu et al., 2000) and BMPRIa (Mishina et al., 2002) and the effector Smad, 
Smad8 (Arnold et al., 2006).  In a similar manner to Nodal-/- mice, those embryos null for 
BMPRIa and BMPRII die early in embryonic development, therefore double heterozygotes 
were predominantly studied.  The Smad8 line is, however, viable and fertile as homozygotes 
allowing a full range of genotypes to be examined (See Appendix IV for crosses and expected 
offspring).  Additional studies were attempted using a Smad4 line, however Arkadia2C and 
Smad4 were found to be only 4Mb apart on Chromosome 18 preventing transmission of two 
mutant alleles on a single chromosome.  This resulted in the birth of very low numbers of 
Akd2C+/+:Smad4+/+ (possibly misgenotyped, see Appendix Vb) and prevented the origin of 
the loss of Akd2C-/-:Smad4-/- from being distinguished. 
 
Examination of offspring from the Arkadia2C/BMPRIa cross found no visible paw phenotype 
in double heterozygous Akd2C+/-:BMPRIa+/- mice at birth, animals were born in similar 
numbers to Akd2C+/- mice and all lived to weaning (Raw data in Appendix Va).  All Akd2C-/- 
mice born from this cross died prior to weaning independent of the BMPRIa genotype.  This 
suggests that reduction in BMPRIa expression does not alter the Akd2C-/- phenotype and may 
reflect the limited expression pattern of BMPRIa within the nervous system.  However, 
examination of double heterozygous offspring from the Akd2C/BMPRII cross found that 
significantly fewer than expected Akd2C+/-:BMPRII+/- were born with a compensatory 
increase in numbers of wildtype mice (χ2 test on pups live at postnatal day 2 excluding 
Akd2C-/- individuals, P<0.001) (Table 6.1a, Raw data in Appendix Vb).  A weak clenched 
paw phenotype was observed in approximately 50% of those Akd2C+/-:BMPRII+/- alive at P2, 
however all pups survived to weaning at which point they were indistinguishable from 
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Table 6.1: Offspring from crosses showing a genetic interaction with Arkadia2C 
 
Offspring from the (a) Arkadia2C+/-:BMPRII+/- X Arkadia2C+/- and (b) Arkadia2C+/-
:Smad8+/- X Arkadia2C+/-:Smad8+/- crosses. N= 138 and 147 respectively.  Arrowheads 
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littermates.  This suggests that Arkadia2C and BMPRII interact and therefore that Arkadia2C 
acts in a BMP signalling pathway.  However, as BMPRII can activate a non-canonical (i.e. 
non-Smad dependent) signalling pathway, this does not show whether Arkadia2C acts upon 
Smads in vivo as it has been shown to in biochemical studies.  Additionally, as BMPRII is 
widely expressed this does not address whether the interaction between Arkadia2C and the 
BMP pathway occurs in a cell intrinsic manner within the motor neuron. 
To study whether Arkadia2C acts in the canonical BMP pathway the Arkadia2C line was 
crossed with the Smad8 null line.  As Smad8 has a highly restricted expression pattern in the 
nervous system (Arnold et al., 2006) and chapter 7) and is absent from the limb mesenchyme 
and muscle, this cross also addressed whether the interaction between Arkadia2C and the 
BMP pathway is cell intrinsic.  A clear genetic interaction was observed between Arkadia2C 
and Smad8; Akd2C+/-:Smad8-/- mice were born at lower numbers than expected (χ2 test on 
pups live at postnatal day 2 excluding Akd2C-/- individuals, P<0.1), 65% of those born held 
their paws in loose fists in a similar manner to Akd2C-/- pups and 28% of pups born died prior 
to weaning (χ2 test on pups live at postnatal day 25 excluding Akd2C-/- individuals, P<0.01) 
(Table 6.1a, Raw data in Appendix Vc).  In addition, Akd2C-/-:Smad8-/- mice were born in 
lower numbers than Akd2C-/-:Smad8+/+ pups and had reduced survival rates.   
Overall, reductions in BMPRII, Smad8 expression all increase the severity of the Akd2C-/- 
phenotype suggesting that Arkadia2C acts in the BMP pathway.  These genetic results 
confirm the data produced by the in ovo and biochemical studies and show that these 
experiments are an appropriate way to examine the function of Arkadia2C in vivo.  As the 
biochemical data suggests that Ski is degraded by Arkadia2C, further crosses between the P9-
3f and Ski lines are planned to fully confirm the in vivo function of Arkadia2C. 
 
6.2.3 Arkadia2C/BMP pathway component compound mutants exhibit adult motor 
phenotypes  
The BMP signalling pathway plays an essential role in many steps of early embryonic 
development.  Therefore, it is possible that the observed decreased birth rates of certain 
genotypes might be due to a failure of embryos to pass early development stages rather than a 
motor neuron defect similar to that observed in Akd2C-/-mice.  Akd2C+/-:Smad8-/- and 
Akd2C+/-:BMPRII+/- are both born at lower than expected frequencies but the majority survive 
to adulthood; therefore whether these adult mice have defective forepaw motor function, in a 
similar manner to Akd2C-/-mice, was examined. 
	   125	  
Figure 6.2: Offspring from the BMP/Arkadia2C genetic crosses have reduced distal 
forelimb extension 
 
(a-b) Dot plot showing mean hang time on inverted cagelid ±SEM for each mouse and 
box/whisker plot showing variations within hangtime of each genotype.  Akd2C+/+, N = 7; 
Akd2C-/- , N = 8; Arkadia2C+/-:BMPRII+/-, N = 16; Arkadia2C+/-:Smad8-/-, N=11; 
Arkadia2C/Smad8 littermates,  N=15; **, P<0.01.  Arkadia2C/Smad8 littermates consist of 
Arkadia2C+/+:Smad8+/-, Arkadia2C+/+:Smad8-/-, Arkadia2C+/-:Smad8+/-. 
(c-d) Histograms presenting measurements of footprint trails of Akd2C+/+, Arkadia2C+/-
:Smad8-/-, Arkadia2C/Smad8 littermates (c), Arkadia2C+/-:BMPRII+/- and Arkadia2C/BMPRII 
littermates (d) shown as average of genotype population±SD.  Akd2C+/+, N= 4; Arkadia2C+/-
:Smad8-/-, N=10; Arkadia2C/Smad8 littermates, N=7; Arkadia2C+/-:BMPRII+/-, N=5; 
Arkadia2C/BMPRII littermates, N=7; *, 0.05>P>0.01;. 
(e) Forelimb muscles from a single Arkadia2C+/-:Smad8-/- mouse; extensor carpi radialis 
longus (ECRL), extensor carpi radialis brevis (ECRB); shows right (R) and left (L) limbs.  
Scale bars = 1mm. 
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The behavioural test that shows the clearest difference between Akd2C-/-and wildtype mice is 
the cage lid test as it measures the function of the extensor muscles in addition to the flexors.  
Therefore, the ability of offspring from the genetic interaction crosses to suspend themselves 
from a cagelid was measured (Figure 6.2a-b).  A subpopulation of 12.5% of Akd2C+/-
:BMPRII+/- (N=16) mice had a performance of less than 30 seconds, however as the majority 
(62%) perform in a similar manner to wildtype mice no significant difference was observed 
between the genotypes.  Akd2C+/-:Smad8-/- mice show a wide range of performances with 
55% of animals failing to reach 30 seconds (N=11) compared with only 7% of littermate 
controls (N=15), these mice performed significantly worse than both wildtype animals and 
Akd2C/Smad8 littermate controls (P=4.07x10-5 and P=8.38x10-4). There was a great 
variability in the performances of the Akd2C/Smad8 intercross littermates (P=0.013 
compared to wildtype animals) which may reflect the different levels of BMP pathway 
activity achieved in the motor neurons of these mice. 
Akd2C-/- adults which have a poor performance in the cage lid test are observed to have 
reduced extension of their forelimb digits and reduced spread of their hindlimb digits, 
therefore the forelimb pawprints of Akd2C+/-:Smad8-/- and Akd2C+/-:BMPRII+/- mice were 
studied.  A different cohort of mice was used for these experiments than in the above cagelid 
tests.  Preliminary cagelid testing showed that the second cohort of animals from the 
Akd2C/Smad8 intercross behaved in a similar manner to those in Figure 6.2a with a subset of 
Akd2C+/-:Smad8-/- performing very poorly and a wide range of performances amongst 
littermate controls.  The mice from the Akd2C/BMPRII intercross all achieved 60 seconds on 
the cagelid test independent of genotype.  However, some Akd2C+/-:BMPRII+/- had observable 
difficulty maintaining a grip suggesting more in-depth studies might reveal a reduced test 
performance.  In light of these results, a pawprint analysis was carried out to look for a subtle 
difference in paw posture amongst offspring from the Akd2C/BMPRII intercross.  In addition 
to the measurements shown in Figure 4.2a, the percentage of footprints from each mouse 
which have visible toe prints which are fully spread (“normal prints”) was counted and each 
mouse was scored on its ability to produce a “normal footprint trail” in which subsequent 
right and left prints were present.  The lack of such a normal trail may indicate an abnormal 
gait or hesitance coupled with repeated placing of a paw. 
It was found that the majority of measurements were similar between Akd2C+/-:Smad8-/- and 
Akd2C/Smad8 littermates (Akd2C+/+:Smad8+/- Akd2C+/+:Smad8-/- Akd2C+/-:Smad8+/-) although 
the average forepaw length was slightly shorter in Akd2C+/-:Smad8-/- (6.36mm compared to 
7.00mm; P=0.03; Figure 6.2c and Appendix II).  However, studies of the percentage of 
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“normal prints” found no significant difference between Akd2C+/-:Smad8-/- and littermates; 
abnormal trails of footprints were produced by some mice of all genotypes (Appendix II).  As 
a subset of mice of all Akd2C:Smad8  genotypes performed poorly (less than 30 seconds) in 
the cagelid test (Figure 6.2 a and data not shown for this cohort) a correlation between the 
posture/gait of mice and their performance in the cage lid test was hypothesised.  However, no 
significant difference between the two groups was observed (All P≥0.3, Appendix II).  The 
observed decrease in forepaw length reveals a difference between the gaits of Akd2C+/-
:Smad8-/- and littermates.  The lack of observable differences in all other fields studied may be 
due to the fact that the littermate controls had reduced expression of either Arkadia2C or 
Smad8 potentially leading to variability in motor axon function. Comparison between 
Akd2C+/-:Smad8-/- and wildtype animals found a significant decrease in minimum stride 
length, average foot length, inner toe spread and the percentage of prints that appear normal 
(P=0.007, 2.00x10-5, 1.35x10-4, 0.005, 1.71x10-4 respectively) and an increase in average and 
maximum stride width (P=0.008, 0.027).  While comparisons between these mice is 
complicated by differences in genetic background it appears that Akd2C+/-:Smad8-/- mice have 
abnormal gait/posture. 
No significant differences were observed between Akd2C+/-:BMPRII+/- mice and their 
littermates (Akd2C+/+:BMPRII+/+, Akd2C+/+:BMPRII+/-, Akd2C+/-:BMPRII+/+), however 
differences were again observed between Akd2C+/-:BMPRII+/- and wildtype mice (Figure 6.2c 
and Appendix II).  Average foot length, inner toe spread and the percentage of prints that 
appear normal were all significantly reduced in Akd2C+/-:BMPRII+/- (P=1.00x10-6, 9.20x10-4, 
0.08, 0.08 respectively).  Together these data suggest that the genetic reduction of BMP 
pathway activity in vivo produces mice with abnormal gait/posture in a similar manner to 
Akd2C-/- mice. 
 
As forelimb extensor muscles are observed to be smaller in Akd2C-/- adult mice than in 
wildtype, the forelimb muscles of Akd2C+/-:Smad8-/- individuals with the strongest phenotype 
were examined Some of these mice were observed to hold only one paw in a loose fist with 
the second paw in a normal posture (70% of animals have a stronger phenotype in one paw, 
split evenly between right and left limbs).  The forelimbs of three 7-month old mice with a 
stronger phenotype in one paw were dissected.  It was found that the limb in which the paw 
was held in a fist had greatly reduced extensor muscle mass compared to the other limb 
(Figure 6.2e).  The extensor carpi muscles that control the wrist were atrophied and were 
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found to be much smaller than normal while the extensor digiti muscles had atrophied almost 
completely.  The muscle from the healthy arm appeared to be larger than those from wildtype 
mice of a similar age (data not shown), this may allow it to compensate for the reduced 
function of the affected limb. 
 
Overall, there is evidence that both Akd2C+/-:BMPRII+/- and Akd2C+/-:Smad8-/- animals have 
reduced extensor function in the forelimb although there is variation between individuals.  
This suggests that reduced activity in the BMP pathway produces a motor axon phenotype in 
conjunction with a decrease in Arkadia2C expression and that the loss of NMJ maintenance 
observed in Akd2C-/- individuals is mediated by Smad dependent signalling.  As Smad8 is not 
expressed in the limb and only within restricted regions of the nervous system (See Chapter 
7), this suggests that BMP signalling responses are required within the motor neurons 
themselves. 
 
6.2.4 Arkadia2C/BMP pathway component compound mutants exhibit embryonic 
motor phenotypes  
An observable clenched paw phenotype is present in some Akd2C+/-:Smad8-/- and Akd2C+/-
:BMPRII+/- individuals at birth in a similar manner to the phenotype of Akd2C-/- pups.  This 
suggests that, as in the case of Akd2C-/-, the Akd2C+/-:Smad8-/- and Akd2C+/-:BMPRII+/- 
phenotypes might have a developmental aspect.  To study embryonic motor axon growth in 
these genotypes the Hb9-eGFP transgene was introduced into the genetic interaction crosses 
and offspring scored according to the method described in Chapter 5 and Appendix III.   
No motor phenotype was previously reported in heterozygotes from the BMPRII line (Beppu 
et al., 2000) and Akd2C+/- also appear to have normal motor function, this is reflected by the 
fact that normal motor axon growth in the E13.5 forelimb was observed in embryos of these 
genotypes (Figure 6.3a).  However, two of six Akd2C+/-:BMPRII+/- forelimbs were observed 
to have lost the innervation of the dorsal forelimb (phenotype score 2) as observed in Akd2C-/- 
embryos.  In addition, Akd2C-/-: BMPRII+/- embryos were found to have a more severe 
phenotype than that observed in any Akd2C-/- individuals previously studied (Figure 6.3b, 
phenotype score of 1-0).  However, previous studies have found variation in the Akd2C-/- 
embryonic axon growth phenotype particularly between individuals with different genetic 
backgrounds.  Therefore, the strong phenotype observed in Akd2C-/-: BMPRII+/- might be due 
to variation in the phenotype within the small number of mice studied, rather than a true 
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Figure 6.3: Offspring from the BMP/Arkadia2C genetic crosses have forelimb axon 
growth defects 
(a-c) Whole-mount immunofluorescence with anti-GFP showing forelimb innervation at 
E13.5 in HB9-eGFP transgenic embryos and histograms showing percentages of forelimbs 
with each classification of phenotype from the (a-b) Arkadia2C+/-:BMPRII+/- X Arkadia2C+/- 
and (c) Arkadia2C+/-:Smad8+/- X Arkadia2C+/-:Smad8+/- crosses.  Yellow arrowheads, distal 
dorsal limb innervation; proximal limb to the left.  
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increase in severity.Similarly, no motor phenotype was previously reported in animals from 
any of the Smad8 null lines that have been produced (Arnold et al., 2006; Huang et al., 2009).  
As Akd2C+/-:Smad8-/- adult mice have reduced limb function and muscle size, the embryonic 
forelimb innervation of this genotype was studied.  No reduction was seen in the forelimb 
motor axon growth of Akd2C+/-:Smad8-/- embryos at either E13.5 or 14.5 (37 and 20 Hb9-
eGFP positive embryos of all genotypes studied respectively) (Figure 6.3c).  This suggests 
that at this developmental stage there is no decrease in forelimb motor axon growth due to a 
combined reduction in Smad8 and Arkadia2C expression in the mice studied.  Study of the 
expression pattern of Smad8 found that very little was expressed in the spinal cord prior to 
E14.5 (see Chapter 6).  This is likely, therefore, to rule out a role of Smad8 in embryonic axon 
growth, however it does not discount that this event is mediated by Smad dependent BMP 
signalling 
 
6.2.5 BMP pathway component compound mutants rarely exhibit adult motor 
phenotypes  
The genetic interaction experiments between Arkadia2C suggest that decreased BMP 
signalling leads to reduced motor axon growth and maintenance whether signalling reduction 
is achieved by lowered expression of Arkadia2C alone or a combination with components of 
the BMP pathway.  It would therefore be predicted that genetic removal of BMP pathway 
components without reduced Arkadia2C expression may also reduce BMP signalling in motor 
neurons to produce an axon growth phenotype.  The Smad8 null line produces a motor axon 
phenotype in conjunction with Arkadia2C but are other wise completely viable as Smad8 has 
functional redundancy with Smad 1 and 5.  Despite this functional redundancy, it is likely that 
Smad8-/- mice have less tolerance to fluctuations in BMP signalling levels, and therefore 
introduction of a mutation in a second pathway component might produce an Akd2C-/--like 
phenotype.  To examine whether reduced expression of Smad8 in combination with Smad4 or 
BMPRII lowers BMP signalling sufficiently to produce such a phenotype, the birth and 
weaning rates of offspring from Smad8+/-:Smad4+/-X Smad8-/- and Smad8+/-:BMPRII+/-X 
Smad8-/- crosses were studied and adults were tested for a phenotype of weakness in the 
forelimb extensor muscles.	   
The offspring from these crosses were found to be born at expected numbers in all genotypes 
and the majority survived to weaning, although survival of Smad8-/-BMPRII+/- pups was 
reduced by 5% (Table 6.2).  Some individuals with the greatest reduction in BMP signalling 
	   133	  
Table 6.2: Birth and weaning rates from BMP crosses	  
 
Offspring from the (a) Smad8+/-:BMPRII+/- X Smad8-/-, and  (b) Smad8+/-:Smad4+/- X Smad8-
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 component expression (Smad8-/-:Smad4+/- and Smad8-/-:BMPRII+/-) were observed to hold 
their paws in a loose fist in a similar manner to Akd2C-/- mice both as pups and adults.  
However, phenotypes were seen in individuals of all genotypes suggesting it is not unique to 
those genotypes with the greatest decrease in BMP pathway component expression. 
It was found that only 8% (3/37) of all animals from the Smad8/Smad4 intercross tested on 
the cagelid test performed poorly, one of these was Smad8-/-:Smad4+/- (this mouse was the 
worst performer) and two of which were Smad8+/-:Smad4+/- (Figure 6.4a).  The remaining 
mice showed a spread of scores between 30 and 60 seconds independent of genotype with no 
trend or significance seen between the different genotypes.  Offspring from the 
Smad8/BMPRII cross produced cagelid test performances of 5 to 60 seconds completely 
independent of genotype with no trend or significance (Figure 6.4b). 
Analysis of the pawprints from a subset of the mice tested on the cagelid test was carried out 
and no significant difference was found in any measurement made between Smad8-/-:Smad4+/- 
or Smad8-/-:BMPRII+/- and their littermates.  As there was a spread in cagelid test performance 
in all genotypes, the mice were grouped into those that achieved scores of 30 seconds or less 
and those that achieved scores of more than 30 seconds and their pawprints analysed.  Again 
there was no significant difference between the pawprints of the two groups produced from 
either cross (See Appendix II).  As all genotypes survived to weaning and there was not a 
clear weakness in the forelimb, these crosses produce an insufficient reduction in BMP 
signalling to result in a motor axon phenotype equivalent to that observed in Akd2C-/- mice.  
The wide range of performances in the cagelid test, in which very few animals performed at a 
wildtype level (60 seconds, see Figure 6.2a) suggests a mild motor defect is produced by the 
reduction in BMP signalling activity achieved in these crosses.  However, this data strongly 
indicates that in the presence of wildtype levels of Arkadia2C expression the BMP pathway is 
sufficiently robust to allow normal development and maintenance of motor neurons. 
 
6.2.6 Arkadia2C also interacts genetically with β-catenin to produce a motor neuron 
phenotype 
Finally, genetic interaction experiments were carried out between Arkadia2C and the gene 
regulatory protein β-catenin, a component of the canonical Wnt signalling pathway.  The 
protein scaffold Axin has been shown to play a critical role in both canonical Wnt signalling 
and the Arkadia mediated degradation of Smad6/7 (Liu et al., 2006).  Increased Wnt 
signalling decreases the repression of Smad6/7 by Arkadia via degradation of Axin.  
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  Figure 6.4: Behavioural phenotypes of mice with reduced BMP pathway expression 
 
(a-b) Dot plot showing mean hang time on inverted cagelid ±SEM for each mouse and 
box/whisker plot showing variations within hangtime of each genotype from a Smad4/Smad8 
cross (a) and BMPRII/Smad8 cross (b). Akd2C+/+, N = 7; Akd2C-/- , N = 8; Smad8+/-:Smad4+/+, 
N=6; Smad8-/-:Smad4+/+, N=7;  Smad8+/-:Smad4+/-, N=12; Smad8-/-:Smad4+/-, N=12; 
Smad8+/-: BMPRII +/+, N=10; Smad8-/-: BMPRII +/+, N=12; Smad8+/-: BMPRII +/-, N=12; 
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Whether Arkadia2C also interacts with Axin has not been examined, however even if this 
were the case as β-catenin is downstream of Axin reduced β-catenin expression is not 
expected to significantly affect activity of Arkadia2C.  Therefore a β-catenin/Arkadia2C cross 
was set up as a negative control in which the expression of β-catenin was not expected to alter 
the Akd2C-/- phenotype .  However, examination of offspring from this cross indicated that a 
genetic interaction did in fact occur between the two genes.  Reduced numbers of Akd2C-/-:β-
cat+/- were born compared to Akd2C-/-:β-cat+/+ suggesting an increased phenotype severity.  
Furthermore Akd2C+/-: β-cat+/- mice were born in slightly lower numbers than expected and 
only 69.2% of those born survived to weaning.  Strikingly, 38.5% of those Akd2C+/-:β-cat+/- 
mice born held their paws in a loose fist in a similar manner to Akd2C-/- pups (Table 6.3, Raw 
data in Appendix VIb).  This suggests that, like BMP signalling, the Wnt pathway plays a role 
in the motor innervation of the forelimb. 
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Table 6.3: Offspring from genetic interaction cross  between  Arkadia2C and β-catenin 
 
Offspring from the Arkadia2C+/-:β-catenin+/- X Arkadia2C+/- crosses.  N= 142.  Arrowheads 
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6.3 Discussion 
Biochemical/molecular evidence showed that Arkadia2C enhances signalling through the 
BMP-Smad1/5/8 pathway.  While loss of BMP enhancement leads to a motor axon growth 
and maintenance defect in Akd2C-/- mice, the canonical BMP pathway has not previously been 
shown to play such roles, raising the possibility that the Akd2C-/- phenotype is not a result of 
decreased levels of BMP signalling.  To test whether the Akd2C-/- phenotype is mediated by 
BMP signalling and whether certain threshold levels of BMP activity are required in motor 
neurons, murine genetic interactions were used.  It was found that the severity of the Akd2C-/- 
phenotype increases in the absence of one allele of BMPRII or both alleles of Smad8.  
Additionally, an Akd2C-/--like phenotype was observed in Akd2C+/-:BMPRII+/- and Akd2C+/-
:Smad8-/- pups while Akd2C+/- pups have no phenotype.  As these genes act in the BMP-
Smad1/5/8 branch of the TGF-β pathway, these results suggest that the Akd2C-/- axon growth 
phenotype is, to a large extent, mediated by this pathway and requires downstream target gene 
activation.  In addition, as Smad8 expression is highly restricted the interaction between 
Arkadia2C and Smad8 most likely occurs within the motor neurons suggesting these cells 
contain active BMP signalling. 
Genetic interaction experiments allow a decrease in the activation of a signalling pathway by 
removal of alleles of pathway components.  If the level of signalling falls below a threshold 
required for a specific developmental or physiological event then the relevant phenotype is 
produced, for instance Akd2C+/-:Smad8-/- mice have reduced BMP signalling to an extent that 
they fail to fully maintain neuromuscular connectivity.  In addition to failing to maintain 
axons, Akd2C+/-:BMPRII+/- mice have reduced developmental axon elongation suggesting that 
they have reduced BMP signalling levels below the thresholds required for both events (see 
Figure 6.5). 
These genetic interactions also showed that the BMP requirement in motor neurons is 
relatively robust, such that a large reduction is required to produce connectivity defects in 
either the embryo or adult.  This suggests that the thresholds of signalling required for these 
events are relatively low (see Figure 6.5) and that the function of Arkadia2C is not to greatly 
increase the level of signalling but instead to provide intracellular enhancement in motor 
neurons exposed to exceedingly low levels of active ligand.  The knockout of pathway 
components sufficient to reduce signalling below the required threshold is also likely to affect 
early embryonic development; this might explain why the BMP pathway has not previously 
been recognised to play a role in motor neuron development.  However, the removal of 
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Figure 6.5: Developmental outcomes of Arkadia2C compound mutants 
 
Graph showing relative amounts of Arkadia2c enhanced BMP signalling present in mice of 
different genotypes.  Approximate threshold levels required for different developmental and 
physiological events are shown, genotypes which do not reach the appropriate threshold fail 
to undergo the event and present with the relevant phenotype. 
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Arkadia2C, a neuronal specific component, revealed a novel late developmental role for the 
BMP pathway as the thresholds required for early embryonic development were maintained in 
non-neuronal cells. 
Finally, these genetic interaction experiments have shown that relatively minor changes in the 
level of signalling produced by variation in pathway modifier expression can be sufficient to 
surpass the threshold required for a specific event.  Expression of such pathway modifiers is 
likely dependent upon genetic background; fertile transgenic animals are likely to express 
such modifiers to limit the effect of loss of any gene and therefore breeding of these lines is 
likely to artificially select for such modifiers.  It was found that some Akd2C-/- individuals on 
the Smad8 background have a very mild phenotype independent of the Smad8 genotype and 
most adult Akd2C-/- mice are produced on this background.  This suggests that intercrossing of 
homozygous Smad8 for several generations selected for a factor which enhances BMP 
signalling and therefore rescues possible defects increasing the fitness of Smad8-/- animals.  If 
this is indeed the case it might explain why Akd2C+/-:Smad8-/-, Smad8-/-:Smad4+/- and Smad8-
/-:BMPRII+/- mice all had milder phenotypes than might otherwise be predicted. 
Biochemical evidence suggests that Arkadia2C directly binds components of the BMP 
signalling pathway including PSmad1/5/8 and the repressors SnoN/Ski and Smad6/7 (Figure 
3.1) and therefore directly enhances BMP signalling responses in a cell intrinsic manner.  The 
genetic interaction between Smad8 and Arkadia2C provides further evidence that Arkadia2C 
acts upon the BMP pathway in a cell intrinsic manner and the collected results form the 
genetic interaction experiments reveal a novel role of BMP signalling in motor neuron 
connectivity. 
 
Despite the biochemical evidence that Arkadia2C acts in the BMP pathway and the in vivo 
evidence that reduced signalling through this pathway enhances the Arkadia2C null 
phenotype, there is some evidence that it might also act in the canonical Wnt signalling 
pathway.  Akd2C+/-: β-cat+/- double heterozygous offspring from the β-catenin/Arkadia2C 
cross were found to have reduced survival rate both at birth and prior to weaning and 38.5% 
of pups born held their forepaws in a loose fist.  Both the frequency and severity of this 
phenotype are greater than those observed in live Akd2C+/-:BMPRII+/- pups suggesting that 
the interaction between Arkadia2C and Wnt signalling is as of much relevance as that 
between Arkadia2C and BMP signalling.  This unexpected result suggests that Arkdia2C 
interacts with β-catenin to act towards the same developmental outcome, motor axon growth.  
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This could be produced in three different manners; Arkadia2C directly enhances Wnt 
signalling in motor neurons via binding to a component of the pathway, possibly Axin, a β-
catenin-dependent function acts together with Arkadia2C enhanced BMP signalling in motor 
neurons to augment axon growth or a β-catenin dependent function acts in a different cell to 
enhance axon growth.  Evidence for the Arkadia2C null phenotype being mediated, at least in 
part, by Wnt signalling is provided by the fact that Smad8/Smad4 and Smad8/BMPRII 
intercrosses do not produce a strong clenched paw phenotype.  Instead all offspring from 
these crosses show subtle decreases in adult motor behaviour suggesting that reduced BMP 
pathway activity may act in conjunction with a reduction in a second process to produce the 
phenotype. 
The expression pattern of Arakdia2C suggests that it acts in a cell intrinsic manner within 
motor neurons.  Previous studies into the role of β-catenin in motor axons found that motor 
neuron specific β-catenin null mice show no developmental abnormalities (Li et al., 2008).  
However, loss of β-catenin expression in the muscle causes misrouting of the phrenic nerve, 
compensatory excessive growth of the terminal branches and abnormal AChR clusters in 
developing synapses (Li et al., 2008).  Li et al hypothesise that Wnt-β-catenin signalling 
occurs within the muscle and affects the motor axon in a retrograde manner, if this is the case 
then the Akd2C+/-: β-cat+/- phenotype is most likely mediated by a combined reduction in 
neuronal Arkadia2C enhanced BMP signalling and muscular Wnt signalling.  While this does 
not rule out a direct interaction between Arkadia2C and proteins in the Wnt pathway it 
suggests it may not be critical for the production of the Arkadia2C null phenotype.  A full 
analysis of any interaction between the Wnt pathway and Arkadia2C requires much further 
work and is beyond the scope of this thesis. 
Overall the genetic interaction experiments ddescribed in this chapter indicate that while 
Arkadia2C mediated BMP signalling is critical for motor innervation, it is likely that it acts in 
combination with other signalling pathways in vivo. 
 
.
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7 The role of BMP signalling in brachial motor neurons  
	  
7.1 Introduction 
The previous three chapters show that Arkadia2C functions in the nervous system and 
enhances BMP signalling.  Loss of Arkadia2C in mice leads to decreased motor axon 
elongation during development and NMJ during postnatal growth.  The most severely 
affected motor neurons are those of the dorsal forelimb, however the defect encompasses 
other motor neurons as the animals exhibit hypoxia and waste and die prior to weaning.  
Genetic interaction experiments confirm in vivo that this motor neuron phenotype is mediated 
by BMP-Smad dependent signalling and furthermore, suggest that there is a threshold of 
signalling required for normal motor neuron connectivity.  The data imply that there is active 
BMP signalling in developing motor neurons, particularly those of the LMC, however 
PSmad1/5/8 has not been observed in these cells previously and it therefore remains unknown 
whether the genetic interaction between Smad8 and Arkadia2C occurs in a cell intrinsic 
manner. 
Furthermore, to understand the developmental mechanisms of the interaction between 
Arkadia2C and BMP signalling and the role of the signalling pathway in the LMC the 
identification of motor neuron specific BMP target genes is required.  Finally, as the Akd2C-/- 
phenotype manifests after axons have entered the limb, it is unclear whether signal 
stimulation originates in the spinal cord or the growth cone. 
 
7.1.1 BMP signalling in the motor neurons 
BMP ligands are highly expressed from a dorsal source during the initial patterning of the 
spinal cord; however BMP activity inhibits the differentiation of ventral cells, including 
motor neurons (Lee and Jessell, 1999; Derynck and Miyazono, 2008), and therefore the role 
of BMP signalling in motor neurons has not been examined in depth.  BMP signalling has 
previously been suggested to play a role in thoracic motor neurons; BMP4 and 5 are 
expressed in the Column of Terni, the preganglionic cells in the thoracic chick spinal cord 
(William et al., 2003).  In addition nuclear PSmad1/5/8, an indication of active BMP 
signalling, has been observed in mammalian PGC cells (Dasen et al., 2008).  However, no 
PSmad1/5/8 was observed in the motor columns at the brachial level, nor has Smad8 
expression previously been described in theses cells (Arnold et al., 2006).  Examination of the 
LMC and other brachial motor neurons for the presence of Smad8 and BMP activity has the 
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potential to support the evidence from the genetic interaction experiments that Arkadia2C 
mediated enhancement of BMP-signalling interacts with Smad8 within these cells.   
 
7.1.2 BMP target genes within motor neurons 
BMP/Gbb signalling has been known to play a critical role in Drosophila neuromuscular 
junction formation and synapse stability for a number of years (Aberle et al., 2002; Marques 
et al., 2002; McCabe et al., 2003; McCabe et al., 2004).  The decreased growth of NMJ in 
response to reduced BMP signalling bears a striking resemblance to the decreased growth of 
the terminal branches of the phrenic nerve in Akd2C-/- mice.  This similarity suggests that 
BMP dependent axon growth in mammals might share certain features with the highly studied 
growth of the Drosophila NMJ. 
Until recently the events that occurred downstream of Gbb signalling in motor neurons had 
not been identified.  A microarray study comparing wildtype and wit mutant gene patterns 
(Kim and Marques, 2010) found 101 genes that were differentially expressed in the nervous 
system, however none appeared to play an obvious role in motor synapse growth.  A separate 
approach was used to show that synapses grow in a Rac dependent manner which in turn is 
regulated by the PMad (PSmad1) target gene Trio (Ball et al., 2010).  Trio is a guanine 
exchange factor (GEF) which activates Rho GTPases (Rac, RhoA and RhoG in mammals) by 
replacing GDP with GTP (Rabiner et al., 2005).  Such GTPases have multiple functions 
including the regulation of actin polymerization which is required in the growth cone (see 
Chapter 1 and (Heasman and Ridley, 2008)).  As Rac has prominent roles in axonal growth, 
branching and guidance in addition to synaptic growth, it seems likely that BMP activation of 
Trio also influences motor neuron development prior to synaptogenesis and therefore might 
be downstream of Arkadia2C enhanced BMP signalling responses.  Arkadia proteins act by 
enhancing the transcriptional response of a cell rather than altering the basal levels of pathway 
activation.  Identification of BMP target genes within motor neurons is critical to allow 
molecular differences between wildtype and Akd2C-/- embryos to be observed and to 
understand the mechanism of axon elongation. 
 
7.1.3 Sources of BMP signalling within motor neurons 
A second key feature of BMP signalling at the Drosophila NMJ is that the signalling occurs in 
a retrograde manner, from the muscle to the neuron.  The Wit receptor (BMPRII) is required 
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for NMJ growth and is specifically expressed in the nervous system.  The activation of Wit 
leads to accumulation of PMad within the motor neuron nucleus and the activation of target 
genes including Trio (Aberle et al., 2002; Marques et al., 2002; Shi and Massague, 2003).  
The Gbb ligand activates the receptor in these neurons, however while it is expressed at low 
levels in the CNS, it is expressed much more highly in the postsynaptic muscle.  Ectopic 
nervous system specific expression of the ligand in a Gbb-/- background leads to a small 
nuclear accumulation of PMad while reintroduction of expression in the muscle fully rescues 
the Gbb-/- phenotype (McCabe et al., 2003).  This suggests that the majority of Gbb signal 
which is required for NMJ growth originates in the muscle and therefore must act in a 
retrograde manner to activate presynaptic receptors.  If BMP signalling within the mammalian 
motor neurons shares features with that in Drosophila, it is possible that retrograde signalling 
from the target muscle occurs. 
The retrograde movement of PSmad1/5/8 has not been observed in mammalian motor 
neurons, it has however been described in other axons including those of the sensory neurons 
of the trigeminal ganglia (Hodge et al., 2007).  While such retrograde signalling by BMP 
patterns neuronal differentiation rather than axon extension; signalling from target tissue is 
essential for axonal growth (Charron and Tessier-Lavigne, 2005) suggesting that retrograde 
BMP signalling could influence motor axon extension in the limb and diaphragm.  For 
retrograde signalling to occur BMP ligand must be expressed by the tissue that the motor 
axons innervate.  The developing limb is well known to express multiple BMP ligands at the 
developmental time point at which innervation occurs (Robert, 2007).  BMP2, 4 and 7 play 
critical roles in the dorsal-ventral patterning and outgrowth of the limb bud as well as 
patterning of the digits.  In later developmental stages GDF5 and 6 are required for joint 
formation maintaining the presence of BMP-type ligands in the limb.  However, BMP ligands 
are less well documented in the diaphragm; expression has not been described in the 
embryonic or adult diaphragm muscle, however the septum transversum mesenchyme, once 
thought to contribute to the development of the diaphragm expresses a number of BMP 
ligands. 
 
This chapter examines whether there is active BMP signalling within the motor neurons of the 
LMC and MMC, including the phrenic nerve, and investigates the conservation of BMP 
signalling in motor neurons.  PSmad1/5/8 and Smad8 are found in the brachial motor neurons 
suggesting that Arkadia2C enhances BMP signalling within the motor neurons themselves.  
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BMP signalling in motor neurons is shown to regulate RhoGTPases and may originate in the 
target tissue of the motor axon suggesting a signalling mechanism conserved between 
mammals and Drosophila. 
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7.2 Results 
 
7.2.1 Active BMP signalling is present in the brachial LMC 
Arkadia2C mediates BMP signalling to allow axon growth in the limb and diaphragm 
however, no active BMP signalling has previously been observed in the brachial motor pools 
of the LMC and MMC.  Therefore these neurons were examined for the presence of nuclear 
PSmad1/5/8 which indicates that the signalling pathway is active.  As PSmad1/5/8 must 
complex with Smad 4 to enter the nucleus, the technique of proximity ligation assay was used 
by Efstathia Thymiakou to examine the presence of active BMP signalling (Thymiakou and 
Episkopou, 2011) in the brachial spinal cord.  It was found that, as expected, there was a high 
number of PSmad/Smad4 complexes in the dorsal spinal cord where BMP ligands are 
expressed and high levels of signalling is known to occur (Lee and Jessell, 1999; Chizhikov 
and Millen, 2005).  Additionally a small pool of cells with PSmad/Smad4 complexes was 
found in the ventral spinal cord in the position of the LMC suggesting that the BMP signalling 
pathway may be active in these cells (Figure 7.1a).  To show whether the ventral cells with 
active BMP signalling are part of the LMC the expression pattern of the LMC molecular 
marker FoxP1 was compared to the pool of cells containing PSmad1/5/8 using 
immunofluorescence.  It was found that in both Akd2C+/+ and Akd2C-/- spinal cords 
PSmad1/5/8 is located in a small number of ventral cells including those which express FoxP1 
and are therefore part of the LMC (Figure 7.1b).  The presence of PSmad1/5/8 suggests that 
all the motor neurons that innervate the forelimb respond to a BMP signal in both the 
presence and absence of Arkadia2C expression.  A further group of cells containing 
PSmad1/5/8 is located in the adjacent medial ventral domain which contains the MMC, this 
suggests that cells within the MMC are also BMP responsive. 
The existence of PSmad1/5/8 in the LMC suggests that these neurons should express a subset 
of BMP target genes dependent upon the levels of activation of the pathway.  While Smad8 is 
generally thought to act in the same manner as Smad1 and 5 it is not essential, however as it is 
expressed in regions of known BMP signalling it was proposed that it is a BMP target gene 
which can act to boost signalling through the pathway (Arnold et al., 2006).  RNA sequencing 
(analysed by Mehdi Motallebipour) and Q-PCR were carried out using cDNA extracted from 
embryoid bodies differentiated towards a motor neuron fate (Wichterle and Peljto, 2008) 
subsequently exposed to BMP4.  It was found that Smad8 expression levels increased with 
prolonged exposure to BMP while removal of BMP signalling (ensured by addition of the 
BMP antagonist Noggin) reduced Smad8 expression.  Known BMP target genes such as 
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Figure 7.1: Smads are phosphorylated and BMP target genes activated within brachial 
motor neurons 
 
(a) PLA showing nuclear complexes of PSmad1/5/8 and Smad4 in the dorsal and ventral 
E13.5 spinal cord. Red dots, protein complexes; Blue, nuclear DAPI scale bars=50µm. 
(b) Immunofluorescence showing PSmad1/5/8 and FoxP1 in brachial motor pools of E13.5 
spinal cords. 
(c) QPCR showing the expression of Smad8 in motor neurons differentiated from ES cells in 
response to BMP treatment, two primer pairs were used to amplify different regions of 
Smad8. 0h, 3h, 5h, 9h, indicates time of treatment (hours) with 25ng/ml BMP4, dashed line 
indicates 3 hours treatment with 25ng/ml BMP4 followed by 2 hours in 100ng/ml Noggin 
(dashed line). 
(d) X-gal staining showing Smad8 expression on sagittal and transverse (d’, d’’) sections of 
the E14.5 spinal cord.  Scale bars=100µm; white arrowhead, DRG; black arrowhead, first rib. 
(e) X-gal stain with subsequent immunocytochemistry showing Smad8 expression in the 
E14.5 spinal cord.  Scale bars=100µm. 
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Msx1 and Id4 show a similar expression profile although the response of such known targets 
appears to be faster (see Appendix VII). 
Smad8 has previously been shown to have a highly restricted expression pattern in the late 
embryo including in all sites of cartilage formation and specific cells within the kidney, lungs 
and heart.  In the developing CNS the expression was previously reported to be highly 
restricted within the choroids plexus and low expression in a small number of neurons in the 
rostral ventral spinal cord and the DRG (Arnold et al., 2006).  To examine whether Smad8 is 
expressed at low levels in the BMP responsive cells in the brachial LMC, prolonged X-gal 
staining was carried out on embryos from the Smad8 null LacZ line (Arnold et al., 2006).  
The strongest staining was seen in the developing bones (black arrowhead in Figure 7.1d) and 
DRG, however in the brachial and rostral thoracic spinal cord three additional stripes of 
Smad8 expression were observed (Figure 7.1d).  Transverse sections through the spinal cord 
showed the majority of the brachial region to contain one group of cells expressing Smad8 
predicted to be the same group observed with PLA in the correct position to be the LMC.  In 
the caudal most brachial/rostral thoracic region three groups of cells in the ventral spinal cord 
were found to express Smad8, two in the approximate location of the LMC and one in the 
location of the MMC.  This lac-Z staining was not observed in the spinal cord at E11.5 and 
was very faint at E12.5, however the strength of staining increased as the animal aged to 
E16.5 (data not shown).  This suggests that BMP signalling is increasing during this period 
and the expression of Smad8 acts as a positive feedback loop allowing the cell to respond to a 
greater extent as the embryo develops. 
The position of the Smad8 expressing cells and the presence of PSmad1/5/8 in FoxP1 positive 
cells suggests that Smad8 is expressed in the LMC.  To show that this is the case and to 
examine whether a restricted Smad8 expression could be the cause of the LMCl specificity of 
the Akd2C-/- phenotype, the pattern of Smad8 expression was compared to that of molecular 
markers of the motor columns (see Figure 5.1) and the presence of PSmad1/5/8 (Figure 7.1e).  
It was found that in both the rostral and more caudal domains X-gal staining of Smad8 
positive cells corresponded with a subset of PSmad1/5/8 containing cells.  While all the 
lateral Smad8 expressing regions contain FoxP1 positive LMC cells, a large number of FoxP1 
expressing cells do not express Smad8.  Additionally Isl1 expression, indicative of LMCm 
cells, was found within this Smad8 positive region.  Together these data show that Smad8 is 
expressed in a subset of BMP responsive LMC cells which includes cells in both the medial 
and lateral LMC.  The location of all Smad8 positive cells within the domain of PSmad 
activation is consistent with the finding that Smad8 is a BMP target gene and suggests it acts  
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Figure 7.2: Expression of the Rho GEF Kalirin is upregulated in the presence of BMP 
signalling 
 
QPCR showing the expression of Trio and Kalirin in response to BMP treatment, a Taqman 
probe and a primer pair were used to amplify different regions of Kalirin. 0h, 5h, 9h, 12h 
indicates time of treatment (hours) with 25ng/ml BMP4 (solid line) or 9hours 25ng/ml BMP4 
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as a positive feedback mechanism indicating a demand for enhanced levels of signalling 
within motor neurons. 
 
7.2.2 Rho GEF proteins are targets of BMP in mammalian presumptive motor 
neurons 
The Rac GEF Trio is the only gene which can be clearly related to synaptic growth that has 
been shown to be activated by retrograde Gbb/PMad signalling in Drosophila.  To examine 
whether Trio was also a target gene of the BMP-PSmad1/5/8 pathway in mammalian motor 
neurons, the expression levels of the gene in embryoid bodies differentiated towards motor 
neurons after varying times of BMP exposure was examined by QPCR (Figure 7.2).  The 
level of Trio expression was found to not alter upon exposure to BMP (compare to known 
BMP target gene expression in Appendix VII or Smad8 expression in Figure 7.1c). 
Trio is one of more than 20 Rho GEF proteins that are expressed in the mammalian CNS, 
however it is unusual as it has two Rho GEF domains.  The Dual Rho GEF family consists of 
only Trio in Drosophila, however in mammals there is a second member: the Trio homologue 
Kalirin.  As Kalirin has been shown to induce the outgrowth of processes it appears to be a 
potential candidate for the mediation of the Akd2C-/- phenotype and therefore its 
responsiveness to BMP was studied.  Two different regions of Kalirin were amplified by 
QPCR to examine the expression of a greater number of the many functionally different 
isoforms.  Both amplified regions showed an increase in expression with prolonged exposure 
to BMP4 and a reduction in expression in response to pathway inhibition.  This suggests that, 
in a similar manner to in Drosophila, mammalian Dual Rho GEF proteins are target genes of 
the BMP pathway and provides a conserved mechanism downstream of this pathway within 
motor axons and synapses. 
 
7.2.3 BMP ligands may act in a retrograde manner in motor neurons 
The motor neurons of the LMC have been shown to contain active BMP signalling, therefore 
potential sources of the ligand were studied in order to establish whether this activation occurs 
in a retrograde manner as in Drosophila.  The extremely localised presence of PSmad1/5/8-
Smad4 complexes (Figure 7.1a) suggests that there is no diffusible BMP ligand within the 
ventral spinal cord.  While RT-PCR suggests that a number of BMP ligands are expressed at 
an unknown location within the ventral half of the spinal cord (data not shown), study of  
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Figure 7.3: BMP ligands are expressed in the diaphragm and throughout the developing 
limb  
 
(a) RT-PCR showing expression of BMP ligands in cDNA from E15.5 diaphragm muscle.  
Samples shown from 4 littermates, size of bands as indicated. 
(b) In situ hybridisation of BMP ligands in the developing limb.  Images were taken from an 
anterior (E11.5, E13.5) and dorsal (E13.5 paws) position; dorsal-ventral axis of whole limbs 
as indicated; red arrowhead, dorsal source of ligand; blue arrowhead, ventral source of ligand. 
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individual neurons in the adult spinal cord suggested that no ligand transcription occurs 
within motor neurons (Wang et al., 2007).  Instead, as the axon grows through target tissues it 
is likely to be exposed to BMP ligands. 
The Akd2C-/- phrenic nerve shows reduced terminal axon growth once the growth cones have 
entered the diaphragm muscle.  To examine whether this phenotype is mediated by a reduced 
response to retrograde BMP signalling, the expression of BMP ligands in the diaphragm was 
examined.  RT-PCR was carried out using cDNA from E15.5 diaphragm muscles, a 
developmental time point coinciding with the formation of the terminal branches of the 
phrenic (Greer et al., 1999).  BMP2, 4, 6 and 7 are all expressed in the diaphragm muscle 
(Figure 7.3a) suggesting that these ligands could activate BMP signalling within the phrenic 
nerve in a retrograde manner. 
The developing limb is well known to express many BMP ligands in both the ectoderm and 
mesoderm (Robert, 2007) implying that it could act as a source of retrograde BMP signalling 
in the LMC.  While PSmad1/5/8 is present throughout the LMC, the expression of Smad8 is 
limited to a subset of these cells and the Akd2C-/- phenotype is specific to the LMCl motor 
neurons that innervate the distal dorsal region.  This suggests that different cells within the 
LMC are exposed to various levels of BMP ligand and pathway activation.  Those cells that 
require Arkadia2C expression are exposed to insufficient activation of the BMP pathway 
necessitating an intracellular enhancement of the transcriptional response.  If this is the case 
then the expression pattern of BMP ligands as motor axons enter the limb might play a role in 
determining which cells require Arkadia2C expression.  To examine the expression pattern of 
BMP ligands at the point where motor axons enter the limb, in situ hybridisation against 
BMP2, 4 and 7 was carried out in E11.5-13.5 embryos (Figure 7.3b).  As descirbed previously 
(Robert, 2007), at E11.5 it was found that BMP2 and 4 were relatively localised while BMP7 
was expressed much more broadly.  All three ligands had regions of high expression in the 
dorsal limb (red arrowhead) while BMP2 and 7 also had a ventral source (blue arrowhead).  
By E13.5 expression of BMP2 is mostly limited to the interdigital webbing and BMP4 is 
hardly expressed.  However, BMP7 continues to be expressed throughout the limb making it a 
potential likely source of continued PSmad1/5/8 activation in motor neurons.  This shows that 
expression of BMP ligands in the limb is highly dynamic; the path of individual axons is 
therefore likely to encounter areas of low ligand in which intracellular boosting of pathway 
activity by Arkadia2C is required. 
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7.3  Discussion 
 
Previous chapters showed that neuronal Arkadia2C mediates motor axon extension and 
maintenance by enhancing signalling through the Smad dependent canonical BMP pathway, 
however whether brachial motor neurons harbour active BMP signalling and the mechanism 
of BMP mediated axon growth was unknown.  Here it was shown that activation of the 
canonical BMP pathway occurs in brachial motor neurons and a subset of these cells express 
the BMP target gene Smad8 which most likely functions as a positive feedback mechanism.  
The Rho GEF Kalirin is a BMP target gene in presumptive neurons and BMP ligands are 
expressed in both the limb and diaphragm at the time of axonal growth.  Therefore, the 
brachial motor neurons respond to BMP signalling, the mechanism of this response appears to 
share features of the BMP signalling within the Drosophila NMJ. 
 
The motor neuron phenotypes studied in Akd2C-/- mice are located in those cells that innervate 
the forelimb and the diaphragm.  PSmad1/5/8 was found throughout the LMC which 
innervates the limb and the presence of PSmad1/5/8 in a more medial group of cells most 
likely represents active signalling within the phrenic neurons.  Therefore BMP signalling 
occurs in neurons which express Arkadia2C confirming that the genetic interactions seen in 
Chapter 6 occur within motor neurons.  While the presence of PSmad1/5/8 in these brachial 
motor neurons is a novel finding, activated Smads have previously been observed in both the 
preganglionic column of motor neurons and the sensory dorsal root ganglia.  The role of BMP 
signalling within these cells have not been fully studied raising the possibility that BMP target 
genes might also function to control axon growth here.  Additionally if these cells are exposed 
to low levels of pathway activation Arkadia2C may be required for axon growth. 
The dorsal root ganglia (DRG) contain sensory neurons, the peripheral branches of sensory 
axons terminate in tissues including the skin and muscles and therefore require extended 
growth in a similar manner to motor axons.  If BMP target genes are required for extension of 
long axons it seems likely that they might also play a role in sensory axons.  However, high 
levels of PSmad1/5/8 and Smad8 expression are observed in the DRG (Figure 7.1 and data 
not shown) suggesting that these cells receive sufficient pathway activation to activate the 
required target genes even in the absence of Arkadia2C expression.  Although a sensory 
phenotype has not been studied in detail in Akd2C-/- mice they respond normally to touch 
suggesting that their sensory axon connectivity in the periphery is normal. 
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The preganglionic neurons are part of the sympathetic branch of the autonomic nervous 
system.  They form synapses upon the postganglionic cells located in the sympathetic chain 
which flanks the spinal cord, while the PGC is specifically found in the thoracic spinal cord 
each neuron synapses upon multiple cells along the length of the sympathetic chain (Kandel et 
al., 2000).  Certain preganglionic neurons are required to grow long axons to innervate rostral 
ganglia which in turn innervate the salivary glands, other preganglionic axons grow out 
through the splanchnic nerve to innervate distal prevertebral ganglia which control the 
gastrointestinal system (Kandel et al., 2000).  It is therefore possible that specific BMP target 
genes are required for growth of these axons and reduced BMP signalling would lead to 
lowered food intake.  Late stage Akd2C-/- mice are observed to have very little food in their 
stomachs.  While this could be due to reduced motor activity involved in swallowing, an 
alternative explanation is that this phenotype is due to reduced preganglionic axon growth.  
Further studies into the cause of this phenotype in Akd2C-/- mice is therefore likely to focus 
upon the role of the sympathetic nervous system. 
 
The guanine nucleotide exchange factor Trio is a direct PMad target gene in Drosophila, 
while murine Trio does not respond to BMP, expression of its homologue, Kalirin increases in 
response to prolonged BMP exposure.  This suggests that BMP activation of Rho GEF is a 
conserved mechanism in motor neurons.  Drosophila Trio activates Rac which in turn 
enhances actin polymerisation required for normal synaptic growth.  As actin polymerisation 
is also required for axon growth (Stiess and Bradke, 2010), the activity of Rac or other Rho 
GTPases is likely to be critical for motor axon growth and guidance in addition to synaptic 
development.  Therefore, modulation of RhoGTPases by genes which are either direct or 
indirect BMP target genes may allow the pathway to control murine motor axon growth. 
Kalirin expression is highest in the nervous system and many studies have been carried out 
exploring its neuronal role.  Different Kalirin isoforms are expressed at different 
developmental stages; the full length Kalirin 12 and the Kalirin 9 isoforms are expressed 
throughout embryonic and early postnatal development while other isoforms are highly 
expressed in the adult.  It has been found that overexpression of Kalirin 12 induces ectopic 
RhoG mediated axonal growth (May et al., 2002) indicating that Kalirin is likely to mediate 
embryonic axon growth.  Kalirin 12 is the predominant isoform detected by the amplification 
of the C-terminal exons 68-69 (Figure 7.2) indicating that it is a target gene of BMP 
signalling in motor neurons.  Together these data associate Kalirin with BMP mediated axon 
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growth although further studies of its role in this system are required.  Interestingly, the 
experiments carried out by May et al to examine the role of Kalirin in axon growth were done 
using sympathetic ganglia (May et al., 2002), cells in which BMP signalling is likely occur. 
 
Retrograde signals from the environment surrounding the growth cone play a critical role in 
determining axonal growth and guidance and in Drosophila they have also been shown to be 
required for synaptic growth and maintenance.  The expression of BMP ligands in the limb 
and diaphragm at the developmental point that the Akd2C-/- phenotype forms suggests that 
retrograde activation of the BMP pathway occurs in these cells and is required for axon 
growth.  This hypothesis can not be tested using genetic models due to the requirement of 
BMP ligands for limb patterning and other developmental events.  However, disruption of 
axonal retrograde signalling by physical or chemical means is expected to lead to decreased 
nuclear PSmad1/5/8 accumulation in a similar manner to that observed in Drosophila 
(McCabe et al., 2003).  The observation that BMP signalling has a conserved function in 
motor neurons between Drosophila and mammals suggests that this work may play a critical 
role in linking studies of motor neuron development and disease in flies to neurodegenerative 
disease in humans. 
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8 Main Discussion 
	  
8.1 Enhancement of PSmad1/5/8 activity by Arkadia2C revealed a novel role of the 
BMP signalling pathway in motor neuron axon growth. 
 
Previous to this thesis it was unknown whether elongation of motor axons was a distinct 
process of connectivity dependent upon activation of specific signalling pathways.  Here a 
line of evidence is presented to show that BMP-Smad signalling enhancement by Arkadia2C 
is required for axon elongation of certain motor neurons. 
The E3 ubiquitin ligase Arkadia2C is expressed specifically in the nervous system (Chapter 3) 
and its loss leads to motor neuron connectivity defects.  Akd2C-/- mice are born but die before 
weaning due to wasting and symptoms reminiscent of motor neuron diseases (Chapter 4).  
During embryonic development the extension of motor axons in the distal dorsal forelimb is 
severely disrupted, while a milder defect is observed in the phrenic nerve that forms short 
terminal branches (Chapter 5).  In adult Akd2C-/- mice the motor synapses in the dorsal 
forelimb muscles exhibit degeneration (Chapter 4).  The phenotypes analysed here all relate to 
an inability of motor axons to elongate; some axons fail to reach their targets while others 
exhibit shorter terminal branches within their targets. The observed postnatal degeneration of 
NMJ also seems likely to occur as axons extend with the growing muscle. 
The molecular function of Arkadia2C is highly similar to that of its homologue Arkadia, 
which also acts as ubiquitin ligases that derepress the TGF-β signalling pathway.  While 
Arkadia degrades repressors acting to block PSmad2/3 effectors, Arkadia2C degrades 
repressors acting upon PSmad1/5/8.  The function of Arkadia2C was tested using gain of 
function experiments in the chick spinal cord which showed that overexpression of 
Arkadia2C enhances the PSmad1/5/8 transcriptional response by two-fold (Chapter 3).  This 
function of Arkadia2C within the BMP signalling pathway was further validated in vivo.  
Reduction of BMP signalling by genetic removal of BMPRII or Smad8 alleles in Akd2C+/- 
mice, which otherwise do not exhibit motor neuron defects, caused the appearance of similar 
forelimb innervation defects to those observed in Akd2C-/- mice (Chapter 6).  The forelimb 
innervating LMC motor neurons, which display a strong phenotype in Akd2C-/- mice, exhibit 
active Smad1/5/8 signalling.  Furthermore, a subset of LMC neurons activate Smad8 creating 
a positive feedback loop (Chapter 7).  The production of a motor phenotype on reduced 
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expression of Arkadia2C and/or Smad8 suggests that motor neurons require intracellular BMP 
signalling enhancement to reach a specific threshold essential for connectivity.  The 
similarities between Arkadia and Arkadia2C may also extend to an interaction with the 
canonical Wnt signalling pathway as genetic removal of a β-catenin allele leads to the 
manifestation of forelimb movement defects in Akd2C+/- mice (Chapter 6).  The possible 
interaction between the Wnt and BMP signalling pathways in motor axon growth suggests 
that, like other developmental processes, a single signalling pathway might not be sufficient 
to drive this event in vivo.  
Multiple studies in Drosophila have shown that BMP-Smad signalling is required for motor 
neuron synaptic growth and plasticity but there were no data linking BMP signalling to motor 
neuron connectivity in mammals.  The data presented here show that mammalian motor 
neuron connectivity requires BMP, suggesting that the developmental mechanism is 
conserved. As interactions between BMP signalling and motor neurodegenerative disease 
genes have been shown to exist in Drosophila, the findings presented here support the 
existence of a similar mechanism in mammals showing the relevance of Drosophila models 
of disease. 
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8.2 Axon elongation is a distinct property of connectivity 
Highly specific connections between neurons and their target cells are required for the 
formation and maintenance of functional neuronal circuits.  This requires a number of 
developmental steps, including the differentiation and specification of each neuron following 
an intrinsic genetic program.  Later stages of circuit formation such as axon guidance and 
synapse formation and maturation have been shown to occur in response to extrinsic signals 
provided by the matrix through which the axon grows, and by its target cell (Shirasaki and 
Pfaff, 2002; Hippenmeyer et al., 2004; Salie et al., 2005; Stiess and Bradke, 2010).  The 
elongation and guidance of axons require modulation of growth cone dynamics allowing 
extension of the axon in a particular direction (Lowery and Van Vactor, 2009) and are 
therefore often treated as a single event.  These two events are hard to distinguish in cells 
which grow relatively short axons with a complex axon path.  In contrast many neurons, 
including those that innervate peripheral tissue, have axons which must grow for a 
considerable distance without making many guidance decisions.  Whether such growth is a 
property of connectivity that requires extrinsic signals independent of axon guidance has not 
previously been resolved. 
This analysis of the Akd2C-/- phenotype revealed that axon elongation is a distinct property 
that is required for axon connectivity, at least in the case of the long axons of motor neurons.  
Additionally, the reduced food consumption and hypoxia observed in Akd2C-/- pups revealed 
that embryonic and postnatal axon elongation are critical for the formation and maintenance 
of the functional motor circuits required for postnatal survival. 
Evidence supporting the conclusion that the Akd2C-/- motor phenotype uniquely affected 
axonal extension was derived from a series of experiments in the embryo (Chapter 5).  The 
cell intrinsic specification the LMCl and LMCm divisions of motor columns are normal in the 
absence of Arkadia2C, as is the initial cell driven outgrowth of axons established by the 
presence of axons in the limb at E10.5-11.5.  The successful bifurcation of the axons entering 
the forelimb at E11.5 and the correct pattern of diaphragm innervation suggest that the axons 
respond correctly to guidance cues in the developing embryo.  Synapse formation and 
maturation were studied in the diaphragm, where they were found to form normally and have 
matured to the active uniquly innervated pretzel shape by weaning age.  This maturation of 
the synapse shows that motor axons in Akd2C-/- mice are active and are able to retract in 
response to competitive signals from other axons during the process of synapse elimination.  
Despite the fact that many developmental aspects of connectivity occur normally in Akd2C-/- 
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motor neurons, reduced motor axon length is observed in the dorsal forelimb and in the 
terminal branches of the phrenic nerve.  This evidence suggests that unique cues are involved 
in the regulation of the extension of axons during circuit formation.  The distinction between 
axon growth and guidance in these cells is especially critical given that they both originate in 
the growth cone, and suggests that subtle differences might exist in the growth cone’s 
responses to different signals. 
Further evidence that Akd2C-/- mice suffer from an axon elongation defect can be found in the 
postnatal phenotype (Chapter 4).  The severity of the phenotype appears to increase during the 
first three postnatal weeks leading to fatality when there is a dramatic somatic growth of pups 
(1.5g at birth to 10g at three weeks).  During this growth stage the coordinated expansion and 
plasticity of neuromuscular branches and development of the synaptic structure are required 
to maintain intact and active NMJ (Sanes and Lichtman, 1999; Sanes and Lichtman, 2001).  
The increasing postnatal severity of the Akd2C-/- phenotype during the time when NMJ are 
maturing and axons are extending as the mouse grows suggests that Arkadia2C is required for 
some of these events as well.  The continuing postnatal degeneration of the NMJ suggests that 
Arkadia2C is also required for synaptic growth and maintenance, and therefore influences 
synaptic plasticity. 
It is likely that the growth of motor axons other than those in the forelimb and diaphragm are 
affected by the loss of Arkadia2C.  Akd2C-/- pups display reduced food intake and consequent 
wasting, providing evidence that there are also connectivity defects amongst the motor 
neurons involved in eating.  There is also growing evidence that Arkadia2C enhances 
connectivity in the central brain.  Connectivity defects have been hypothesised to cause 
psychiatric diseases including Bipolar Disorder (McIntosh et al., 2009).  As Arkadia2C has 
been linked to Bipolar Disorder in humans (Pickard et al., 2005) it seems likely that it is 
required to establish or maintain connectivity in the brain.  Examination of Akd2C+/- and 
Akd2C-/- mice (Chapter 4) showed them to exhibit behavioural defects.  In both genotypes 
axons do not form the corpus callosum, which is the largest commissural tract in the 
vertebrate brain (Sanchez-Camacho et al., 2011)  The absence of the corpus callosum 
therefore suggests that Arkadia2C is required for the growth of the long axons of the central 
nervous system, in addition to those in the periphery. 
In addition to indicating that axon elongation is a distinct aspect of connectivity, this study 
also sheds light on the molecular mechanisms which control the process.  It shows that the E3 
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ubiquitin ligase Arkadia2C is required for extension of specific axons and reveals a 
previously unknown role for the Smad-mediated BMP signalling pathway in mammals. 
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8.3 The role of extrinsic signalling in axon elongation 
 
8.3.1 Arkadia2C enhances BMP signalling 
Arkadia2C is a homologue of the E3 ubiquitin ligase Arkadia (Dixon, 2006).  Arkadia 
ubiquitinates and mediates the degradation of Smad6/7 and the nuclear proteins Ski/SnoN.  
These proteins act to repress signalling through both branches of the TGF-β pathway so by 
driving their degradation Arkadia enhances TGF-β transcriptional responses.  Arkadia 
specifically recognises Ski/SnoN when they are bound to PSmad2/3 and are actively 
repressing the pathway.  Due to this specificity, Arkadia only enhances the PSmad2/3 
transcription responses which suggests that Arkadia2C acts in a similar manner to enhance 
PSmad1/5/8 responses. 
Evidence from biochemical experiments (Chapter 3, work by Efstathia Thymiakou) confirms 
Arkadia2C to have complementary substrate specificity to Arkadia.  Arkadia2C binds 
PSmad1/5/8, Smad6/7 and Ski/SnoN, and ubiquitinates Smad6/7 and Ski leading to their 
degradation.  Evidence of the downstream effects of this degradation was observed in the 
chick neural tube where Arkadia2C was found to specifically enhance Smad1/5/8 
transcriptional responses in an ubiquitin ligase dependent manner (Chapter 3).  As loss of 
Arkadia2C expression reduces motor axon extension, it seems likely that intracellular 
boosting of the BMP signal by Arkadia2C increases axonal extension.  
 
8.3.2 Induction of axon extension by BMP signalling 
The binding of BMP ligands to receptor complexes leads to the phosphorylation of receptor 
Smad1/5/8 and activation of downstream target genes in the canonical BMP signalling 
pathway (Miyazawa et al., 2002).  A non-canonical manner of signalling also exists, in which 
activation of BMPRII leads to the release and subsequent activation of LIMK1 (Foletta et al., 
2003).  The binding of Arkadia2C to PSmad1/5/8 and its inhibitors implies that Arkadia2C 
activates the canonical BMP pathway only and does not affect LIMK1 mediated signalling. 
While guidance cues such as Semaphorins and Ephrins are classically thought to drive axon 
outgrowth and direction, morphogens including BMP ligands are increasingly being shown to 
act in a similar manner (Charron and Tessier-Lavigne, 2005).  Studies of BMP signalling in 
the spinal cord have shown that ligand binding to BMPRII causes LIMK1 to phosphorylate 
Cofilin, reducing actin depolymerisation in the axons of commissural neurons (Stiess and 
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Bradke, 2010).  This direct alteration of actin dynamics modulates both the speed and 
direction of axon growth (Butler and Dodd, 2003; Phan et al., 2010).  However, as this 
signalling is not Smad mediated it is unlikely to be affected in Akd2C-/- mice.   
Recently Smad1 dependent BMP signalling has been shown to influence sensory axon 
outgrowth and regeneration in mammals (Parikh et al., 2011).  Phosphorylation of Smad1 in 
the DRG corresponds to time of axon outgrowth, both during embryonic development and in 
response to injury.  The genes downstream of this activation of Smad has not been examined, 
nor has whether the BMP pathway plays a role in axon outgrowth in other mammalian cells.  
However the homologous pathway in Drosophila is well known to affect the presynaptic 
growth and maintenance of the NMJ.  Release of postsynaptic Gbb ligand activates 
postsynaptic receptors, Mad phosphorylated by the receptor then moves in a retrograde 
manner along the axon to the nucleus.  Loss or reduction in expression of any component of 
the BMP pathway results in the normal formation of synapses, however the presynaptic 
structures cannot grow as the larvae increases in size (Aberle et al., 2002; Marques et al., 
2002; McCabe et al., 2003).  In a similar manner, the increasing severity of the Akd2C-/- 
phenotype is predicted to be due to an inability of the presynaptic structures to enlarge as the 
animal grows.  These parallels suggest that a role of BMP signalling in presynaptic motor 
axon growth is conserved between species, and that in mice certain neurons also require 
Arkadia2C to boost the efficiency of the signal. 
The study of the Akd2C-/- phenotype provided a number of lines of evidence that canonical 
BMP signalling enhances the motor axon outgrowth.  The presence of PSmad1/5/8 in spinal 
motor pools showed for the first time that the pathway is active in the motor neurons that 
innervate the forelimb (Chapter 7).  The in vivo BMP transcriptional response was decreased 
in Akd2C-/-, Akd2C+/-:Smad8-/- and Akd2C+/-:BMPRII+/- mice and in all cases a motor 
phenotype was observed in the forelimb (Chapter 6).  The direct interaction between 
Arkadia2C and BMP signalling observed in biochemical experiments was confirmed in vivo.  
Arkadia2C is neuronally expressed while Smad8 is expressed in a small pool of LMC motor 
neurons at E14.5 and not in the developing muscle (Chapters 3 and 7).  The fact that the 
Akd2C-/- and Akd2C+/-:Smad8-/- motor phenotypes manifest within the LMC cells in which 
both genes are expressed implies that modulation of canonical BMP signalling within these 
cells affects axon extension. 
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8.3.3 Conserved downstream effects of BMP signalling in motor neurons  
The conserved role of BMP signalling in motor neuron enlargement between Drosophila and 
mammals suggests that there might be further similarities in the precise mechanisms of 
signalling between species.  Components of the BMP signalling pathway in mammals and 
Drosophila are highly conserved (Derynck and Miyazono, 2008) suggesting that there may 
also be shared target genes.  Relatively few BMP target genes are known, in part because 
PSmad1/5/8 binding sites are not well defined (Miyazawa et al., 2002).  Trio is the only direct 
BMP target gene identified in Drosophila that has been shown to influence presynaptic 
growth, by altering RhoGTPase activity and actin dynamics (Ball et al., 2010).  As expansion 
of the growth cone, axon and presynaptic region all require modulation of actin and 
microtubule dynamics, it seems likely that a small number of conserved BMP target genes 
including Trio may act upon presynaptic structures. 
The fact that expression of the Trio homologue Kalirin is enhanced by BMP (Chapter 7) 
provides evidence that BMP regulation of RhoGTPase signalling in neurons is a conserved 
mechanism.  Further studies of genes activated by exposure to BMP using RNA sequencing 
showed that in addition to Kalirin, Rhob and members of the Arhgap family are BMP target 
genes (Mehdi Motallebipour and Vasso Episkopou, unpublished data).  Kalirin has been 
shown to increase the rate of axon growth and to enhance neurite branching (Rabiner et al., 
2005).  Therefore, if lowered BMP signalling reduced Kalirin expression, the result would be 
slower growing axons with less extensive intramuscular branches, a similar phenotype to that 
observed in Akd2C-/- embryos.  While further studies are required to ascertain whether the 
Akd2C-/- phenotype is in part mediated by loss of RhoGTPase control of actin dynamics, this 
seems a promising line of investigation and would further emphasise the similarities in motor 
neuron BMP signalling between Drosophila and mammals.  The investigation of these targets 
genes in other neuron types may also allow the mechanisms by which BMP regulates axon 
outgrowth in sensory axons to be investigated. 
 
8.3.4 The periphery as a source of BMP ligand 
Another feature of BMP signalling within Drosophila motor neurons is the release of the Gbb 
ligand by postsynaptic muscle, which then activates receptors on the presynaptic axon 
(McCabe et al., 2003).  In a similar manner, target derived ligands other than BMP released 
from the postsynaptic muscle, are critical for the development and maturation of the 
mammalian NMJ (Sanes and Lichtman, 1999; Sanes and Lichtman, 2001).  However, while 
	   167	  
target-derived BMP signalling has been shown to play a role in determining mammalian 
peripheral neuronal identity (Hodge et al., 2007; Apostolova and Dechant, 2009) such 
retrograde BMP signals have not been shown to influence motor neurons. 
In addition to showing a requirement for BMP signalling in normal motor axon extension, this 
study shows for the first time that the peripheral target tissue could act as a source of ligand to 
drive axonal elongation as well as specification.  This prediction is supported by the presence 
of PSmad1/5/8 in highly localised regions of the ventral spinal cord including those motor 
neurons innervating the forelimb (Chapter 7).  Such a specific location suggests that there is 
no local source of BMP ligand; instead the neurites of certain neurons encounter it at a 
distance from the cell body.  Further evidence for retrograde signalling is provided by the 
expression of a number of BMP ligands in the developing limb and diaphragm (Chapter 7) 
suggesting that the mesenchyme/muscle acts as the source of neuronal BMP pathway activity, 
as in Drosophila.  High BMP expression was found to coincide with the timing of the 
formation of the Akd2C-/- phenotype (E11.5-12 in the forelimb and E15-18 in the diaphragm) 
indicating that decreased intracellular responses to such signals are responsible for the 
reduction in axon extension.  As limb patterning and growth requires plentiful BMP it is 
perhaps unsurprising that the motor axons extending into this tissue also use this signal to, at 
least in part, determine their growth. 
 
8.3.5 The extent of the requirement for BMP signalling within motor neurons 
The examination of the Akd2C-/- phenotype suggests that an intracellular boost of BMP 
provided by Arkadia2C is required for motor axon extension.  However, the null phenotype 
does not encompass all motor neurons.  This is particularly clear in the forelimb where a 
severe phenotype is observed in the distal dorsal forelimb, while the axons of the ventral limb 
appear to be normal.  To explain this apparent difference a model has been proposed to 
address the variation in BMP and Arkadia2C requirement within the forelimb.  
While the dorsal specificity of the Akd2C-/- phenotype suggests that only a subset of forelimb 
motor neurons require BMP for axon elongation, PSmad1/5/8 was found to be present in all 
forelimb motor neurons.  This suggests that it is the requirement for Arkadia2C rather than 
BMP signalling which determines the specificity and severity of the phenotype.  As 
Arkadia2C boosts BMP signalling in an intracellular manner it is logical to suggest that 
enhancement of signalling is required only in those neurons in the LMCl which innervate the 
distal dorsal limb.  The BMP target gene Smad8 is expressed in a subset of PSmad1/5/8 
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 Figure 8.1: Models of Arkadia2C enhancement of BMP signalling within the forelimb 
 
(a) Levels of derepressed PSmad1/5/8 within the motor axons innervating the developing 
forelimb (shown in purple, more intense colour indicates higher level of active PSmad1/5/8 in 
neurons).  Those axons which innervate the ventral limb have high activation of the BMP 
pathway while those in the dorsal region have the least.  In the presence of Arkadia2C 
derepressed PSmad1/5/8 levels surpass the threshold required for axon growth even in the 
most dorsal axons.  In the absence of Arkadia2C PSmad1/5/8 is repressed to a greater degree 
in all neurons and those in the dorsal limb no longer achieve the axon growth threshold. 
(b) Potential BMP ligand gradients produced from the dorsal and ventral sources observed at 
E11.5 in Figure 7.3.  If a combination of the protein gradients result in the lowest levels of 
total BMP protein in the dorsal limb then PSmad activation shown in (a) would occur. 
(c) Alternatively, high levels of BMP ligand in the dorsal limb could result in expression of 
pathway antagonists such as Noggin.  This would reduce the availability of active ligand in 
the dorsal region and result in PSmad activation as shown in (a). 
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containing cells in both the ventral and dorsal innervating LMC.  This suggests that axons 
which innervate the forelimb activate the BMP pathway to different degrees and that this is 
not cleanly split along dorsal/ventral lines. 
Differences in BMP pathway activation within the LMC are likely driven by the highly 
dynamic expression of ligands within the limb both described previously (Vargesson and 
Laufer, 2009) and seen here (Chapter 7).  This pattern of expression suggests both that an 
individual growth cone in the limb will be exposed to different levels of BMP at different 
time points and that different growth cones will be exposed to different stimulation.  It seems 
likely that many forelimb innervating neurons are exposed to sufficient BMP to activate the 
pathway above the required threshold.  However the cells which innervate the distal dorsal 
limb phosphorylate less Smad1/5/8 and therefore require Arkadia2C expression (Figure 8.1a).  
As previously observed for Arkadia (Koinuma et al., 2003), removal of repressor proteins by 
Arkadia2C enhances transcription by approximately two-fold (Chapter 3).  The presence of 
Arkadia2C therefore alters the ratio of repressed to free PSmad1/5/8 within a cell which in 
turn determines how many Smad molecules can activate target genes.  It seems likely that in 
the absence of Arkadia2C the ratio in dorsal neurons is such that there is not sufficient free 
PSmad1/5/8 to reach the threshold required for axon elongation. 
The dynamic expression of the BMP ligands in the limb combined with the likely subtle 
differences in activation between regions conceals the origin of the predicted difference in 
PSmad1/5/8 activation shown in Figure 8.1a.  A simple explanatory model is that a 
combination of BMP2/4/7 ligand gradients within the limb results in lower levels of available 
ligand in the dorsal limb (Figure 8.1b).  This would produce reduced activation of 
PSmad1/5/8 in dorsal growth cones, sensitising them to a loss of Arkadia2C expression.  
However, this model is not supported by the expression pattern of BMP ligands in the E11-
13.5 forelimb which suggest high levels of ligand exist in the dorsal region (Chapter 7).  An 
alternative model incorporates the fact that high concentrations of BMP ligand activate 
autoregulatory mechanisms including expression of the BMP antagonist Noggin (Akizu et al., 
2010).  Therefore, high total ligand levels in the dorsal limb result in the formation of 
antagonist-BMP complexes and low levels of free BMP available to activate PSmad1/5/8 
(Figure 8.1c), again leaving the dorsal growth cones sensitive to loss of Arkadia2C. 
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8.3.6 The role of Wnt signalling in axon outgrowth 
Evidence from the genetic interaction between Arkadia2C and β-catenin suggest that Wnt and 
BMP signalling act together in motor axon outgrowth.  Wnt binding to its Frizzled receptor 
has been implicated in many steps of neuronal development including axon guidance 
(Sanchez-Camacho and Bovolenta, 2009) although only a limited number of these events 
require canonical β-catenin-dependent signalling.  However, the canonical pathway plays a 
role in neurite growth and guidance in a number of neuron types; knockdown of the Frizzled 
co-receptor Ryk produces guidance defects in the glossopharyngeal and vagus nerves and 
craniofacial motor neurons (Lu et al., 2004).  Critical to this study Wnt/β-catenin signalling 
within the diaphragm muscle has been shown to retrogradely influence motor axon growth 
and patterning (Li et al., 2008).  It is therefore possible that a combination of reduced Wnt 
signalling within the limb muscle and BMP signalling within the neuron act together to 
produce the weak forelimb movement in Akd2C+/-: β-cat+/- pups.  
 In a similar manner to BMP, activation of the different Wnt signalling pathways is required 
for limb development. Wnt/β-catenin activation plays a role in limb bud inititiation, AER 
induction and maintenance, myogenesis and regulation of bone length (Yang, 2003).  
Therefore, components of the pathway must be expressed throughout the developing limb as 
motor axons extend into the tissue.  Study of the expression of Wnt3, 5a, 7, 10a, 10b and 11 
showed varying dynamic patterns of expression (Yang, 2003) similar to that of the BMP 
ligands examined in Chapter 7.  It is therefore possible that Wnt availability may also play a 
role in determining the dorsal specificity of the Akd2C-/- phenotype. 
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8.4 BMP signalling and motor neuron disease 
Loss of maintenance of neuromuscular connections leads to degenerative neuromuscular 
diseases such as ALS and SMA.  While many cases of adult onset ALS are sporadic, a 
number of causative genes have been identified from familial cases.  About 1.5% of all ALS 
cases are caused by mutations in SOD1 resulting in increased levels of superoxide radicals in 
the cell.  Extensive studies have shown that a combination of oxidative stress and disrupted 
axonal transport leads to cell death resulting in symptoms of ALS (Dion et al., 2009).  The 
mechanisms by which other causative genes cause motor neuron degeneration are less well 
understood.  Mutations in two multifunctional RNA processing proteins, TDP43 and FUS, 
have been shown to cause ALS.  In diseased cells these proteins mislocate to cytoplasmic 
aggregates however subsequent steps in axonal degeneration are not known (Neumann et al., 
2006; Kwiatkowski et al., 2009).  Mutant forms of the ER membrane protein VapB have been 
shown to cause the formation of ubiquitinated protein aggregates and subsequent motor 
neuron death in ALS patients (Chen et al., 2010).  However, again the mechanism of cell 
death induction is not known.  In contrast to ALS, the majority of cases of infant onset SMA 
have been linked to the loss of the single gene SMN1.  The SMN proteins are shRNP 
assembly proteins, however as with TDP43 and FUS, the link between RNA processing and 
neurodegeneration has not been established in SMA (Burghes and Beattie, 2009). 
Attempts to find links between known motor neuron disease causative genes and 
neurodegeneration have frequently used Drosophila as a model system.  As BMP signalling is 
known to be required for both the growth and maintenance of the neuromuscular junction in 
this model system (McCabe et al., 2003; Eaton and Davis, 2005), a number of studies have 
searched for a link between this pathway and genes linked to neurodegeneration (Bayat et al., 
2010).  It has been found that overexpression of wildtype versions of the ALS causative gene 
VapB results in high levels of presynaptic PMad while mutant forms of VapB limit the levels 
of active PMad (Ratnaparkhi et al., 2008).  Loss of expression of the SMA causative gene 
SMN produces abnormal synaptic structures in Drosophila and modulation of expression of 
BMP pathway components was found to modify this phenotype.  Additionally, lowered SMN 
expression results in reduced nuclear PMad levels (Chang et al., 2008), suggesting that as in 
the case of VapB, BMP signalling is downstream of genes mutated in motor neuron diseases.  
Despite these extensive studies of connections between BMP signalling and 
neurodegeneration in Drosophila, no equivalent role of BMP in motor neuron diseases has 
been established in mammals.  While anterograde Wnt signalling between the neuron and 
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muscle is required for Drosophila NMJ development, this pathway has not been linked to any 
motor neuron desease causative genes (Bayat et al., 2010). 
In this study, a link between BMP signalling and neuromuscular connectivity has been 
established for the first time in mammals.  Loss of expression of the BMP regulator 
Arkadia2C causes NMJ degeneration and a phenotype with striking similarities to known 
motor neuron diseases.  Furthermore, reduction of expression of BMP signalling components 
in conjunction with Arkadia2C (Akd2C+/-:Smad8-/- and Akd2C+/-:BMPRII+/-) produces a 
similar phenotype.  Symptoms including failure to extend the distal limb (Detmer et al., 2008) 
and inefficient breathing (Monani et al., 2000; Llado et al., 2006) have previously been 
described in mouse models of a variety of motor neuron diseases in addition to Akd2C-/- mice.  
On a cellular level, both ALS and SMA have been described as distal neuropathies where 
synaptic abnormalities and retraction of the axon from the synapse occur prior to the 
manifestation of symptoms (Murray et al., 2010).  As denervated synaptic structures are 
observed in Akd2C-/- forelimb muscles which have not yet begun to degenerate it seems likely 
that this is an early event and that the observed disease is also a distal neuropathy.  The 
production of a disease with similarities to both ALS and SMA by the reduction of BMP 
activity in Akd2C-/- mice suggests that the role of BMP signalling in motor neuron diseases is 
conserved between Drosophila and mammals.  The studies in Drosophila suggest that the 
activation of the BMP pathway and expression of its target genes are downstream of known 
motor neuron disease causing mutations.  Identification of BMP target genes in motor neurons 
is therefore likely to complete the link between disease causing genes and the maintenance of 
neuromuscular connectivity.  Modulation of the expression of these target genes or the 
activity of the BMP pathway would be expected to provide a treatment for certain symptoms 
of such diseases. 
In addition to BMP this study has suggested that canonical Wnt signalling plays a role in 
motor neuron connectivity as reduced expression of β-catenin in conjunction with Arkadia2C 
(Akd2C+/-:β-catenin+/-) produces a motor neuron disease-like phenotype.  As loss of β-catenin 
expression in muscle but not in motor neurons affects axon growth and patterning (Li et al., 
2008) this result suggests that non-autonomous mechanisms may play a role in motor neuron 
diseases.  Many of the genes that have been linked to such diseases are ubiquitously expressed 
yet loss of expression only produces a defect in motor neurons (Neumann et al., 2006; 
Burghes and Beattie, 2009; Dion et al., 2009).  It is therefore possible that abnormal Wnt 
signalling between motor neurons and surrounding cells plays a role in the manifestation of 
disease symptoms. 
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There is growing evidence that BMP signalling may also be required for connectivity in the 
brain and its loss results in central neuronal diseases (Bayat et al., 2010).  Arkadia2C is 
expressed broadly in the nervous system including areas of the central brain such as the cortex 
and hippocampus.  The preliminary analysis of Akd2C+/- behaviour and the observed loss of 
the corpus callosum in certain genetic backgrounds suggest that Arkadia2C enhanced BMP 
signalling influences axon elongation and connectivity in the central brain.  Arkadia2C is a 
candidate gene for Bipolar Disorder in a family with an inversion in chromosome 18 (Pickard 
et al., 2005).  While the inversion did not disrupt a gene, its proximity to the Arkadia2C 
promoter and the neuronal specificity of Arkadia2C expression led to the proposal of 
Arkadia2C as the causative gene.  Furthermore, other genes which have been linked to 
neurodegenerative diseases such as Multiple Sclerosis and Huntington's Disease have been 
shown to regulate the activation of BMP signaling in  the Drosophila model (Bayat et al., 
2010).  Together this evidence suggests that BMP and perhaps Arkadia2C, play a role in 
central axon growth and connectivity and disruption in this signalling leads to disease.  It is 
therefore possible that in a similar manner to motor neuron diseases, modulation of the BMP 
pathway could provide a therapeutic approach for these central neurodegenerative diseases. 
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8.5 Significance of this research 
This study has shown that Arkadia2C enhances BMP signalling and that this enhancement is 
required both for the embryonic growth of motor axons and their maintenance in adults.  The 
specificity of Arkadia2C function sheds light on novel roles of the BMP signalling pathway in 
development and physiology.  Additionally as the BMP pathway has dose-dependent 
outcomes, study of its enhancement by Arkadia2C furthers the understanding of the 
regulation of such outcomes.  Identification of BMP target genes activated by specific levels 
of signalling within motor neurons will inspire research into mechanisms of dose-dependent 
activation of such genes.  Furthermore, as this study indicates a role for Wnt/β-catenin 
signalling in the same motor neurons it forms a basis for research into the interaction between 
the two pathways in these cells. 
Loss of Arkadia2C mediated axonal growth and maintenance results in a motor neuron 
disease-like phenotype, linking the BMP pathway to such disorders.  As the routes from 
individual genes to neuronal degeneration have not yet been established this provides a 
crucial missing link in the study of motor neuron diseases and the conception of treatments.  
This research will stimulate further studies that would reveal whether BMP pathway 
components or target genes cause motor neuron diseases in humans.  Kalirin provides a 
starting point for the study of the role of BMP target genes in axons, however further targets 
are likely to exist; such genes must be identified and their role in human patients studied.  
Understanding the mechanisms involved in neurodegenerative diseases will allow the 
development of means to modulate these pathways in neurons.  Such modulation is likely to 
have therapeutic potential to prevent further neuronal degeneration or possibly even to induce 
regrowth of axons which have lost their connections. 
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10 Appendices 
 
Appendix I: Example of raw data from chick neural tube luciferase assays 
 
BRE-luciferase activity normalised against renilla luciferase activity for each individual live 
chick embryo 22 hours after electroporation. 
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Appendix III: Classes of  forelimb innervation defects 
Examples of E13.5 limbs in arbitary classes for quantification of forelimb innervation. 
Class 1: loss of distal dorsal innervation and thining of proximal innervation 
Class 2: loss of distal dorsal innervation 
Class 3: thinning of distal dorsal innervation 
Class 4: normal forelimb innervation. 
Blue arrow; distal dorsal innervation; yellow arrows, proximal dorsal innervation. 
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Appendix IV: Schematics of crosses to show in vivo interactions between Arkadia2C and 
various signalling pathways 
 
a) The cross used to examine the genetic interaction between Arkadia2C and genes which are 
lethal in homozygous mutant forms.  X represents BMPRIa, BMPRII, Nodal or β-catenin.  
Phenotypes and survival rates were compared between Akd2C+/-:X+/+ and Akd2C+/-:X+/- in 
addition to Akd2C-/-:X+/+ and Akd2C-/-:X+/-. 
b) The cross used to examine the genetic interaction between Arkadia2C and the RRH119 
genetrap mutation in SnoN which is viable as homozygous.  Arkadia2C-/-:SnoN-/- mice were 
examined for a paw phenotype and survival to weaning. 
c) The cross used to examine the genetic interaction between Arkadia2C and Smad8, which is 
viable as homozygous mutant.  The phenotypes and survival rates of Akd2C+/-:Smad8-/- was 
compared to Akd2C+/-:Smad8+/+ or +/-and the survival rates of different Akd2C-/- were 
compared.
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Appendix V: Offspring from crosses used to examine the genetic interaction between 
Arkadia2C and components of the BMP pathway 
 
The expected numbers of each genotype born, actual numbers born, numbers weaned and 
numbers presenting a clenched paw phenotype from the a) Akd2C+/- X Akd2C+/-:BMPRIa+/-, 
b) Akd2C+/- X Akd2C+/-:BMPRII +/-,c) Akd2C+/-:Smad8+/- X Akd2C+/-:Smad8+/- and d) 
Akd2C+/- X Akd2C+/-:Smad4+/- crosses. 
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Appendix VI: Offspring from crosses used to examine the genetic interaction between 
Arkadia2C and components of the Nodal and Wnt pathways 
 
The expected numbers of each genotype born, actual numbers born, numbers weaned and 
numbers presenting a clenched paw phenotype from the a) Akd2C+/- X Akd2C+/-:Nodal+/-, b) 
Akd2C+/-:SnoN-/- X Akd2C+/-:SnoN-/- and c) Akd2C+/-- X Akd2C+/-:β-catenin+/- crosses. 
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Appendix VII: Expression of known BMP target is upregulated in the presence of BMP 
signalling  
QPCR showing the expression of the known BMP target genes Id4 and Msx1 in response to 
BMP.  0h, 1h, 2h, 5h, 9h, 12h indicates time of treatment (hours) with 25ng/ml BMP4, 1+2h 
indicates 1hour treatment with 25ng/ml BMP4 followed by 2 hours in 100ng/ml Noggin 
(dashed line). 
 
 
 
 
 
